US Patent & Trademark Office Patent Public Search | Text View

United States Patent

Kind Code

B2
Date of Patent

Inventor(s)

12390114

August 19, 2025

Novak, Jr.; Jerome J. et al.

Wearable device for monitoring health status

Abstract

A system for remotely monitoring and managing health statuses of a plurality of users includes software instructions storable on a memory device usable by a computing device, the software instructions causing a hardware processor of the computing device to receive a plurality of sets of health-related information from a plurality of mobile computing devices of a plurality of users. The health-related information includes physiological information derived from wearable devices of the users indicative of an onset of symptoms associated with an infection, contact tracing data, and diagnosis data. The hardware processor determines exposure levels based on at least the contact tracing data, and determines user-specific risk states based on physiological information, diagnosis data, and exposure levels.

Inventors: Novak, Jr.; Jerome J. (Lake Forest, CA), Ahmed; Omar (Lake Forest, CA),

Michalopoulos; Kostantinos (Irvine, CA), Al-Ali; Ammar (San Juan Capistrano,

CA)

Applicant: Masimo Corporation (Irvine, CA)

Family ID: 1000008767022

Assignee: Masimo Corporation (Irvine, CA)

Appl. No.: 17/207055

Filed: March 19, 2021

Prior Publication Data

Document IdentifierUS 20210290177 A1
Publication Date
Sep. 23, 2021

Related U.S. Application Data

us-provisional-application US 63106273 20201027 us-provisional-application US 63065961 20200814

us-provisional-application US 63056925 20200727 us-provisional-application US 63049478 20200708 us-provisional-application US 63010669 20200415 us-provisional-application US 62992779 20200320 us-provisional-application US 62992808 20200320

Publication Classification

Int. Cl.: A61B5/0205 (20060101); A61B5/00 (20060101); A61B5/01 (20060101); A61B5/024 (20060101); A61B5/026 (20060101); A61B5/08 (20060101); A61B5/145 (20060101); A61B5/1455 (20060101); G06F3/04842 (20220101); G06F9/451 (20180101); G16H10/60 (20180101); G16H15/00 (20180101); G16H40/20 (20180101); G16H50/30 (20180101); G16H50/70 (20180101); G16H50/80 (20180101); H04B17/318 (20150101); H04W4/021 (20180101)

U.S. Cl.:

CPC A61B5/02055 (20130101); A61B5/0004 (20130101); A61B5/0008 (20130101); A61B5/002 (20130101); A61B5/0022 (20130101); A61B5/01 (20130101); A61B5/0205 (20130101); A61B5/08 (20130101); A61B5/0816 (20130101); A61B5/14542 (20130101); A61B5/6801 (20130101); A61B5/6814 (20130101); A61B5/6823 (20130101); A61B5/6824 (20130101); A61B5/6826 (20130101); A61B5/7275 (20130101); A61B5/7282 (20130101); A61B5/7435 (20130101); A61B5/7466 (20130101); A61B5/7465 (20130101); A61B5/747 (20130101); A61B5/7475 (20130101); G06F9/451 (20180201); G16H10/60 (20180101); G16H15/00 (20180101); G16H40/20 (20180101); G16H40/67 (20180101); G16H50/20 (20180101); G16H50/30 (20180101); G16H50/70 (20180101); G16H50/80 (20180101); H04B17/318 (20150115); H04W4/021 (20130101); A61B5/024 (20130101); A61B5/026 (20130101); A61B5/14551 (20130101); A61B2562/0271 (20130101); G06F3/04842 (20130101)

Field of Classification Search

CPC: A61B (2562/0271); A61B (5/00-7495); H04B (17/318); G16H (50/80); G08B (21/0247)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
4960128	12/1989	Gordon et al.	N/A	N/A
4964408	12/1989	Hink et al.	N/A	N/A
5319355	12/1993	Russek	N/A	N/A
5337744	12/1993	Branigan	N/A	N/A
5341805	12/1993	Stavridi et al.	N/A	N/A
D353195	12/1993	Savage et al.	N/A	N/A
D353196	12/1993	Savage et al.	N/A	N/A
5377676	12/1994	Vari et al.	N/A	N/A
D359546	12/1994	Savage et al.	N/A	N/A
5431170	12/1994	Mathews	N/A	N/A
5436499	12/1994	Namavar et al.	N/A	N/A

D361840	12/1994	Savage et al.	N/A	N/A
D362063	12/1994	Savage et al.	N/A	N/A
D363120	12/1994	Savage et al.	N/A	N/A
5456252	12/1994	Vari et al.	N/A	N/A
5479934	12/1995	Imran	N/A	N/A
5482036	12/1995	Diab et al.	N/A	N/A
5494043	12/1995	O'Sullivan et al.	N/A	N/A
5533511	12/1995	Kaspari et al.	N/A	N/A
5561275	12/1995	Savage et al.	N/A	N/A
5590649	12/1996	Caro et al.	N/A	N/A
5602924	12/1996	Durand et al.	N/A	N/A
5638816	12/1996	Kiani- Azarbayjany et al.	N/A	N/A
5638818	12/1996	Diab et al.	N/A	N/A
5645440	12/1996	Tobler et al.	N/A	N/A
5671914	12/1996	Kalkhoran et al.	N/A	N/A
5726440	12/1997	Kalkhoran et al.	N/A	N/A
D393830	12/1997	Tobler et al.	N/A	N/A
5743262	12/1997	Lepper, Jr. et al.	N/A	N/A
5747806	12/1997	Khalil et al.	N/A	N/A
5750994	12/1997	Schlager	N/A	N/A
5758644	12/1997	Diab et al.	N/A	N/A
5760910	12/1997	Lepper, Jr. et al.	N/A	N/A
5890929	12/1998	Mills et al.	N/A	N/A
5919134	12/1998	Diab	N/A	N/A
5987343	12/1998	Kinast	N/A	N/A
5997343	12/1998	Mills et al.	N/A	N/A
6002952	12/1998	Diab et al.	N/A	N/A
6010937	12/1999	Karam et al.	N/A	N/A
6027452	12/1999	Flaherty et al.	N/A	N/A
6040578	12/1999	Malin et al.	N/A	N/A
6066204	12/1999	Haven	N/A	N/A
6115673	12/1999	Malin et al.	N/A	N/A
6124597	12/1999	Shehada et al.	N/A	N/A
6128521	12/1999	Marro et al.	N/A	N/A
6129675	12/1999	Jay	N/A	N/A
6144868	12/1999	Parker	N/A	N/A
6152754	12/1999	Gerhardt et al.	N/A	N/A
6184521	12/2000	Coffin, IV et al.	N/A	N/A
6232609	12/2000	Snyder et al.	N/A	N/A
6241683	12/2000	Macklem et al.	N/A	N/A
6253097	12/2000	Aronow et al.	N/A	N/A
6255708	12/2000	Sudharsanan et al.	N/A	N/A
6280381	12/2000	Malin et al.	N/A	N/A
6285896	12/2000	Tobler et al.	N/A	N/A
6308089	12/2000	von der Ruhr et al.	N/A	N/A
6317627	12/2000	Ennen et al.	N/A	N/A
6321100	12/2000	Parker	N/A	N/A
6334065	12/2000	Al-Ali et al.	N/A	N/A
6360114	12/2001	Diab et al.	N/A	N/A

6368283	12/2001	Xu et al.	N/A	N/A
6411373	12/2001	Garside et al.	N/A	N/A
6415167	12/2001	Blank et al.	N/A	N/A
6430437	12/2001	Marro	N/A	N/A
6430525	12/2001	Weber et al.	N/A	N/A
6463311	12/2001	Diab	N/A	N/A
6470199	12/2001	Kopotic et al.	N/A	N/A
6487429	12/2001	Hockersmith et al.	N/A	N/A
6505059	12/2002	Kollias et al.	N/A	N/A
6525386	12/2002	Mills et al.	N/A	N/A
6526300	12/2002	Kiani et al.	N/A	N/A
6534012	12/2002	Hazen et al.	N/A	N/A
6542764	12/2002	Al-Ali et al.	N/A	N/A
6580086	12/2002	Schulz et al.	N/A	N/A
6584336	12/2002	Ali et al.	N/A	N/A
6587196	12/2002	Stippick et al.	N/A	N/A
6587199	12/2002	Luu	N/A	N/A
6595316	12/2002	Cybulski et al.	N/A	N/A
6597932	12/2002	Tian et al.	N/A	N/A
6606511	12/2002	Ali et al.	N/A	N/A
6635559	12/2002	Greenwald et al.	N/A	N/A
6639668	12/2002	Trepagnier	N/A	N/A
6640116	12/2002	Diab	N/A	N/A
6640117	12/2002	Makarewicz et al.	N/A	N/A
6658276	12/2002	Kiani et al.	N/A	N/A
6661161	12/2002	Lanzo et al.	N/A	N/A
6697656	12/2003	Al-Ali	N/A	N/A
6697658	12/2003	Al-Ali	N/A	N/A
RE38476	12/2003	Diab et al.	N/A	N/A
RE38492	12/2003	Diab et al.	N/A	N/A
6738652	12/2003	Mattu et al.	N/A	N/A
6760607	12/2003	Ai-Ai	N/A	N/A
6788965	12/2003	Ruchti et al.	N/A	N/A
6816241	12/2003	Grubisic	N/A	N/A
6822564	12/2003	Al-Ali	N/A	N/A
6850787	12/2004	Weber et al.	N/A	N/A
6850788	12/2004	Al-Ali	N/A	N/A
6876931	12/2004	Lorenz et al.	N/A	N/A
6920345	12/2004	Al-Ali et al.	N/A	N/A
6934570	12/2004	Kiani et al.	N/A	N/A
6943348	12/2004	Coffin, IV	N/A	N/A
6956649	12/2004	Acosta et al.	N/A	N/A
6961598	12/2004	Diab	N/A	N/A
6970792	12/2004	Diab	N/A	N/A
6985764	12/2005	Mason et al.	N/A	N/A
6990364	12/2005	Ruchti et al.	N/A	N/A
6998247	12/2005	Monfre et al.	N/A	N/A
7003338	12/2005	Weber et al.	N/A	N/A
7015451	12/2005	Dalke et al.	N/A	N/A
7027849	12/2005	Ai-Ali	N/A	N/A

D526719	12/2005	Richie, Jr. et al.	N/A	N/A
7096052	12/2005	Mason et al.	N/A	N/A
7096054	12/2005	Abdul-Hafiz et al.	N/A	N/A
D529616	12/2005	Deros et al.	N/A	N/A
7133710	12/2005	Acosta et al.	N/A	N/A
7142901	12/2005	Kiani et al.	N/A	N/A
7225006	12/2006	Al-Ali et al.	N/A	N/A
RE39672	12/2006	Shehada et al.	N/A	N/A
7254429	12/2006	Schurman et al.	N/A	N/A
7254431	12/2006	Al-Ali et al.	N/A	N/A
7254434	12/2006	Schulz et al.	N/A	N/A
7274955	12/2006	Kiani et al.	N/A	N/A
D554263	12/2006	Al-Ali et al.	N/A	N/A
7280858	12/2006	Al-Ali et al.	N/A	N/A
7289835	12/2006	Mansfield et al.	N/A	N/A
7292883	12/2006	De Felice et al.	N/A	N/A
7341559	12/2007	Schulz et al.	N/A	N/A
7343186	12/2007	Lamego et al.	N/A	N/A
D566282	12/2007	Al-Ali et al.	N/A	N/A
7356365	12/2007	Schurman	N/A	N/A
7371981	12/2007	Abdul-Hafiz	N/A	N/A
7373193	12/2007	Al-Ali et al.	N/A	N/A
7377794	12/2007	Al-Ali et al.	N/A	N/A
7395158	12/2007	Monfre et al.	N/A	N/A
7415297	12/2007	Al-Ali et al.	N/A	N/A
7438683	12/2007	Al-Ali et al.	N/A	N/A
7483729	12/2008	Al-Ali et al.	N/A	N/A
D587657	12/2008	Al-Ali et al.	N/A	N/A
7500950	12/2008	Al-Ali et al.	N/A	N/A
7509494	12/2008	Al-Ali	N/A	N/A
7510849	12/2008	Schurman et al.	N/A	N/A
7514725	12/2008	Wojtczuk et al.	N/A	N/A
7519406	12/2008	Blank et al.	N/A	N/A
D592507	12/2008	Wachman et al.	N/A	N/A
7530942	12/2008	Diab	N/A	N/A
7593230	12/2008	Abul-Haj et al.	N/A	N/A
7596398	12/2008	Al-Ali et al.	N/A	N/A
7606608	12/2008	Blank et al.	N/A	N/A
7620674	12/2008	Ruchti et al.	N/A	N/A
D606659	12/2008	Kiani et al.	N/A	N/A
7629039	12/2008	Eckerbom et al.	N/A	N/A
7640140	12/2008	Ruchti et al.	N/A	N/A
7647083	12/2009	Al-Ali et al.	N/A	N/A
D609193	12/2009	Al-Ali et al.	N/A	N/A
D614305	12/2009	Al-Ali et al.	N/A	N/A
7697966	12/2009	Monfre et al.	N/A	N/A
7698105	12/2009	Ruchti et al.	N/A	N/A
RE41317	12/2009	Parker	N/A	N/A
RE41333	12/2009	Blank et al.	N/A	N/A
7729733	12/2009	Al-Ali et al.	N/A	N/A

7761127	12/2009	Al-Ali et al.	N/A	N/A
7764982	12/2009	Dalke et al.	N/A	N/A
D621516	12/2009	Kiani et al.	N/A	N/A
7791155	12/2009	Diab	N/A	N/A
RE41912	12/2009	Parker	N/A	N/A
7880626	12/2010	Al-Ali et al.	N/A	N/A
7904133	12/2010	Gehman et al.	N/A	N/A
7909772	12/2010	Popov et al.	N/A	N/A
7919713	12/2010	Al-Ali et al.	N/A	N/A
7937128	12/2010	Al-Ali	N/A	N/A
7937129	12/2010	Mason et al.	N/A	N/A
7941199	12/2010	Kiani	N/A	N/A
7957780	12/2010	Lamego et al.	N/A	N/A
7962188	12/2010	Kiani et al.	N/A	N/A
7976472	12/2010	Kiani	N/A	N/A
7990382	12/2010	Kiani	N/A	N/A
8008088	12/2010	Bellott et al.	N/A	N/A
RE42753	12/2010	Kiani-	N/A	N/A
		Azarbayjany et al.		
8028701	12/2010	Al-Ali et al.	N/A	N/A
8048040	12/2010	Kiani	N/A	N/A
8050728	12/2010	Al-Ali et al.	N/A	N/A
RE43169	12/2011	Parker	N/A	N/A
8118620	12/2011	Al-Ali et al.	N/A	N/A
8130105	12/2011	Al-Ali et al.	N/A	N/A
8182443	12/2011	Kiani	N/A	N/A
8190223	12/2011	Al-Ali et al.	N/A	N/A
8203438	12/2011	Kiani et al.	N/A	N/A
8203704	12/2011	Merritt et al.	N/A	N/A
8219172	12/2011	Schurman et al.	N/A	N/A
8224411	12/2011	Al-Ali et al.	N/A	N/A
8229532	12/2011	Davis	N/A	N/A
8233955	12/2011	Al-Ali et al.	N/A	N/A
8255026	12/2011	Al-Ali Mallala et al	N/A	N/A
8265723	12/2011	McHale et al.	N/A	N/A
8274360 8280473	12/2011 12/2011	Sampath et al. Al-Ali	N/A N/A	N/A N/A
8290574	12/2011	Feild et al.	N/A	N/A N/A
8315683	12/2011	Al-Ali et al.	N/A	N/A N/A
8315687	12/2011	Cross et al.	N/A	N/A N/A
RE43860	12/2011	Parker	N/A	N/A
8346330	12/2011	Lamego	N/A	N/A
8353842	12/2012	Al-Ali et al.	N/A	N/A
0333042	12/2012	MacNeish, III et	1 \ / /\frac{1}{1}	11/11
8355766	12/2012	al.	N/A	N/A
8374665	12/2012	Lamego	N/A	N/A
8388353	12/2012	Kiani et al.	N/A	N/A
8401602	12/2012	Kiani	N/A	N/A
8414499	12/2012	Al-Ali et al.	N/A	N/A
8418524	12/2012	Al-Ali	N/A	N/A

8428967	12/2012	Olsen et al.	N/A	N/A
8430817	12/2012	Al-Ali et al.	N/A	N/A
8437825	12/2012	Dalvi et al.	N/A	N/A
D684071	12/2012	Greenwood et al.	N/A	N/A
8455290	12/2012	Siskavich	N/A	N/A
8457707	12/2012	Kiani	N/A	N/A
8471713	12/2012	Poeze et al.	N/A	N/A
8473020	12/2012	Kiani et al.	N/A	N/A
8509867	12/2012	Workman et al.	N/A	N/A
8515509	12/2012	Bruinsma et al.	N/A	N/A
8523781	12/2012	Al-Ali	N/A	N/A
D692145	12/2012	Al-Ali et al.	N/A	N/A
8571617	12/2012	Reichgott et al.	N/A	N/A
8571618	12/2012	Lamego et al.	N/A	N/A
8571619	12/2012	Al-Ali et al.	N/A	N/A
8577431	12/2012	Lamego et al.	N/A	N/A
8584345	12/2012	Al-Ali et al.	N/A	N/A
8588880	12/2012	Abdul-Hafiz et al.	N/A	N/A
8630691	12/2013	Lamego et al.	N/A	N/A
8639319	12/2013	Hugh et al.	N/A	N/A
8641631	12/2013	Sierra et al.	N/A	N/A
8652060	12/2013	Al-Ali	N/A	N/A
8666468	12/2013	Al-Ali	N/A	N/A
8670811	12/2013	O'Reilly	N/A	N/A
RE44823	12/2013	Parker	N/A	N/A
RE44875	12/2013	Kiani et al.	N/A	N/A
8688183	12/2013	Bruinsma et al.	N/A	N/A
8690799	12/2013	Telfort et al.	N/A	N/A
8702627	12/2013	Telfort et al.	N/A	N/A
8712494	12/2013	MacNeish, III et	N/A	N/A
		al.		
8715206	12/2013	Telfort et al.	N/A	N/A
8716629	12/2013	Klewer et al.	N/A	N/A
8723677	12/2013	Kiani	N/A	N/A
8740792	12/2013	Kiani et al.	N/A	N/A
8755535	12/2013	Telfort et al.	N/A	N/A
8755872	12/2013	Marinow	N/A	N/A
8764671	12/2013	Kiani Shakaanaara at al	N/A	N/A
8768423	12/2013	Shakespeare et al. Telfort et al.	N/A	N/A
8771204	12/2013	Al-Ali et al.	N/A	N/A
8781544 8790268	12/2013 12/2013	Al-Ali	N/A N/A	N/A N/A
8801613	12/2013	Al-Ali et al.	N/A	N/A
8821397	12/2013	Al-Ali et al.	N/A	N/A
8821415	12/2013	Al-Ali et al.	N/A	N/A
8830449	12/2013		N/A	N/A
8840549	12/2013	Lamego et al. Al-Ali et al.	N/A	N/A
8852094	12/2013	Al-Ali et al.	N/A	N/A
8852994	12/2013	Wojtczuk et al.	N/A	N/A
8897847	12/2013	Al-Ali	N/A	N/A
003/0 1 /	14/4010	1 11 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1/ 1 1	11/11

8911377	12/2013	Al-Ali	N/A	N/A
8989831	12/2014	Al-Ali et al.	N/A	N/A
8998809	12/2014	Kiani	N/A	N/A
9028405	12/2014	Tran	N/A	N/A
9066666	12/2014	Kiani	N/A	N/A
9066680	12/2014	Al-Ali et al.	N/A	N/A
9095316	12/2014	Welch et al.	N/A	N/A
9106038	12/2014	Telfort et al.	N/A	N/A
9107625	12/2014	Telfort et al.	N/A	N/A
9131881	12/2014	Diab et al.	N/A	N/A
9138180	12/2014	Coverston et al.	N/A	N/A
9153112	12/2014	Kiani et al.	N/A	N/A
9192329	12/2014	Al-Ali	N/A	N/A
9192351	12/2014	Telfort et al.	N/A	N/A
9195385	12/2014	Al-Ali et al.	N/A	N/A
9211095	12/2014	Al-Ali	N/A	N/A
9218454	12/2014	Kiani et al.	N/A	N/A
9245668	12/2015	Vo et al.	N/A	N/A
9267572	12/2015	Barker et al.	N/A	N/A
9277880	12/2015	Poeze et al.	N/A	N/A
9307928	12/2015	Al-Ali et al.	N/A	N/A
9323894	12/2015	Kiani	N/A	N/A
D755392	12/2015	Hwang et al.	N/A	N/A
9326712	12/2015	Kiani	N/A	N/A
9392945	12/2015	Al-Ali et al.	N/A	N/A
9408542	12/2015	Kinast et al.	N/A	N/A
9436645	12/2015	Al-Ali et al.	N/A	N/A
9445759	12/2015	Lamego et al.	N/A	N/A
9459089	12/2015	Ganton et al.	N/A	N/A
9474474	12/2015	Lamego et al.	N/A	N/A
9480435	12/2015	Olsen	N/A	N/A
9510779	12/2015	Poeze et al.	N/A	N/A
9517024	12/2015	Kiani et al.	N/A	N/A
9532722	12/2016	Lamego et al.	N/A	N/A
9560996	12/2016	Kiani	N/A	N/A
9579039	12/2016	Jansen et al.	N/A	N/A
9622692	12/2016	Lamego et al.	N/A	N/A
D788312	12/2016	Al-Ali et al.	N/A	N/A
9649054	12/2016	Lamego et al.	N/A	N/A
9697928	12/2016	Al-Ali et al.	N/A	N/A
9717458	12/2016	Lamego et al.	N/A	N/A
9724016	12/2016	Al-Ali et al.	N/A	N/A
9724024	12/2016	Al-Ali	N/A	N/A
9724025	12/2016	Kiani et al.	N/A	N/A
9749232	12/2016	Sampath et al.	N/A	N/A
D796363	12/2016	Ross et al.	N/A	N/A
9750442	12/2016	Olsen Tolfort	N/A	N/A
9750461	12/2016	Telfort	N/A	N/A
9775545 9778079	12/2016 12/2016	Al-Ali et al. Al-Ali et al.	N/A	N/A
3//00/3	12/2010	AI-AII et al.	N/A	N/A

9782077	12/2016	Lamego et al.	N/A	N/A
9787568	12/2016	Lamego et al.	N/A	N/A
9808188	12/2016	Perea et al.	N/A	N/A
9839379	12/2016	Al-Ali et al.	N/A	N/A
9839381	12/2016	Weber et al.	N/A	N/A
9847749	12/2016	Kiani et al.	N/A	N/A
9848800	12/2016	Lee et al.	N/A	N/A
9861298	12/2017	Eckerbom et al.	N/A	N/A
9861305	12/2017	Weber et al.	N/A	N/A
9870533	12/2017	Ross	N/A	N/A
9877650	12/2017	Muhsin et al.	N/A	N/A
9891079	12/2017	Dalvi	N/A	N/A
9907473	12/2017	Tran	N/A	N/A
9924897	12/2017	Abdul-Hafiz	N/A	N/A
9936917	12/2017	Poeze et al.	N/A	N/A
D817784	12/2017	Swenson et al.	N/A	N/A
9955937	12/2017	Telfort	N/A	N/A
9965946	12/2017	Al-Ali et al.	N/A	N/A
D820865	12/2017	Muhsin et al.	N/A	N/A
9986952	12/2017	Dalvi et al.	N/A	N/A
D822215	12/2017	Al-Ali et al.	N/A	N/A
D822216	12/2017	Barker et al.	N/A	N/A
10010276	12/2017	Al-Ali et al.	N/A	N/A
10086138	12/2017	Novak, Jr.	N/A	N/A
10111591	12/2017	Dyell et al.	N/A	N/A
D833624	12/2017	DeJong et al.	N/A	N/A
10123729	12/2017	Dyell et al.	N/A	N/A
D835282	12/2017	Barker et al.	N/A	N/A
D835283	12/2017	Barker et al.	N/A	N/A
D835284	12/2017	Barker et al.	N/A	N/A
D835285	12/2017	Barker et al.	N/A	N/A
10149616	12/2017	Al-Ali et al.	N/A	N/A
10154815	12/2017	Al-Ali et al.	N/A	N/A
10159412	12/2017	Lamego et al.	N/A	N/A
10188348	12/2018	Al-Ali et al.	N/A	N/A
RE47218	12/2018	Al-Ali	N/A	N/A
RE47244	12/2018	Kiani et al.	N/A	N/A
RE47249	12/2018	Kiani et al.	N/A	N/A
10205291	12/2018	Scruggs et al.	N/A	N/A
10226187	12/2018	Al-Ali et al.	N/A	N/A
10231657	12/2018	Al-Ali et al.	N/A	N/A
10231670	12/2018	Blank et al.	N/A	N/A
RE47353	12/2018	Kiani et al.	N/A	N/A
10279247	12/2018	Kiani	N/A	N/A
10292664	12/2018	Al-Ali	N/A	N/A
10299720	12/2018	Brown et al.	N/A	N/A
10327337	12/2018	Schmidt et al.	N/A	N/A
10327713	12/2018	Barker et al.	N/A	N/A
10332630	12/2018	Al-Ali	N/A	N/A
10362002	12/2018	Ross et al.	N/A	N/A

10383520	12/2018	Wojtczuk et al.	N/A	N/A
10383527	12/2018	Al-Ali	N/A	N/A
10388120	12/2018	Muhsin et al.	N/A	N/A
D864120	12/2018	Forrest et al.	N/A	N/A
10441181	12/2018	Telfort et al.	N/A	N/A
10441196	12/2018	Eckerbom et al.	N/A	N/A
10448844	12/2018	Al-Ali et al.	N/A	N/A
10448871	12/2018	Al-Ali et al.	N/A	N/A
10456038	12/2018	Lamego et al.	N/A	N/A
10463340	12/2018	Telfort et al.	N/A	N/A
10471159	12/2018	Lapotko et al.	N/A	N/A
10505311	12/2018	Al-Ali et al.	N/A	N/A
10506953	12/2018	Ross et al.	N/A	N/A
10524726	12/2019	Wang et al.	N/A	N/A
10524738	12/2019	Olsen	N/A	N/A
10532174	12/2019	Ai-Ali	N/A	N/A
10537285	12/2019	Shreim et al.	N/A	N/A
10542903	12/2019	Al-Ali et al.	N/A	N/A
10555678	12/2019	Dalvi et al.	N/A	N/A
10568553	12/2019	O'Neil et al.	N/A	N/A
RE47882	12/2019	Al-Ali	N/A	N/A
10608817	12/2019	Haider et al.	N/A	N/A
D880477	12/2019	Forrest et al.	N/A	N/A
10617302	12/2019	Al-Ali et al.	N/A	N/A
10617335	12/2019	Al-Ali et al.	N/A	N/A
10637181	12/2019	Al-Ali et al.	N/A	N/A
D886849	12/2019	Muhsin et al.	N/A	N/A
D887548	12/2019	Abdul-Hafiz et al.	N/A	N/A
D887549	12/2019	Abdul-Hafiz et al.	N/A	N/A
10667764	12/2019	Ahmed et al.	N/A	N/A
D890708	12/2019	Forrest et al.	N/A	N/A
10721785	12/2019	Al-Ali	N/A	N/A
10736518	12/2019	Al-Ali et al.	N/A	N/A
10743091	12/2019	Wang et al.	N/A	N/A
10750984	12/2019	Pauley et al.	N/A	N/A
D897098	12/2019	Al-Ali	N/A	N/A
10758164	12/2019	Derkx	N/A	N/A
10779098	12/2019	Iswanto et al.	N/A	N/A
10827961	12/2019	Iyengar et al.	N/A	N/A
10828007	12/2019	Telfort et al.	N/A	N/A
10832818	12/2019	Muhsin et al.	N/A	N/A
10849554	12/2019	Shreim et al.	N/A	N/A
10856750	12/2019	Indorf et al.	N/A	N/A
D906970	12/2020	Forrest et al.	N/A	N/A
D908213	12/2020	Abdul-Hafiz et al.	N/A	N/A
10918281	12/2020	Al-Ali et al.	N/A	N/A
10932705	12/2020	Muhsin et al.	N/A	N/A
10932729	12/2020	Kiani et al.	N/A	N/A
10939878	12/2020	Kiani et al.	N/A	N/A
10956950	12/2020	Al-Ali et al.	N/A	N/A

D917046 12/2020 Abdul-Hafiz et al. N/A N/A D917550 12/2020 Indorf et al. N/A N/A D917564 12/2020 Indorf et al. N/A N/A D917704 12/2020 Al-Ali et al. N/A N/A L7/2020 Al-Ali et al. N/A N/A L7/2020 Al-Ali et al. N/A N/A L7/2020 Al-Ali et al. N/A N/A D919094 12/2020 Al-Ali et al. N/A N/A L7/2020 Al-Ali et al. N/A N/A L7/2020 Al-Ali et al. N/A N/A L7/2020 Al-Ali et al. N/A N/A N/A L7/2020 Al-Ali N/A N/A N/A L7/2020 Al-Ali N/A N/A N/A L7/2020 Al-Ali et al. N/A	D916135	12/2020	Indorf et al.	N/A	N/A
D917550					
D917564 12/2020					
10987066 12/2020					
10991135 12/2020		12/2020			
10991135			Chandran et al.		
D919094					
11006867 12/2020 Al-Ali N/A N/A N/A D921202 12/2020 Al-Ali et al. N/A N/A N/A 11024064 12/2020 Muhsin et al. N/A N/A N/A 11026604 12/2020 Chen et al. N/A N/A D925597 12/2020 Chandran et al. N/A N/A N/A D927699 12/2020 Al-Ali et al. N/A N/A N/A 11076777 12/2020 Lee et al. N/A N/A N/A 1114188 12/2020 Poeze et al. N/A N/A N/A D933232 12/2020 Al-Ali et al. N/A N/A N/A D933233 12/2020 Al-Ali et al. N/A N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A N/A 11191444 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A N/A D946617 12/2021 Al-Ali et al. N/A N/A N/A 11289199 12/2021 Al-Ali et al. N/A N/A N/A 11289199 12/2021 Al-Ali et al. N/A N/A N/A 11298021 12/2021 Al-Ali et al. N/A N/A N/A D950495 12/2021 Al-Ali et al. N/A N/A N/A D950599 12/2021 Al-Ali et al. N/A N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A N/A D9507648 12/20	D919094	12/2020	Al-Ali et al.	N/A	N/A
D921202	D919100	12/2020	Al-Ali et al.	N/A	N/A
11024064 12/2020 Muhsin et al. N/A N/A 11026604 12/2020 Chen et al. N/A N/A D925597 12/2020 Chandran et al. N/A N/A D927699 12/2020 Al-Ali et al. N/A N/A 11076777 12/2020 Lee et al. N/A N/A 111488 12/2020 Al-Ali et al. N/A N/A D933232 12/2020 Al-Ali et al. N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A 11145408 12/2020 Sampath et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 1191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021	11006867	12/2020	Al-Ali	N/A	N/A
11026604 12/2020 Chen et al. N/A N/A D925597 12/2020 Chandran et al. N/A N/A N/A D927699 12/2020 Al-Ali et al. N/A N/A N/A 11076777 12/2020 Lee et al. N/A N/A N/A 1114188 12/2020 Poeze et al. N/A N/A N/A D933232 12/2020 Al-Ali et al. N/A N/A N/A D933233 12/2020 Al-Ali et al. N/A N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A N/A N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A N/A N/A N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A N/A D946596 12/2021 Ahmed N/A N/A N/A D946596 12/2021 Ahmed N/A N/A N/A D946597 12/2021 Ahmed N/A N/A N/A D946617 12/2021 Ahmed N/A N/A N/A 11289199 12/2021 Al-Ali et al. N/A N/A N/A 11289199 12/2021 Al-Ali et al. N/A N/A N/A 11289093 12/2021 Al-Ali et al. N/A N/A N/A N/A D950492 12/2021 Al-Ali et al. N/A N/A N/A D950492 12/2021 Al-Ali et al. N/A N/A N/A D950495 12/2021 Al-Ali et al. N/A N/A N/A D950580 12/2021 Al-Ali et al. N/A N/A D950580 12/2021 Al-Ali et al. N/A N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A N/A D950748 12/2021 Al-Ali et al. N/A N/A N/A 11382567 12/2021 Al-Ali et al. N/A N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A N/A 1145948 12/2021 Al-Ali et al. N/A N/A N/A 11462410 12/2021 Al-Ali et al. N/A N/A N/A 11462455 12/2021 Al-Ali et al. N/A N/A N/A 11462455 12/2021 Al-Ali et al. N/A N/A N/A 11462455 12/2021 Al-Ali et al. N/A N/A 11462455 12/2021 Al-Ali et al. N/A N/A	D921202	12/2020	Al-Ali et al.	N/A	N/A
D925597 12/2020 Chandran et al. N/A N/A D927699 12/2020 Al-Ali et al. N/A N/A 11076777 12/2020 Lee et al. N/A N/A 11114188 12/2020 Poeze et al. N/A N/A D933233 12/2020 Al-Ali et al. N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A 11145408 12/2020 Sampath et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Chan et al. N/A N/A 11191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A 1127939 12/2021 Al-Ali </td <td>11024064</td> <td>12/2020</td> <td>Muhsin et al.</td> <td>N/A</td> <td>N/A</td>	11024064	12/2020	Muhsin et al.	N/A	N/A
D927699 12/2020 Al-Ali et al. N/A N/A 11076777 12/2020 Lee et al. N/A N/A 11114188 12/2020 Poeze et al. N/A N/A D933232 12/2020 Al-Ali et al. N/A N/A D933233 12/2020 Al-Ali et al. N/A N/A 11145408 12/2020 Al-Ali et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11172909 12/2020 Al-Ali et al. N/A N/A 11185262 12/2020 Kiani et al. N/A N/A 11191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A 1122839 12/2021 Al-Ali et	11026604	12/2020	Chen et al.	N/A	N/A
11076777 12/2020 Lee et al. N/A N/A 11114188 12/2020 Poeze et al. N/A N/A D933232 12/2020 Al-Ali et al. N/A N/A D933233 12/2020 Al-Ali et al. N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A 11145408 12/2020 Sampath et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 11191484 12/2020 Kiani et al. N/A N/A 11946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali N/A N/A 11289199 12/2021 Al-Ali	D925597	12/2020	Chandran et al.	N/A	N/A
11114188	D927699	12/2020	Al-Ali et al.	N/A	N/A
D933232 12/2020 Al-Ali et al. N/A N/A D933233 12/2020 Al-Ali et al. N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A 11145408 12/2020 Sampath et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 1191484 12/2020 Kiani et al. N/A N/A 11946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A 1128021 12/2021 Al-Ali N/A N/A 1128021 12/2021 Muhsin et al.	11076777	12/2020	Lee et al.	N/A	N/A
D933233 12/2020 Al-Ali et al. N/A N/A D933234 12/2020 Al-Ali et al. N/A N/A 11145408 12/2020 Sampath et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 11191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A 11272839 12/2021 Ahmed N/A N/A 11289199 12/2021 Al-Ali N/A N/A 11298021 12/2021 Al-Ali N/A N/A D950492 12/2021 Wang et al. N/A<	11114188	12/2020	Poeze et al.	N/A	N/A
D933234 12/2020 Al-Ali et al. N/A N/A 11145408 12/2020 Sampath et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 1191484 12/2021 Ahmed N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946617 12/2021 Ahmed N/A N/A 1128319 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A 11289021 12/2021 Al-Ali N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A <td>D933232</td> <td>12/2020</td> <td>Al-Ali et al.</td> <td>N/A</td> <td>N/A</td>	D933232	12/2020	Al-Ali et al.	N/A	N/A
11145408 12/2020 Sampath et al. N/A N/A 11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 11191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946591 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali N/A N/A 11289199 12/2021 Al-Ali N/A N/A 11289021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A	D933233	12/2020	Al-Ali et al.	N/A	N/A
11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 11191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A 11272839 12/2021 Ahmed N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Wang et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A	D933234	12/2020	Al-Ali et al.	N/A	N/A
11147518 12/2020 Al-Ali et al. N/A N/A 11172909 12/2020 Chan et al. N/A N/A 11185262 12/2020 Al-Ali et al. N/A N/A 11191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946617 12/2021 Ahmed N/A N/A D946617 12/2021 Al-Ali et al. N/A N/A 1127839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A 11289199 12/2021 Al-Ali N/A N/A 11289021 12/2021 Muhsin et al. N/A N/A 11298021 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. <td< td=""><td>11145408</td><td>12/2020</td><td>Sampath et al.</td><td>N/A</td><td>N/A</td></td<>	11145408	12/2020	Sampath et al.	N/A	N/A
11185262 12/2020 Al-Ali et al. N/A N/A 11191484 12/2021 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946617 12/2021 Ahmed N/A N/A 1127839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A RE49034 12/2021 Muhsin et al. N/A N/A 1128021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A 11382567 12/2021 O'Brien et al. N/A	11147518	12/2020	-	N/A	N/A
11191484 12/2020 Kiani et al. N/A N/A D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946617 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950738 12/2021 Ahmed N/A N/A D957648 12/2021 Al-Ali et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/	11172909	12/2020	Chan et al.	N/A	N/A
D946596 12/2021 Ahmed N/A N/A D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946617 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11406286 12/2021 Triman et al.	11185262	12/2020	Al-Ali et al.	N/A	N/A
D946597 12/2021 Ahmed N/A N/A D946598 12/2021 Ahmed N/A N/A D946617 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali et al. N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11439329 12/2021 Buhsin et al. <	11191484	12/2020	Kiani et al.	N/A	N/A
D946598 12/2021 Ahmed N/A N/A D946617 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11439329 12/2021 Muhsin et al. N/A<	D946596	12/2021	Ahmed	N/A	N/A
D946617 12/2021 Ahmed N/A N/A 11272839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11439329 12/2021 Muhsin et al. N/A N/A 11445948 12/2021 Scruggs et al.	D946597	12/2021	Ahmed	N/A	N/A
11272839 12/2021 Al-Ali et al. N/A N/A 11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11406286 12/2021 Triman et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al.	D946598	12/2021	Ahmed	N/A	N/A
11289199 12/2021 Al-Ali N/A N/A RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11496286 12/2021 Triman et al. N/A N/A 11417426 12/2021 Al-Ali et al. N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Wang et al.	D946617	12/2021	Ahmed	N/A	N/A
RE49034 12/2021 Al-Ali N/A N/A 11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Al-Ali et al. N/A N/A D950738 12/2021 Al-Ali N/A N/A D957648 12/2021 Al-Ali N/A N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11445948 12/2021 Lamego N/A N/A 11445948 12/2021 Al-Ali et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Muhsin N/A N/A N/A 11464410 12/2021 Muhsin N/A N/A N/A 11464410 12/2021 Muhsin N/A N/A N/A N/A 11464410 12/2021 Muhsin N/A N/A N/A N/A 11464410 12/2021 Muhsin N/A N/A N/A N/A N/A 11484265 12/2021 Muhsin N/A N/A N/A	11272839	12/2021	Al-Ali et al.	N/A	N/A
11298021 12/2021 Muhsin et al. N/A N/A D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al.	11289199	12/2021	Al-Ali	N/A	N/A
D950492 12/2021 Wang et al. N/A N/A D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al.	RE49034	12/2021	Al-Ali	N/A	N/A
D950495 12/2021 Wang et al. N/A N/A D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. <td>11298021</td> <td>12/2021</td> <td>Muhsin et al.</td> <td>N/A</td> <td>N/A</td>	11298021	12/2021	Muhsin et al.	N/A	N/A
D950580 12/2021 Ahmed N/A N/A D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	D950492	12/2021	Wang et al.	N/A	N/A
D950599 12/2021 Ahmed N/A N/A D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	D950495	12/2021	Wang et al.	N/A	N/A
D950738 12/2021 Al-Ali et al. N/A N/A D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	D950580	12/2021	Ahmed	N/A	N/A
D957648 12/2021 Al-Ali N/A N/A 11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	D950599	12/2021	Ahmed	N/A	N/A
11382567 12/2021 O'Brien et al. N/A N/A 11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	D950738	12/2021	Al-Ali et al.	N/A	N/A
11389093 12/2021 Triman et al. N/A N/A 11406286 12/2021 Al-Ali et al. N/A N/A 11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	D957648	12/2021	Al-Ali	N/A	N/A
1140628612/2021Al-Ali et al.N/AN/A1141742612/2021Muhsin et al.N/AN/A1143932912/2021LamegoN/AN/A1144594812/2021Scruggs et al.N/AN/AD96578912/2021Al-Ali et al.N/AN/AD96743312/2021Al-Ali et al.N/AN/A1146441012/2021MuhsinN/AN/A1148426512/2021Wang et al.N/AN/A	11382567	12/2021	O'Brien et al.	N/A	N/A
11417426 12/2021 Muhsin et al. N/A N/A 11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	11389093	12/2021	Triman et al.	N/A	N/A
11439329 12/2021 Lamego N/A N/A 11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	11406286	12/2021	Al-Ali et al.	N/A	N/A
11445948 12/2021 Scruggs et al. N/A N/A D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	11417426	12/2021	Muhsin et al.	N/A	N/A
D965789 12/2021 Al-Ali et al. N/A N/A D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	11439329	12/2021	Lamego	N/A	N/A
D967433 12/2021 Al-Ali et al. N/A N/A 11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	11445948	12/2021	Scruggs et al.	N/A	N/A
11464410 12/2021 Muhsin N/A N/A 11484265 12/2021 Wang et al. N/A N/A	D965789	12/2021	Al-Ali et al.	N/A	N/A
11484265 12/2021 Wang et al. N/A N/A	D967433	12/2021	Al-Ali et al.	N/A	N/A
8	11464410	12/2021	Muhsin	N/A	N/A
11504058 12/2021 Sharma et al. N/A N/A	11484265	12/2021	Wang et al.	N/A	N/A
	11504058	12/2021	Sharma et al.	N/A	N/A

11504066	12/2021	Dalvi et al.	N/A	N/A
D971933	12/2021	Ahmed	N/A	N/A
D973072	12/2021	Ahmed	N/A	N/A
D973685	12/2021	Ahmed	N/A	N/A
D973686	12/2021	Ahmed	N/A	N/A
D974193	12/2022	Forrest et al.	N/A	N/A
D979516	12/2022	Al-Ali et al.	N/A	N/A
D980091	12/2022	Forrest et al.	N/A	N/A
11596363	12/2022	Lamego	N/A	N/A
11627919	12/2022	Kiani et al.	N/A	N/A
11637437	12/2022	Al-Ali et al.	N/A	N/A
D985498	12/2022	Al-Ali et al.	N/A	N/A
11653862	12/2022	Dalvi et al.	N/A	N/A
D989112	12/2022	Muhsin et al.	N/A	N/A
D989327	12/2022	Al-Ali et al.	N/A	N/A
11678829	12/2022	Al-Ali et al.	N/A	N/A
11679579	12/2022	Al-Ali	N/A	N/A
11684296	12/2022	Vo et al.	N/A	N/A
11692934	12/2022	Normand et al.	N/A	N/A
11701043	12/2022	Al-Ali et al.	N/A	N/A
D997365	12/2022	Hwang	N/A	N/A
11721105	12/2022	Ranasinghe et al.	N/A	N/A
11730379	12/2022	Ahmed et al.	N/A	N/A
D998625	12/2022	Indorf et al.	N/A	N/A
D998630	12/2022	Indorf et al.	N/A	N/A
D998631	12/2022	Indorf et al.	N/A	N/A
D999244	12/2022	Indorf et al.	N/A	N/A
D999245	12/2022	Indorf et al.	N/A	N/A
D999246	12/2022	Indorf et al.	N/A	N/A
11766198	12/2022	Pauley et al.	N/A	N/A
D1000975	12/2022	Al-Ali et al.	N/A	N/A
11803623	12/2022	Kiani et al.	N/A	N/A
11832940	12/2022	Diab et al.	N/A	N/A
D1013179	12/2023	Al-Ali et al.	N/A	N/A
11872156	12/2023	Telfort et al.	N/A	N/A
11879960	12/2023	Ranasinghe et al.	N/A	N/A
11883129	12/2023	Olsen	N/A	N/A
D1022729	12/2023	Forrest et al.	N/A	N/A
11951186	12/2023	Krishnamani et al.	N/A	N/A
11974833	12/2023	Forrest et al.	N/A	N/A
11986067	12/2023	Al-Ali et al.	N/A	N/A
11986289	12/2023	Dalvi et al.	N/A	N/A
11986305	12/2023	Al-Ali et al.	N/A	N/A
D1031729	12/2023	Forrest et al.	N/A	N/A
12004869	12/2023	Kiani et al.	N/A	N/A
12014328	12/2023	Wachman et al.	N/A	N/A
D1036293	12/2023	Al-Ali et al.	N/A	N/A
D1037462	12/2023	Al-Ali et al.	N/A	N/A
12029844	12/2023	Pauley et al.	N/A	N/A
12048534	12/2023	Vo et al.	N/A	N/A

12064217 12/2023 Ahmed et al. N/A	N/A
12066426 12/2023 Lapotko et al. N/A	N/A
D1041511 12/2023 Indorf et al. N/A	N/A
D1042596 12/2023 DeJong et al. N/A	N/A
D1042852 12/2023 Hwang N/A	N/A
12076159 12/2023 Belur Nagaraj et al. N/A	N/A
12082926 12/2023 Sharma et al. N/A	N/A
D1044828 12/2023 Chandran et al. N/A	N/A
D1048571 12/2023 Yu et al. N/A	N/A
D1048908 12/2023 Al-Ali et al. N/A	N/A
12106752 12/2023 Campbell et al. N/A	N/A
12114974 12/2023 Al-Ali et al. N/A	N/A
12126683 12/2023 Koo et al. N/A	N/A
12127838 12/2023 Olsen et al. N/A	N/A
12128213 12/2023 Kiani et al. N/A	N/A
12131661 12/2023 Pauley et al. N/A	N/A
D1050910 12/2023 Al-Ali et al. N/A	N/A
12178572 12/2023 Pauley et al. N/A	N/A
12178581 12/2023 Telfort et al. N/A	N/A
12178852 12/2023 Kiani et al. N/A	N/A
D1057159 12/2024 DeJong et al. N/A	N/A
D1057160 12/2024 DeJong et al. N/A	N/A
12198790 12/2024 Al-Ali N/A	N/A
12200421 12/2024 Campbell et al. N/A	N/A
12207901 12/2024 Lapotko et al. N/A	N/A
2001/0034477 12/2000 Mansfield et al. N/A	N/A
2001/0039483 12/2000 Brand et al. N/A	N/A
2002/0010401 12/2001 Bushmakin et al. N/A	
2002/0058864 12/2001 Mansfield et al. N/A	
2002/0133080 12/2001 Apruzzese et al. N/A	
2003/0013975 12/2002 Kiani N/A	
2003/0018243 12/2002 Gerhardt et al. N/A	
2003/0144582 12/2002 Cohen et al. N/A	
2003/0156288 12/2002 Barnum et al. N/A	
2003/0204130 12/2002 Colston et al. N/A	
2003/0212312 12/2002 Coffin, IV et al. N/A	
2004/0106163 12/2003 Workman, Jr. et al. N/A	
2005/0055276 12/2004 Kiani et al. N/A	
2005/0234317 12/2004 Kiani N/A	
2006/0073719 12/2005 Kiani N/A	
2006/0189871 12/2005 Al-Ali et al. N/A	
2007/0073116 12/2006 Kiani et al. N/A	
2007/0180140 12/2006 Welch et al. N/A	
2007/0244377 12/2006 Cozad et al. N/A	
2008/0064965 12/2007 Jay et al. N/A	
2008/0094228 12/2007 Welch et al. N/A	
2008/0103375 12/2007 Kiani N/A	
2008/0221418 12/2007 Al-Ali et al. N/A	
2009/0036759 12/2008 Ault et al. N/A	N/A

2009/0095887 12/2008	2009/0076840	12/2008	Boyden	705/2	G16H
2009/0095926 12/2008 MacNeish, III N/A N/A 2009/0247984 12/2008 Lamego et al. N/A N/A 2009/0275844 12/2009 Al-Ali N/A N/A 2010/0030040 12/2009 Vo et al. N/A N/A 2010/0039964 12/2009 O'Reilly et al. N/A N/A 2010/0234718 12/2009 Sampath et al. N/A N/A 2011/00234718 12/2009 Wachman et al. N/A N/A 2011/0028806 12/2010 Merritt et al. N/A N/A 2011/0028809 12/2010 Goodman N/A N/A 2011/0087081 12/2010 Welch et al. N/A N/A 2011/0087081 12/2010 Kiani et al. N/A N/A 2011/018561 12/2010 Kiani et al. N/A N/A 2011/0172498 12/2010 Goodman N/A N/A 2011/0230733 12/2010 Kiani et al. N/A N/A			, and the second		
2009/0247984 12/2008 Lamego et al. N/A N/A 2009/0275844 12/2009 Vo et al. N/A N/A 2010/0030040 12/2009 Vo et al. N/A N/A 2010/0039964 12/2009 Poeze et al. N/A N/A 2010/0234718 12/2009 Sampath et al. N/A N/A 2011/0028806 12/2010 Merritt et al. N/A N/A 2011/0028809 12/2010 Goodman N/A N/A 2011/0082711 12/2010 Welch et al. N/A N/A 2011/0087081 12/2010 Welch et al. N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A 2011/0137297 12/2010 Olsen et al. N/A N/A 2011/0137293 12/2010 Al-Ali N/A N/A 2011/0137294 12/2010 Al-Ali N/A N/A <					
2009/0275844 12/2008					
2010/0004518 12/2009 Vo et al. N/A N/A 2010/0030040 12/2009 Poeze et al. N/A N/A N/A 2010/0039964 12/2009 O'Reilly et al. N/A N/A 2010/00234718 12/2009 Sampath et al. N/A N/A N/A 2010/0270257 12/2009 Wachman et al. N/A N/A 2011/0028806 12/2010 Merritt et al. N/A N/A 2011/0028809 12/2010 Goodman N/A N/A 2011/0040197 12/2010 Welch et al. N/A N/A N/A 2011/0087081 12/2010 Poeze et al. N/A N/A N/A 2011/0087081 12/2010 Tari et al. N/A N/A N/A 2011/018561 12/2010 Kiani et al. N/A N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A N/A 2011/0137297 12/2010 Olsen et al. N/A N/A 2011/0137297 12/2010 Olsen et al. N/A N/A 2011/013230733 12/2010 Olsen et al. N/A N/A 2012/0165629 12/2011 O'Reilly N/A N/A 2012/0165629 12/2011 Olsen et al. N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0233524 12/2011 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/00341591 12/2012 Lamego et al. N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0096672 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2014/0323898 12/2014 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0035600 12/2014 Blank			9		
2010/0030040					
2010/0099964 12/2009 O'Reilly et al. N/A N/A 2010/0234718 12/2009 Sampath et al. N/A N/A 2010/0270257 12/2009 Wachman et al. N/A N/A 2011/0028806 12/2010 Merritt et al. N/A N/A 2011/0028809 12/2010 Goodman N/A N/A N/A 2011/0040197 12/2010 Poeze et al. N/A N/A 2011/0087081 12/2010 Riani et al. N/A N/A 2011/0087081 12/2010 Tari et al. N/A N/A 2011/018561 12/2010 Tari et al. N/A N/A N/A 2011/0137297 12/2010 Glosen et al. N/A N/A 2011/0137297 12/2010 Olsen et al. N/A N/A 2011/0137297 12/2010 Olsen et al. N/A N/A 2011/0137293 12/2010 Olsen et al. N/A N/A 2012/0132331 12/2011 O'Reilly N/A N/A 2012/0165629 12/2011 O'Reilly N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A 2013/004055 12/2012 Garfio N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0396672 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Almogy 706/52 G16H 2013/0345921 12/2012 Almogy 706/52 G16H 2014/018073 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Brown et al. N/A N/A 2014/0316218 12/2013 Brown et al. N/A N/A 2014/0316218 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Brown et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Brown et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0019950 12/2014 Blank et al. N/A N/A 2015/0019950 12/2014 Blank et al. N/A N/A 2015/0019950 12/2014 Al-Ali et al. N/A N/A 2015/0019950 12/2014 Al-Ali et al. N/A N/A 2015/0019950 12/2014 Al-Ali et a					
2010/0234718 12/2009 Sampath et al. N/A N/A 2011/0028806 12/2010 Merritt et al. N/A N/A N/A 2011/0028806 12/2010 Merritt et al. N/A N/A N/A 2011/0028809 12/2010 Welch et al. N/A N/A N/A 2011/0040197 12/2010 Welch et al. N/A N/A N/A 2011/0087081 12/2010 Kiani et al. N/A N/A N/A 2011/018561 12/2010 Kiani et al. N/A N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A N/A 2011/0137297 12/2010 Al-Ali N/A N/A N/A 2011/0230733 12/2010 Al-Ali N/A N/A N/A 2012/0123231 12/2011 O'Reilly N/A N/A 2012/0123231 12/2011 O'Reilly N/A N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/02263524 12/2011 Lamego et al. N/A N/A 2012/02263524 12/2011 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego et al. N/A N/A 2013/0060147 12/2012 Garfio N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Almogy 706/52 50/20 2013/0345921 12/2013 Riani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/01807973 12/2013 Brown et al. N/A N/A 2014/0316218 12/2013 Brown et al. N/A N/A 2014/0316217 12/2013 Brown et al. N/A N/A 2014/033898 12/2013 Brown et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0019652 12/2014 Blank et al. N/A N/A 2015/0019652 12/2014 Blank et al. N/A N/A 2015/0019650 12/2014 Blank et a				•	
2010/0270257 12/2009 Wachman et al. N/A N/A N/A 2011/0028806 12/2010 Merritt et al. N/A N/A N/A 2011/0028809 12/2010 Goodman N/A N/A N/A 2011/0040197 12/2010 Welch et al. N/A N/A N/A 2011/0082711 12/2010 Poeze et al. N/A N/A N/A 2011/0087081 12/2010 Kiani et al. N/A N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A N/A 2011/0137297 12/2010 Goodman N/A N/A N/A 2011/0137297 12/2010 Goodman N/A N/A N/A 2011/0137297 12/2010 Goodman N/A N/A N/A 2011/0123233 12/2010 Olsen et al. N/A N/A N/A 2011/0230733 12/2011 OReilly N/A N/A N/A 2012/0165629 12/2011 Merritt et al. N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0209084 12/2011 Clsen et al. N/A N/A 2013/0023775 12/2011 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego N/A N/A 2013/0060147 12/2012 Garfio N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Almogy 706/52 50/20 2013/0345921 12/2013 Brown et al. N/A N/A 2014/0166076 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Brown et al. N/A N/A 2014/0316218 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/001907 12/2014 Blank et al. N/A N/A 2015/001907 12/2014 Blank et al. N/A N/A 2015/001907 12/2014 Blank et al. N/A N/A 2015/0019050 12/2014 Blank et al. N/A N/A 2015/0019050 12/2014 Blank et al. N/A N/A 2015/0019050 12/2014 Blank et al.			<u>-</u>		
2011/0028806 12/2010 Merritt et al. N/A N/A 2011/0028809 12/2010 Goodman N/A N/A 2011/0040197 12/2010 Welch et al. N/A N/A 2011/0087081 12/2010 Kiani et al. N/A N/A 2011/018561 12/2010 Kiani et al. N/A N/A 2011/0172498 12/2010 Kiani et al. N/A N/A 2011/0123231 12/2010 Al-Ali N/A N/A 2012/0165629 12/2011 O'Reilly N/A N/A 2012/0209084 12/2011 Dlsen et al. N/A N/A 2012/0283524 12/2011 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego et al. N/A N/A 2013/00404591 12/2012 Lamego et al. N/A N/A 2013/0345921 12/2012 Garfio N/A N/A 2014/0180606 12/2013 Kiani et al. N/A N/A					
2011/0028809 12/2010 Goodman N/A N/A 2011/0040197 12/2010 Welch et al. N/A N/A 2011/0087081 12/2010 Kiani et al. N/A N/A 2011/018561 12/2010 Tari et al. N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A 2011/0172498 12/2010 Olsen et al. N/A N/A 2011/0230733 12/2010 Al-Ali N/A N/A 2012/0165629 12/2011 O'Reilly N/A N/A 2012/029084 12/2011 Olsen et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2013/0023755 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego et al. N/A N/A 2013/00960405 12/2012 Garfio N/A N/A 2013/0318027 12/2012 Al-Ali et al. N/A N/A <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
2011/0040197 12/2010 Welch et al. N/A N/A 2011/0082711 12/2010 Poeze et al. N/A N/A 2011/0087081 12/2010 Kiani et al. N/A N/A 2011/0118561 12/2010 Tari et al. N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A 2011/0230733 12/2010 Olsen et al. N/A N/A 2012/0165629 12/2011 O'Reilly N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0283524 12/2011 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego et al. N/A N/A 2013/00404591 12/2012 Lamego et al. N/A N/A 2013/00404591 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Almogy 706/52 50/20 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
2011/0087081 12/2010 Poeze et al. N/A N/A 2011/0087081 12/2010 Kiani et al. N/A N/A 2011/0118561 12/2010 Tari et al. N/A N/A 2011/0172498 12/2010 Olsen et al. N/A N/A 2011/0230733 12/2011 Olsen et al. N/A N/A 2012/0165629 12/2011 O'Reilly N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/022617 12/2011 Lamego et al. N/A N/A 2013/022775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego et al. N/A N/A 2013/0046045 12/2012 Lamego et al. N/A N/A 2013/004607 12/2012 Garfio N/A N/A 2013/0345921 12/2012 O'Neil et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A					
2011/0087081 12/2010 Kiani et al. N/A N/A 2011/0118561 12/2010 Tari et al. N/A N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A N/A 2011/0172498 12/2010 Olsen et al. N/A N/A N/A 2011/030733 12/2011 O'Reilly N/A N/A N/A 2012/0123231 12/2011 O'Reilly N/A N/A N/A 2012/0165629 12/2011 Merritt et al. N/A N/A N/A 2012/0209084 12/2011 Lamego et al. N/A N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A N/A 2013/0060147 12/2012 Garfio N/A N/A N/A 2013/0396405 12/2012 Garfio N/A N/A N/A 2013/0396672 12/2012 O'Neil et al. N/A N/A 2013/0318027 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Almogy 706/52 50/20 2013/0345921 12/2013 Kiani et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275872 12/2013 Brown et al. N/A N/A 2014/0275872 12/2013 Brown et al. N/A N/A 2014/0316217 12/2013 Brown et al. N/A N/A 2014/0316217 12/2013 Brown et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0009950 12/2014 Purdon et al. N/A N/A 2015/0032652 12/2015 Chapman Bates 706/11 50/20			Welch et al.		
2011/0118561 12/2010 Tari et al. N/A N/A 2011/0137297 12/2010 Kiani et al. N/A N/A 2011/0172498 12/2010 Olsen et al. N/A N/A 2011/023733 12/2011 O'Reilly N/A N/A 2012/0165629 12/2011 Merritt et al. N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0283524 12/2011 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego et al. N/A N/A 2013/0060147 12/2012 Lamego et al. N/A N/A 2013/0040591 12/2012 Lamego et al. N/A N/A 2013/0345921 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A			Poeze et al.	N/A	N/A
2011/0137297 12/2010 Kiani et al. N/A N/A 2011/0172498 12/2010 Olsen et al. N/A N/A 2011/0230733 12/2010 Al-Ali N/A N/A 2012/0123231 12/2011 O'Reilly N/A N/A 2012/0266529 12/2011 Merritt et al. N/A N/A 2012/029084 12/2011 Lamego et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0396672 12/2012 O'Neil et al. N/A N/A 2013/0345921 12/2012 Almogy 706/52 50/20 2013/0345921 12/2013 Kiani et al. N/A N/A 2014/0166076 12/2013 Brown et al. N/A N/A 2014/01801		12/2010	Kiani et al.	N/A	N/A
2011/0172498 12/2010 Olsen et al. N/A N/A 2011/0230733 12/2010 Al-Ali N/A N/A 2012/0123231 12/2011 O'Reilly N/A N/A 2012/0165629 12/2011 Merritt et al. N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2013/0283524 12/2011 Kiani et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A 2013/0060147 12/2012 Welch et al. N/A N/A 2013/03096672 12/2012 O'Neil et al. N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A	2011/0118561	12/2010	Tari et al.	N/A	N/A
2011/0230733 12/2010 Al-Ali N/A N/A 2012/0123231 12/2011 O'Reilly N/A N/A 2012/0165629 12/2011 Merritt et al. N/A N/A 2012/0226117 12/2011 Olsen et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2012/0228524 12/2012 Lamego et al. N/A N/A 2013/023775 12/2012 Lamego et al. N/A N/A 2013/03041591 12/2012 Lamego N/A N/A 2013/03060147 12/2012 Garfio N/A N/A 2013/03096672 12/2012 Garfio N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A <t< td=""><td>2011/0137297</td><td>12/2010</td><td>Kiani et al.</td><td>N/A</td><td>N/A</td></t<>	2011/0137297	12/2010	Kiani et al.	N/A	N/A
2012/0123231 12/2011 O'Reilly N/A N/A 2012/0165629 12/2011 Merritt et al. N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2012/0283524 12/2011 Kiani et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0318027 12/2012 O'Neil et al. N/A N/A 2013/0318027 12/2012 Almogy 706/52 50/20 2013/0318027 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A	2011/0172498	12/2010	Olsen et al.	N/A	N/A
2012/0165629 12/2011 Merritt et al. N/A N/A 2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2012/0283524 12/2011 Kiani et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A 2013/0096405 12/2012 Welch et al. N/A N/A 2013/0318027 12/2012 O'Neil et al. N/A N/A 2013/0345921 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/016076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Brown et al. N/A N/A 2014/0275872 12/2013 Purdon et al. N/A N/A	2011/0230733	12/2010	Al-Ali	N/A	N/A
2012/0209084 12/2011 Olsen et al. N/A N/A 2012/0226117 12/2011 Lamego et al. N/A N/A 2012/0283524 12/2011 Kiani et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0060147 12/2012 Lamego N/A N/A 2013/0396405 12/2012 Garfio N/A N/A 2013/0318027 12/2012 O'Neil et al. N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A	2012/0123231	12/2011	O'Reilly	N/A	N/A
2012/0226117 12/2011 Lamego et al. N/A N/A 2012/0283524 12/2011 Kiani et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A 2013/03060147 12/2012 Welch et al. N/A N/A 2013/03096405 12/2012 Garfio N/A N/A 2013/0318027 12/2012 Almogy 706/52 50/20 2013/0318027 12/2012 Al-Ali et al. N/A N/A 2014/0318027 12/2012 Al-Ali et al. N/A N/A 2014/0316076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0375871 12/2013 Lamego et al. N/A N/A 2014/0375872 12/2013 Purdon et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A	2012/0165629	12/2011	Merritt et al.	N/A	N/A
2012/0283524 12/2011 Kiani et al. N/A N/A 2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A 2013/0060147 12/2012 Welch et al. N/A N/A 2013/03096405 12/2012 Garfio N/A N/A 2013/0318027 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0275872 12/2013 Merritt et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Purdon et al. N/A N/A	2012/0209084	12/2011	Olsen et al.	N/A	N/A
2013/0023775 12/2012 Lamego et al. N/A N/A 2013/0041591 12/2012 Lamego N/A N/A 2013/0060147 12/2012 Welch et al. N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/03296672 12/2012 O'Neil et al. N/A N/A 2013/0318027 12/2012 Almogy 706/52 G16H 50/20 50/20 50/20 50/20 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600	2012/0226117	12/2011	Lamego et al.	N/A	N/A
2013/0041591 12/2012 Lamego N/A N/A 2013/0060147 12/2012 Welch et al. N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0296672 12/2012 O'Neil et al. N/A N/A 2013/0318027 12/2012 Almogy 706/52 G16H 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A	2012/0283524	12/2011	Kiani et al.	N/A	N/A
2013/0060147 12/2012 Welch et al. N/A N/A 2013/0096405 12/2012 Garfio N/A N/A 2013/0296672 12/2012 O'Neil et al. N/A N/A 2013/0318027 12/2012 Al-Ali et al. N/A N/A 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0073241 12/2014 Purdon et al. N/A N/A <td>2013/0023775</td> <td>12/2012</td> <td>Lamego et al.</td> <td>N/A</td> <td>N/A</td>	2013/0023775	12/2012	Lamego et al.	N/A	N/A
2013/0096405 12/2012 Garfio N/A N/A 2013/0296672 12/2012 O'Neil et al. N/A N/A 2013/0318027 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0275872 12/2013 Purdon et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0073241 12/2014 Purdon et al. N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A	2013/0041591	12/2012	Lamego	N/A	N/A
2013/0296672 12/2012 O'Neil et al. N/A N/A 2013/0318027 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0073241 12/2014 Purdon et al. N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A	2013/0060147	12/2012	Welch et al.	N/A	N/A
2013/0318027 12/2012 Almogy 706/52 G16H 50/20 2013/0345921 12/2012 Al-Ali et al. N/A N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A N/A 2015/0073241 12/2014 Purdon et al. N/A N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 50/20	2013/0096405	12/2012	Garfio	N/A	N/A
2013/0318027 12/2012 Almogy 706/52 50/20 2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0316217 12/2013 Merritt et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0073241 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Purdon et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 50/20	2013/0296672	12/2012	O'Neil et al.	N/A	N/A
2013/0345921 12/2012 Al-Ali et al. N/A N/A 2014/0166076 12/2013 Kiani et al. N/A N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0275872 12/2013 Merritt et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Brown et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 50/20	2013/0318027	12/2012	Almogy	706/52	G16H
2014/0166076 12/2013 Kiani et al. N/A N/A 2014/0180160 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0275872 12/2013 Merritt et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0073241 12/2014 Purdon et al. N/A N/A 2015/0089950 12/2014 Purdon et al. N/A N/A 2016/0132652 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 50/20<					
2014/0180160 12/2013 Brown et al. N/A N/A 2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0275872 12/2013 Merritt et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2015/0005600 12/2013 Purdon et al. N/A N/A 2015/0011907 12/2014 Blank et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2014/0187973 12/2013 Brown et al. N/A N/A 2014/0275871 12/2013 Lamego et al. N/A N/A 2014/0275872 12/2013 Merritt et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/008073241 12/2014 Lamego N/A N/A 2015/0099950 12/2014 Purdon et al. N/A N/A 2016/0132652 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2014/027587112/2013Lamego et al.N/AN/A2014/027587212/2013Merritt et al.N/AN/A2014/031621712/2013Purdon et al.N/AN/A2014/031621812/2013Purdon et al.N/AN/A2014/032389712/2013Brown et al.N/AN/A2014/032389812/2013Purdon et al.N/AN/A2015/000560012/2014Blank et al.N/AN/A2015/001190712/2014Purdon et al.N/AN/A2015/007324112/2014LamegoN/AN/A2015/008075412/2014Purdon et al.N/AN/A2015/009995012/2014Al-Ali et al.N/AN/A2016/013265212/2015Chapman Bates706/11G16H 50/20					
2014/0275872 12/2013 Merritt et al. N/A N/A 2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H 50/20					
2014/0316217 12/2013 Purdon et al. N/A N/A 2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2014/0316218 12/2013 Purdon et al. N/A N/A 2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2014/0323897 12/2013 Brown et al. N/A N/A 2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2014/0323898 12/2013 Purdon et al. N/A N/A 2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2015/0005600 12/2014 Blank et al. N/A N/A 2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2015/0011907 12/2014 Purdon et al. N/A N/A 2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H					
2015/0073241 12/2014 Lamego N/A N/A 2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H 50/20					
2015/0080754 12/2014 Purdon et al. N/A N/A 2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H 50/20					
2015/0099950 12/2014 Al-Ali et al. N/A N/A 2016/0132652 12/2015 Chapman Bates 706/11 G16H 50/20			<u> </u>		
2016/0132652 12/2015 Chapman Bates 706/11 G16H 50/20					
2016/0132652 12/2015 Chapman Bates 706/11 50/20	2015/0099950	12/2014	Al-Ali et al.	N/A	
	2016/0132652	12/2015	Chapman Bates	706/11	
2016/0196388 12/2015 Lamego N/A N/A	2016/0196388	12/2015	Lamego	N/A	

2016/0367173 12/2015 Dalvi et al. N/A N/A 2017/0024531 12/2016 Malaviya N/A N/A 2017/0024748 12/2016 Haider N/A N/A 2017/0173632 12/2016 Al-Ali N/A N/A 2017/0235369 12/2016 Acer et al. N/A N/A 2017/0235369 12/2016 Shreim et al. N/A N/A 2017/0351974 12/2016 Shreim et al. N/A N/A 2017/0352119 12/2016 Pittman et al. N/A N/A 2017/0372026 12/2016 Sanyal N/A S/681 2018/0103874 12/2017 Lee et al. N/A N/A 2018/024926 12/2017 Muhsin et al. N/A N/A 2018/0247353 12/2017 Al-Ali et al. N/A N/A 2018/024936 12/2017 Al-Ali et al. N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0310822 12/2017 Muhsin et al. N/A N/A 2018/0310823 12/2017 Al-Ali et al. N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0329096 12/2018 Muhsin et al. N/A N/A 2019/0329096 12/2018 Pauley et al. N/A N/A 2019/032906 12/2018 Glsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/037413 12/2018 Kiani et al. N/A N/A 2020/0069281 12/2019 Telfort et al. N/A N/A 2020/00113488 12/2019 Telfort et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113496 12/2019 Triman et al. N/A N/A 2020/0138288 12/2019 Telfort et al. N/A N/A 2020/0138288 12/2019 Telfort et al. N/A N/A 2020/0138288 12/2019 Telfort et al. N/A N/A 2020/01382984 12/2019 Telfort et al. N/A N/A 2020/0329984 12/2019	2016/0283665	12/2015	Sampath et al.	N/A	N/A
2017/0024531			-		
2017/0024748 12/2016					
2017/0173632 12/2016 Al-Ali N/A N/A 2017/0235369 12/2016 Acer et al. N/A N/A 2017/0251974 12/2016 Shreim et al. N/A N/A 2017/031891 12/2016 Kiani et al. N/A N/A 2017/0372026 12/2016 Sanyal N/A A61B 2018/0103874 12/2017 Lee et al. N/A N/A 2018/0247353 12/2017 Muhsin et al. N/A N/A 2018/0247712 12/2017 Muhsin et al. N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0310823 12/2017 Muhsin et al. N/A N/A 2018/0310823 12/2017 Indorf et al. N/A N/A 2019/011070 12/2018 Monfre N/A N/A 2019/0239787 12/2018 Muhsin et al. N/A N/A 2019/0329987 12/2018 Chandran et al. N/A N/A			_		
2017/0235369 12/2016 Acer et al. N/A N/A 2017/0251974 12/2016 Shreim et al. N/A N/A N/A 2017/0352119 12/2016 Pittman et al. N/A N/A N/A 2017/0352119 12/2016 Pittman et al. N/A N/A N/A 2017/0372026 12/2016 Sanyal N/A S/681 2018/0103874 12/2017 Lee et al. N/A N/A N/A 2018/0242926 12/2017 Muhsin et al. N/A N/A N/A 2018/0247712 12/2017 Al-Ali et al. N/A N/A 2018/0247712 12/2017 Muhsin et al. N/A N/A 2018/0256087 12/2017 Al-Ali et al. N/A N/A 2018/030919 12/2017 Muhsin et al. N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0310822 12/2017 Indorf et al. N/A N/A 2018/0310823 12/2017 Al-Ali et al. N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0015023 12/2018 Muhsin et al. N/A N/A 2019/0200941 12/2018 Chandran et al. N/A N/A 2019/0329787 12/2018 Chandran et al. N/A N/A 2019/0329096 12/2018 Glsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2020/0060669 12/2019 Telfort et al. N/A N/A 2020/0013435 12/2019 Chan et al. N/A N/A 2020/0113455 12/2019 Al-Ali et al. N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113828 12/2019 Al-Ali et al. N/A N/A 2020/0138288 12/2019 Dalvi et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138284 12/2019 Al-Ali et al. N/A N/A 2020/028883 12/2019 Al-Ali et al. N/A N/A 2020/028883 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 A					
2017/0251974 12/2016 Shreim et al. N/A N/A			Acer et al.		
2017/0352119 12/2016 Pittman et al. N/A A61B					
2017/0372026 12/2016 Sanyal N/A 5/681 2018/0103874 12/2017 Lee et al. N/A N/A 2018/0242926 12/2017 Muhsin et al. N/A N/A 2018/0247353 12/2017 Al-Ali et al. N/A N/A 2018/0256087 12/2017 Al-Ali et al. N/A N/A 2018/0300919 12/2017 Al-Ali et al. N/A N/A 2018/0310822 12/2017 Indorf et al. N/A N/A 2018/0310823 12/2017 Al-Ali et al. N/A N/A 2019/0117070 12/2018 Monfre N/A N/A 2019/020941 12/2018 Chandran et al. N/A N/A 2019/0329966 12/2018 Chandran et al. N/A N/A 2019/037413 12/2018 Kiani et al. N/A N/A 2020/0660869 12/2019 Telfort et al. N/A N/A 2020/0113495 12/2019 Ahmed N/A N/A <tr< td=""><td>2017/0311891</td><td>12/2016</td><td>Kiani et al.</td><td>N/A</td><td>N/A</td></tr<>	2017/0311891	12/2016	Kiani et al.	N/A	N/A
2017/03/2026 12/2016 Sanyal N/A 5/681	2017/0352119	12/2016	Pittman et al.	N/A	N/A
2018/0103874 12/2017 Lee et al. N/A N/A 2018/0242926 12/2017 Muhsin et al. N/A N/A N/A 2018/0247353 12/2017 Al-Ali et al. N/A N/A N/A 2018/0247712 12/2017 Muhsin et al. N/A N/A N/A 2018/0256087 12/2017 Al-Ali et al. N/A N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A N/A 2018/0310822 12/2017 Indorf et al. N/A N/A N/A 2018/0310823 12/2017 Al-Ali et al. N/A N/A N/A 2019/0015023 12/2018 Monfre N/A N/A N/A 2019/0015023 12/2018 Muhsin et al. N/A N/A N/A 2019/0200941 12/2018 Muhsin et al. N/A N/A N/A 2019/0200941 12/2018 Chandran et al. N/A N/A 2019/0200941 12/2018 Chandran et al. N/A N/A 2019/0320906 12/2018 Olsen N/A N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0060869 12/2019 Wang et al. N/A N/A 2020/00113435 12/2019 Wang et al. N/A N/A 2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Ahmed N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113496 12/2019 Triman et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113497 12/2019 Kiani et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113497 12/2019 Hahel et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A N/A 2020/0138368 12/2019 Muhsin et al. N/A N/A N/A 2020/0138368 12/2019 Muhsin et al. N/A N/A N/A 2020/0138288 12/2019 Muhsin et al. N/A N/A N/A 2020/0138368 12/2019 Al-Ali et al. N/A N/A N/A 2020/0138368 12/2019 Al-Ali et al. N/A N/A N/A 2020/025344 12/2019 Telfort et al. N/A N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2	2017/0272026	12/2016	Convol	NT/A	A61B
2018/0242926 12/2017 Muhsin et al. N/A N/A 2018/0247353 12/2017 Al-Ali et al. N/A N/A 2018/0256087 12/2017 Muhsin et al. N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0310822 12/2017 Indorf et al. N/A N/A 2018/0310823 12/2017 Al-Ali et al. N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0117070 12/2018 Muhsin et al. N/A N/A 2019/0239787 12/2018 Chandran et al. N/A N/A 2019/0324713 12/2018 Glsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0069281 12/2019 Wang et al. N/A N/A 2020/0113495 12/2019 Muhsin N/A N/A			-		
2018/0247353 12/2017 Al-Ali et al. N/A N/A 2018/0247712 12/2017 Muhsin et al. N/A N/A 2018/036087 12/2017 Al-Ali et al. N/A N/A 2018/0310822 12/2017 Muhsin et al. N/A N/A 2018/0310823 12/2017 Al-Ali et al. N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0210941 12/2018 Muhsin et al. N/A N/A 2019/0239787 12/2018 Chandran et al. N/A N/A 2019/0374139 12/2018 Glsen N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0606869 12/2019 Telfort et al. N/A N/A 2020/0608613 12/2019 Telfort et al. N/A N/A 2020/0113493 12/2019 Ahmed N/A N/A 2020/0113496 12/2019 Al-Ali et al. N/A N/A <tr< td=""><td></td><td></td><td></td><td></td><td></td></tr<>					
2018/0247712 12/2017 Muhsin et al. N/A N/A 2018/0256087 12/2017 Al-Ali et al. N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0310822 12/2017 Indorf et al. N/A N/A 2018/0310823 12/2018 Monfre N/A N/A 2019/010700 12/2018 Monfre N/A N/A 2019/0117070 12/2018 Chandran et al. N/A N/A 2019/0239787 12/2018 Chandran et al. N/A N/A 2019/0329006 12/2018 Olsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0069281 12/2019 Telfort et al. N/A N/A 2020/00113435 12/2019 Wang et al. N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A <tr< td=""><td></td><td></td><td></td><td></td><td></td></tr<>					
2018/0256087 12/2017 Al-Ali et al. N/A N/A 2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0310822 12/2017 Indorf et al. N/A N/A 2018/0310823 12/2018 Monfre N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0117070 12/2018 Muhsin et al. N/A N/A 2019/0209941 12/2018 Chandran et al. N/A N/A 2019/0329787 12/2018 Olsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0669281 12/2019 Telfort et al. N/A N/A 2020/0611552 12/2019 Wang et al. N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Al-Ali et al. N/A N/A					
2018/0300919 12/2017 Muhsin et al. N/A N/A 2018/0310822 12/2017 Indorf et al. N/A N/A 2018/0310823 12/2018 Monfre N/A N/A 2019/015023 12/2018 Monfre N/A N/A 2019/017070 12/2018 Muhsin et al. N/A N/A 2019/0239787 12/2018 Chandran et al. N/A N/A 2019/0374139 12/2018 Glsen N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0069281 12/2019 Chan et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0113435 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Al-Ali et al. N/A N/A 2020/0113497 12/2019 Abdul-Hafiz et al. N/A N/A <tr< td=""><td></td><td></td><td></td><td></td><td></td></tr<>					
2018/0310822 12/2017 Indorf et al. N/A N/A 2018/0310823 12/2017 Al-Ali et al. N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0200941 12/2018 Muhsin et al. N/A N/A 2019/0239787 12/2018 Chandran et al. N/A N/A 2019/0329906 12/2018 Olsen N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2019 Telfort et al. N/A N/A 2020/0069281 12/2019 Chan et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0113495 12/2019 Ahmed N/A N/A 2020/0113496 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Triman et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A					
2018/0310823 12/2017 Al-Ali et al. N/A N/A 2019/0015023 12/2018 Monfre N/A N/A 2019/0117070 12/2018 Muhsin et al. N/A N/A 2019/0220941 12/2018 Chandran et al. N/A N/A 2019/0239787 12/2018 Chandran et al. N/A N/A 2019/0374139 12/2018 Clisen N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0086133 12/2019 Chan et al. N/A N/A 2020/0113455 12/2019 Ahmed N/A N/A 2020/0113488 12/2019 Muhsin N/A N/A 2020/0113496 12/2019 Al-Ali et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A		· -			
2019/0015023 12/2018 Monfre N/A N/A 2019/0117070 12/2018 Muhsin et al. N/A N/A 2019/0200941 12/2018 Chandran et al. N/A N/A 2019/03239787 12/2018 Pauley et al. N/A N/A 2019/0320906 12/2018 Olsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/066869 12/2019 Telfort et al. N/A N/A 2020/0686133 12/2019 Wang et al. N/A N/A 2020/0113435 12/2019 Ahmed N/A N/A 2020/0113488 12/2019 Scruggs et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A					
2019/0117070 12/2018 Muhsin et al. N/A N/A 2019/0209941 12/2018 Chandran et al. N/A N/A 2019/0329787 12/2018 Pauley et al. N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2019 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0069281 12/2019 Chan et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0113435 12/2019 Al-Mmed N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113828 12/2019 Al-Ali et al. N/A N/A 2020/0138268 12/2019 Kiani et al. N/A N/A <					
2019/0200941 12/2018 Chandran et al. N/A N/A 2019/0239787 12/2018 Pauley et al. N/A N/A 2019/0320906 12/2018 Olsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0111552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Al-Ali et al. N/A N/A 2020/0113488 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113828 12/2019 Al-Ali et al. N/A N/A 2020/0146621 12/2019 Kiani et al. N/A N/A 2020/0163597 12/2019 Wang et al. N/A N/A <					
2019/0239787 12/2018 Pauley et al. N/A N/A 2019/0320906 12/2018 Olsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0086133 12/2019 Chan et al. N/A N/A 2020/0111552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Al-Ali et al. N/A N/A 2020/0113488 12/2019 Scruggs et al. N/A N/A 2020/0113496 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A 2020/0166597 12/2019 Wang et al. N/A N/A 2020/0253474 12/2019 Wushsin et al. N/A N/A					
2019/0320906 12/2018 Olsen N/A N/A 2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0111552 12/2019 Ahmed N/A N/A 2020/0113455 12/2019 Al-Ali et al. N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A 2020/0166527 12/2019 Wang et al. N/A N/A 2020/0168898 12/2019 Wang et al. N/A N/A					
2019/0374139 12/2018 Kiani et al. N/A N/A 2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0069281 12/2019 Chan et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/011552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Scruggs et al. N/A N/A 2020/0113496 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0196877 12/2019 Dalvi et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A			_		
2019/0374713 12/2018 Kiani et al. N/A N/A 2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0069281 12/2019 Chan et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0111552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Wang et al. N/A N/A 2020/0253474 12/2019 Wuhsin et al. N/A N/A				-	
2020/0060869 12/2019 Telfort et al. N/A N/A 2020/0069281 12/2019 Chan et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0111552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A					
2020/0069281 12/2019 Chan et al. N/A N/A 2020/0086133 12/2019 Wang et al. N/A N/A 2020/0111552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Wang et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/025344 12/2019 Telfort et al. N/A N/A 2020/0258983 12/2019 Telfort et al. N/A N/A					
2020/0086133 12/2019 Wang et al. N/A N/A 2020/0111552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A				-	
2020/0111552 12/2019 Ahmed N/A N/A 2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0253474 12/2019 Wo et al. N/A N/A 2020/0253544 12/2019 Telfort et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A					
2020/0113435 12/2019 Muhsin N/A N/A 2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Telfort et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A					
2020/0113488 12/2019 Al-Ali et al. N/A N/A 2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Wang et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Telfort et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A <td></td> <td></td> <td></td> <td></td> <td></td>					
2020/0113496 12/2019 Scruggs et al. N/A N/A 2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0253474 12/2019 Wuhsin et al. N/A N/A 2020/0253544 12/2019 Muhsin et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N					
2020/0113497 12/2019 Triman et al. N/A N/A 2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0253474 12/2019 Wuhsin et al. N/A N/A 2020/0253544 12/2019 Belur Nagaraj et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A					
2020/0113520 12/2019 Abdul-Hafiz et al. N/A N/A 2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Telfort et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0328983 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A			88		
2020/0138288 12/2019 Al-Ali et al. N/A N/A 2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Telfort et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A					
2020/0138368 12/2019 Kiani et al. N/A N/A 2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Telfort et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A					
2020/0146621 12/2019 Wang et al. N/A N/A 2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Belur Nagaraj et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329994 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A					
2020/0163597 12/2019 Dalvi et al. N/A N/A 2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Belur Nagaraj et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A					
2020/0196877 12/2019 Vo et al. N/A N/A 2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Belur Nagaraj et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A			G		
2020/0253474 12/2019 Muhsin et al. N/A N/A 2020/0253544 12/2019 Telfort et al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A					
2020/025354412/2019Belur Nagaraj et al.N/AN/A2020/027584112/2019Telfort et al.N/AN/A2020/028898312/2019Telfort et al.N/AN/A2020/032179312/2019Al-Ali et al.N/AN/A2020/032998312/2019Al-Ali et al.N/AN/A2020/032998412/2019Al-Ali et al.N/AN/A2020/032999312/2019Al-Ali et al.N/AN/A					
2020/0253544 12/2019 al. N/A N/A 2020/0275841 12/2019 Telfort et al. N/A N/A 2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A	2020/0253474	12/2019		N/A	N/A
2020/0288983 12/2019 Telfort et al. N/A N/A 2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A	2020/0253544	12/2019		N/A	N/A
2020/0321793 12/2019 Al-Ali et al. N/A N/A 2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A	2020/0275841	12/2019	Telfort et al.	N/A	N/A
2020/0329983 12/2019 Al-Ali et al. N/A N/A 2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A	2020/0288983	12/2019	Telfort et al.	N/A	N/A
2020/0329984 12/2019 Al-Ali et al. N/A N/A 2020/0329993 12/2019 Al-Ali et al. N/A N/A	2020/0321793	12/2019	Al-Ali et al.	N/A	N/A
2020/0329993 12/2019 Al-Ali et al. N/A N/A	2020/0329983	12/2019	Al-Ali et al.	N/A	N/A
	2020/0329984	12/2019	Al-Ali et al.	N/A	N/A
2020/0330037 12/2019 Al-Ali et al. N/A N/A	2020/0329993	12/2019	Al-Ali et al.	N/A	N/A
	2020/0330037	12/2019	Al-Ali et al.	N/A	N/A

2020/0383639	12/2019	Wang et al.	N/A	N/A
2021/0022628	12/2020	Telfort et al.	N/A	N/A
2021/0058736	12/2020	Ghazzaoui	N/A	H04W 4/80
2021/0104173	12/2020	Pauley et al.	N/A	N/A
2021/0113121	12/2020	Diab et al.	N/A	N/A
2021/0117525	12/2020	Kiani et al.	N/A	N/A
2021/0118581	12/2020	Kiani et al.	N/A	N/A
2021/0121582	12/2020	Krishnamani et al.	N/A	N/A
2021/0161465	12/2020	Barker et al.	N/A	N/A
2021/0236729	12/2020	Kiani et al.	N/A	N/A
2021/0256267	12/2020	Ranasinghe et al.	N/A	N/A
2021/0256835	12/2020	Ranasinghe et al.	N/A	N/A
2021/0275101	12/2020	Vo et al.	N/A	N/A
2021/0290060	12/2020	Ahmed	N/A	N/A
2021/0290072	12/2020	Forrest	N/A	N/A
2021/0290080	12/2020	Ahmed	N/A	N/A
2021/0290120	12/2020	Al-Ali	N/A	N/A
2021/0290177	12/2020	Novak, Jr.	N/A	N/A
2021/0290184	12/2020	Ahmed	N/A	N/A
2021/0296008	12/2020	Novak, Jr.	N/A	N/A
2021/0330228	12/2020	Olsen et al.	N/A	N/A
2021/0386382	12/2020	Olsen et al.	N/A	N/A
2021/0402110	12/2020	Pauley et al.	N/A	N/A
2022/0026355	12/2021	Normand et al.	N/A	N/A
2022/0039707	12/2021	Sharma et al.	N/A	N/A
2022/0053892	12/2021	Al-Ali et al.	N/A	N/A
2022/0071562	12/2021	Kiani	N/A	N/A
2022/0071588	12/2021	Chan et al.	N/A	N/A
2022/0096603	12/2021	Kiani et al.	N/A	N/A
2022/0117520	12/2021	Wang et al.	N/A	N/A
2022/0151521	12/2021	Krishnamani et al.	N/A	N/A
2022/0218244	12/2021	Kiani et al.	N/A	N/A
2022/0287574	12/2021	Telfort et al.	N/A	N/A
2022/0296161	12/2021	Al-Ali et al.	N/A	N/A
2022/0361819	12/2021	Al-Ali et al.	N/A	N/A
2022/0379059	12/2021	Yu et al.	N/A	N/A
2022/0392610	12/2021	Kiani et al.	N/A	N/A
2022/0401037	12/2021	Sadeghzadeh et al.	N/A	N/A
2023/0028745	12/2022	Al-Ali	N/A	N/A
2023/0038389	12/2022	Vo	N/A	N/A
2023/0045647	12/2022	Vo	N/A	N/A
2023/0058052	12/2022	Al-Ali	N/A	N/A
2023/0058342	12/2022	Kiani	N/A	N/A
2023/0069789	12/2022	Koo et al.	N/A	N/A
2023/0087671	12/2022	Telfort et al.	N/A	N/A
2023/0110152	12/2022	Forrest et al.	N/A	N/A
2023/0111198	12/2022	Yu et al.	N/A	N/A
2023/0115397	12/2022	Vo et al.	N/A	N/A
2023/0116371	12/2022	Mills et al.	N/A	N/A
2023/0135297	12/2022	Kiani et al.	N/A	N/A

2023/0138098	12/2022	Telfort et al.	N/A	N/A
2023/0145155	12/2022	Krishnamani et al.	N/A	N/A
2023/0147750	12/2022	Barker et al.	N/A	N/A
2023/0210417	12/2022	Al-Ali et al.	N/A	N/A
2023/0222805	12/2022	Muhsin et al.	N/A	N/A
2023/0222887	12/2022	Muhsin et al.	N/A	N/A
2023/0226331	12/2022	Kiani et al.	N/A	N/A
2023/0284916	12/2022	Telfort	N/A	N/A
2023/0284943	12/2022	Scruggs et al.	N/A	N/A
2023/0301562	12/2022	Scruggs et al.	N/A	N/A
2023/0346993	12/2022	Kiani et al.	N/A	N/A
2023/0368221	12/2022	Haider	N/A	N/A
2023/0371893	12/2022	Al-Ali et al.	N/A	N/A
2023/0389837	12/2022	Krishnamani et al.	N/A	N/A
2024/0016418	12/2023	Devadoss et al.	N/A	N/A
2024/0016419	12/2023	Devadoss et al.	N/A	N/A
2024/0047061	12/2023	Al-Ali et al.	N/A	N/A
2024/0049310	12/2023	Al-Ali et al.	N/A	N/A
2024/0049986	12/2023	Al-Ali et al.	N/A	N/A
2024/0081656	12/2023	DeJong et al.	N/A	N/A
2024/0122486	12/2023	Kiani	N/A	N/A
2024/0180456	12/2023	Al-Ali	N/A	N/A
2024/0188872	12/2023	Al-Ali et al.	N/A	N/A
2024/0245855	12/2023	Vo et al.	N/A	N/A
2024/0260894	12/2023	Olsen	N/A	N/A
2024/0267698	12/2023	Telfort et al.	N/A	N/A
2024/0277233	12/2023	Al-Ali	N/A	N/A
2024/0277280	12/2023	Al-Ali	N/A	N/A
2024/0298920	12/2023	Fernkbist et al.	N/A	N/A
2024/0306985	12/2023	Vo et al.	N/A	N/A
2024/0324953	12/2023	Telfort	N/A	N/A
2024/0380246	12/2023	Moran	N/A	N/A
2024/0380247	12/2023	Moran	N/A	N/A
2024/0404549	12/2023	Campbell et al.	N/A	N/A
2025/0000458	12/2024	Abdul-Hafiz et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
3 541 273	12/2020	EP	N/A
WO 2010/099488	12/2009	WO	N/A
WO 2017/216056	12/2016	WO	N/A
WO 2021/188999	12/2020	WO	N/A
WO 2022/087017	12/2021	WO	N/A

OTHER PUBLICATIONS

US 2024/0016391 A1, 01/2024, Lapotko et al. (withdrawn) cited by applicant International Search Report and Written Opinion in PCT Application No. PCT/US2021/023323, as mailed Sep. 15, 2021 in 17 pages. cited by applicant

Kwok et al., "Epidemic Models of Contact Tracing: Systematic Review of Transmission Studies of

Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome", Computational and Structural Biotechnology Journal, 2019, vol. 17, pp. 186-194. cited by applicant

Primary Examiner: Chen; Tse W

Assistant Examiner: Park; Evelyn Grace

Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear, LLP

Background/Summary

INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS (1) This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Patent Application No. 63/065,961, entitled "HEALTH SCREENING AND MONITORING SYSTEM," filed Aug. 14, 2020, U.S. Patent Application No. 63/106,273, entitled "WEARABLE DEVICE FOR NONINVASIVE BODY TEMPERATURE MEASUREMENT," filed Oct. 27, 2020, U.S. Patent Application No. 63/056,925, entitled "WEARABLE DEVICE FOR NONINVASIVE BODY TEMPERATURE MEASUREMENT," filed Jul. 27, 2020, U.S. Patent Application No. 63/049,478, entitled "REMOTE PATIENT MANAGEMENT AND MONITORING SYSTEMS AND METHODS," filed Jul. 8, 2020, U.S. Patent Application No. 62/992,808, entitled "REMOTE PATIENT MANAGEMENT AND MONITORING," filed Mar. 20, 2020, U.S. Patent Application No. 62/992,779, entitled "OPIOID OVERDOSE MONITORING USER INTERFACE," filed Mar. 20, 2020, and U.S. Patent Application No. 63/010,669, entitled "REMOTE PATIENT MANAGEMENT AND MONITORING," filed Apr. 15, 2020. All of the above-mentioned applications are hereby incorporated by reference herein in their entireties. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.

FIELD

(1) This application relates broadly to remote health screening and/or monitoring systems, devices, and methods that can assist employers, schools, hospitals, and other interested parties monitor one or more user's health and risk of having an infectious disease.

BACKGROUND

(2) The COVID-19 pandemic has re-instilled the need across the globe for remote-based monitoring and health screening. There is an increased need to provide remote monitoring and health screening via a secure remote solution to limit exposure to an infection (e.g., virus), especially in organizations such as offices, schools, and medical facilities.

SUMMARY

(3) The COVID-19 pandemic has raised awareness of the potential transmission and contraction risks of a large number of people gathering, especially in an enclosed location. In response to these risks, some businesses have started screening both employees and customers. For example, an employer may require their employees answer a symptoms questionnaire and/or have their temperature taken before entering an office associated with the employer. However, this type of screening may be ineffective or impractical for an organization (e.g., factory) that needs to clear hundreds to thousands of employees in relatively short periods of time (e.g., every shift). Many organizations need to be able to efficiently and reliably conduct mass screenings of their employees to limit the spread of an infectious disease (e.g., virus or bacterial), such as COVID-19, among others (e.g., seasonal flu). This type of mass screening can enable companies to keep their employees safe and give the employees confidence that they will not be infected by their co-

workers nor will they infect their co-workers.

- (4) Various systems, devices, and methods are disclosed which enable an organization, or a user thereof, to monitor and/or manage health statuses of users associated with the organization in order to limit the spread of an infectious disease or otherwise protect the health of such users. For example, certain aspects of this disclosure describe systems, methods, and devices that can be utilized by an employer to monitor and/or manage health statuses of one or more (or a plurality of) employees and/or other parties (e.g., third party contractors) who may visit or otherwise come into contact with the employer, its facilities, and/or its employees.
- (5) Certain aspects of this disclosure describe wearable devices that can monitor and/or measure one or more physiological parameters of a user and communicate (e.g., wirelessly transmit) such physiological parameters to computing devices that may be separate from such wearable devices (e.g., mobile phones, laptops, tablets, etc.). The disclosed wearable devices can measure and/or monitor a variety of physiological parameters which can provide an indication of a user's health status and/or be indicative of symptoms that may be associated with an infection. The disclosed wearable devices can measure and/or monitor various physiological parameters continuously and/or intermittently and can transmit determined physiological parameters to a separate computing device of the user.
- (6) As discussed elsewhere herein, some aspects of the present disclosure describe wearable devices that can detect proximity to other, separate wearable devices which may be associated with other users, thereby enabling, in turn, determinations of proximity between various users, for example, in an organization, over one or more time periods. Various systems, devices, and methods are disclosed which enable a computing device (e.g., a mobile computing device such as a smart phone) to receive one or more physiological parameters associated with a user from one or more wearable devices coupled with the user and/or receive proximity data indicative of the user's proximity to one or more other users, for example, over a given time period (e.g., 3 days, 5 days, 7 days, 10 days, 14 days, etc.).
- (7) In some aspects, the present disclosure describes computing devices (for example, mobile phones) that can receive one or more physiological parameters from one or more wearable devices associated with a user, proximity data indicative of the user's proximity to one or more other users over a given time period, one or more identifiers associated with the user and/or each of the one or more other users, and/or other information. Advantageously, in some implementations, such computing device can act as a hub (for example, a network and/or communication point) and can transmit information received from the one or more wearable devices to a remote monitoring system (for example, over a network), which can be located at, accessible by, and/or otherwise associated with an organization and/or a monitor user who is tasked with monitoring and/or taking action with respect to the remote monitoring system. Such organization can be, for example, a company, a school, a hospital, a sports or concert venue, etc. The remote monitoring system can receive information from such computing device associated with a user along with similar information from a plurality of other computing devices associated with a plurality of other users (for example, users associated with the organization) and can monitor such information for the purpose of limiting transmission and/or contraction of one or more infections. As discussed herein, such remote monitoring system can be utilized and/or monitored by a "monitor user" associated with an organization. Advantageously, the remote monitoring system can allow an organization to not only monitor health statuses and/or contact tracing information regarding users, but also provide instructions (automatically and/or manually) and/or information (e.g., exposure levels, risk states, etc.) to such users via associated computing devices. Accordingly, the remote monitoring system can allow an organization to dynamically and simultaneously monitor and manage health statuses of its employees to limit the spread of various infections, and relatedly, allow the organization to safely carry out its purpose (e.g., conduct business, manufacture products, care for patients, provide educational services, provide services, etc.).

- (8) A system for remotely monitoring and managing health statuses of a plurality of users of an organization to limit a spread of an infection can comprise software instructions storable on a memory device usable by a computing device. The software instructions can cause a hardware processor of the computing device to receive a plurality of sets of health-related information from a plurality of computing devices of a plurality of users, each of said plurality of sets of health-related information comprising: physiological information associated with one of the plurality of users, said physiological information indicative of one or more symptoms experienced by the one of the plurality of users and associated with an infection, said physiological information comprising at least one or more body temperature values; and contact tracing data comprising information indicative of proximity of the one of the plurality of users to at least one other one of the plurality of users. The software instructions can further cause a hardware processor of the computing device to: determine an exposure level for the one of the plurality of users based on at least said contact tracing data; determine a risk state of the one of the plurality of users based on at least said physiological information and said exposure level, said risk state associated with a likelihood that said one of the plurality of users has said infection; and transmit, to one of the computing devices of the one of the plurality of users, at least one of said risk state and an instruction associated with said risk state.
- (9) In some aspects of the disclosure, said physiological information can be derived from at least one wearable device coupled to the one of the plurality of users. In some aspects, said physiological information can further comprise at least one of: one or more oxygen saturation values; one or more pulse rate values; and one or more respiration rate values.
- (10) In some aspects, said contact tracing data can comprise information indicative of: physical proximity of the one of the plurality of users to said at least one other one of the plurality of users, said physical proximity can be determined based on a detected wireless signal strength between a first wearable device of the one of the plurality of users and a second wearable device of the at least one other one of the plurality of users when the first and second wearable devices are worn. In some aspects, said physical proximity can be determined based on a detected Bluetooth® signal strength between the first and second wearable devices. In some aspects, said software instructions can further cause said hardware processor of the computing device to determine an accumulated duration, over a first time period, that said physical proximity between the one of the plurality of users and the at least one other one of the plurality of users is within a threshold proximity. In some aspects, said exposure level can be determined further based on said accumulated duration. In some aspects, said exposure level for the one of the plurality of users can be determined further based on a risk state of said at least one other one of the plurality of users, said risk state of said at least one other one of the plurality of users associated with a likelihood that said at least one other one of the plurality of users had said infection during at least a portion of said first time period. In some aspects, said threshold proximity can be about 6 ft.
- (11) In some aspects, each of said plurality of sets of health-related information can further comprise diagnosis or test result data, and said risk state of the one of the plurality of users can be based on said physiological information, said exposure level, and said diagnosis or test result data. In some aspects, said diagnosis or test result data can be indicative of a positive or negative test result to the infection.
- (12) In some aspects, the computing device can be operated by a monitor user associated with the organization. In some aspects, said one of the computing devices of said one of the plurality of users can comprise a smartphone.
- (13) In some aspects, said software instructions can further cause said hardware processor of the computing device to determine: an accumulated duration, over a first time period, that said physical proximity between said one of the plurality of users and each other one of the plurality of users confirmed to have said infection is within a threshold proximity; and said exposure level for the one of the plurality of users based on a summation of all of said accumulated durations. In some

aspects, said exposure level can be determined based on at least one of an average of said summation of all of said accumulated durations and a maximum of said summation of all of said accumulated durations.

- (14) A wearable device for monitoring risk of spreading a contagious infection in an organization can comprise: a temperature sensor configured to generate one or more signals responsive to a thermal energy of a first user; a wireless transceiver configured to communicate with a mobile computing device of the first user; and a processor. The processor can be configured to: receive said one or more signals generated by the temperature sensor and determine one or more body temperature values of the first user; and instruct the wireless transceiver to transmit, to the mobile computing device, said one or more body temperature values; determine one or more proximity values indicative of distance between the wearable device and a separate wearable device that is coupled to a second user. The processor can be further configured to, when said wearable device and said separate wearable device are within a threshold proximity, instruct the wireless transceiver to transmit to the mobile computing device: a first identifier associated with the second user; and said one or more proximity values, said mobile computing device configured to wirelessly transmit said first identifier, a second identifier associated with the first user, said one or more proximity values, and said one or more body temperature values to a remote monitoring system for determination of at least one of an exposure level and risk state of the first user, said risk state associated with a likelihood that said first user has an infection.
- (15) In some aspects of the disclosure, the wearable device does not include any other physiological sensors. In some aspects, the wearable device can further comprise a housing configured to at least partially enclose the temperature sensor, wireless transceiver, and processor. In some aspects, the wearable device can further comprise one or more substrates configured to secure the wearable device to skin of the first user.
- (16) In some aspects, the processor can be configured to determine said one or more proximity values when the wearable device and the separate wearable device are within a threshold proximity to one another. In some aspects, said threshold proximity can comprise about 20 ft. In some aspects, the processor can be configured to determine said one or more proximity values based on a detected wireless signal strength between said wearable device and said separate wearable device. In some aspects, the processor can be configured to instruct the wireless transceiver to transmit, to the mobile computing device, said first identifier and said one or more proximity values only when said wearable device and said separate wearable device are within said threshold proximity, and the processor can be configured to instruct the wireless transceiver to transmit, to the mobile computing device, said one or more body temperature values continuously at a first time interval regardless of whether said wearable device and said separate wearable device are within said threshold proximity. In some aspects, said first time interval can comprise every minute. (17) In some aspects, the wearable device can further comprise a battery, and the wearable device does not include any other physiological sensors, thereby maximizing a life of the battery. (18) A system can comprise the wearable device of any one of the preceding paragraphs and said mobile computing device. In some aspects, said wireless transceiver of said wearable device can be configured to transmit said one or more body temperature values, said first identifier, said second identifier, and said one or more proximity values to said mobile computing device via a first wireless communication protocol, and said mobile computing device can be configured to wirelessly transmit said first identifier, said second identifier, said one or more proximity values, and said one or more body temperature values to said remote monitoring system via a second wireless communication protocol that can be different than said first wireless communication
- (19) A method for remotely monitoring and managing a health status of a user to limit a spread of an infection at an organization can comprise providing a wearable device configured to measure one or more physiological parameters of a first user indicative of an onset of symptoms

experienced by the first user and associated with an infection, said wearable device configured to: determine one or more proximity values indicative of distance between the wearable device and a separate wearable device that is configured to measure one or more physiological parameters of a second user indicative of an onset of symptoms experienced by the second user and associated with said infection, said one or more proximity values determined based on detected wireless signal strength between the wearable device of the first user and the separate wearable device of the second user. The method can further comprise providing a mobile software application configured for execution by one or more hardware processors of a mobile computing device configured for wireless communication with said wearable device, the mobile software application configured to execute commands to enable the mobile computing device to: wirelessly receive, from the wearable device, said one or more physiological parameters of the first user; wirelessly receive, from the wearable device when said wearable device and said separate wearable device are within a threshold proximity to one another, a first identifier associated with the first user of the wearable device, a second identifier associated with the second user of the separate wearable device, and said one or more proximity values; wirelessly transmit, to a remote monitoring system, said one or more physiological parameters of the first user, said first identifier, said second identifier, and said determined one or more proximity values; wirelessly receive, from the remote monitoring system, a risk state of the first user, the risk state associated with a likelihood that said first user has said infection; generate a graphical user interface on a display of the mobile computing device; and display, in at least a portion of the graphical user interface, at least one of said risk state and an instruction associated with said risk state.

- (20) In some aspects of the disclosure, said one or more physiological parameters can comprise one or more body temperature values of the first user, and said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly receive, from the wearable device, said one or more body temperature values at a first time interval. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit said one or more body temperature values of said first user, said first identifier, said second identifier, and said determined one or more proximity values at said first time interval. In some aspects, said first time interval can comprise every minute.
- (21) In some aspects, said one or more proximity values can be determined based on detected Bluetooth® signal strength between the wearable device of the first user and the separate wearable device of the second user.
- (22) In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly receive, from the remote monitoring system, information indicative of exposure of the first user to said infection. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to display, in at least a portion of the graphical user interface, at least one of said information indicative of said exposure and an instruction related to said information indicative of said exposure.
- (23) In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit, to the remote monitoring system, information indicative of a test result of the first user associated with said infection and inputted by the first user via the mobile software application. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit, to the remote monitoring system, information indicative of one or more symptoms of the first user associated with said infection and inputted by the first user via the mobile software application. In some aspects, said wearable device can be configured to detect only one type of physiological parameter of the first user, said one type of physiological parameter being body temperature. In some aspects, said threshold proximity can be about 30 ft.

- (24) In some aspects, the wearable device can be configured to wirelessly transmit said one or more proximity values to the mobile computing device at a first time interval and the mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit said determined one or more proximity values over a second time interval. In some aspects, said first time interval can be different than said second time interval. In some aspects, said first time interval can be the same as said second time interval.
- (25) A method for remotely notifying a user of exposure to an infection can comprise providing a wearable device configured to couple to a first user, said wearable device can further be configured to: determine proximity of the wearable device to a separate wearable device that is configured to measure one or more physiological parameters of a second user indicative of an onset of symptoms experienced by the second user and associated with an infection, said proximity determined based on a detected wireless signal strength between the wearable device of the first user and the separate wearable device of the second user. The method can further comprise providing a mobile software application configured for execution by one or more hardware processors of a mobile computing device configured for wireless communication with said wearable device. The mobile software application can be configured to execute commands to enable the mobile computing device to: wirelessly receive, from the wearable device when said proximity is within a first threshold, a first identifier associated with the first user of the wearable device and a second identifier associated with the second user of the separate wearable device; wirelessly transmit said first identifier and said second identifier to a remote monitoring system when said proximity is within the first threshold; wirelessly receive, from the remote monitoring system, a notification configured to alert the first user of at least one of an exposure of the first user to said infection and a risk state of the first user, said risk state associated with a likelihood that said first user has said infection; generate a graphical user interface on a display of the mobile computing device; and display, in at least a portion of the graphical user interface, at least one of said notification received from said remote monitoring system and a visual representation associated with said notification.
- (26) In some aspects of the disclosure, said wearable device can be configured to measure one or more physiological parameters of the first user indicative of an onset of symptoms experienced by the first user and associated with the infection. In some aspects, said mobile software application can further be configured to execute commands to enable the mobile computing device to: wirelessly receive, from the wearable device, said one or more physiological parameters of the first user from said wearable device; and wirelessly transmit, to a remote monitoring system, said one or more physiological parameters of the first user. In some aspects, said one or more physiological parameters one or more body temperature values. In some aspects, said one or more physiological parameter, said one type of physiological parameter, said one type of physiological parameter being body temperature.
- (27) In some aspects, said wearable device can further be configured to determine: one or more proximity values indicative of distance between the wearable device and the separate wearable device when the wearable device and the separate wearable device are within the first threshold from one another; and wirelessly transmit said one or more proximity values to said mobile computing device when the wearable device and the separate wearable device are within the first threshold from one another. In some aspects, said mobile software application can be further configured to execute commands to enable the mobile computing device to: wirelessly receive said one or more proximity values from said wearable device; and wirelessly transmit said one or more proximity values to said remote monitoring system. In some aspects, said wearable device can be configured to wirelessly transmit said one or more proximity values to said mobile computing device at a first time interval. In some aspects, said first time interval can be every minute. In some aspects, said one or more proximity values can be determined based on detected Bluetooth® signal strength between the wearable device of the first user and the separate wearable device of the second user.

- (28) In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit, to the remote monitoring system, information indicative of a test result of the first user associated with said infection and inputted by the first user via the mobile software application. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit, to the remote monitoring system, information indicative of one or more symptoms of the first user associated with said infection and inputted by the first user via the mobile software application. In some aspects, said first threshold can be about 30 ft.
- (29) A system can comprise the wearable device and the mobile software application of any one of the preceding paragraphs.
- (30) A non-transitory computer medium storing instructions that, when executed by one or more processors of a mobile computing device, can cause the one or more processors to perform operations configured to notify a first user of the mobile computing device of a risk state associated with a likelihood that said first user has one or more infections can comprise: receiving, from a first wearable device, one or more physiological parameters of the first user indicative of an onset of one or more symptoms experienced by the first user and associated with said one or more infections; when said first wearable device is within a threshold proximity to a second wearable device configured to measure one or more physiological parameters of a second user, receiving proximity data from said first wearable device, said proximity data including one or more distance values between said first and second wearable devices over a first time period, said proximity data determined based on a detected wireless signal strength between the first and second wearable devices; receiving, from the first wearable device when said first wearable device is within said threshold proximity to the second wearable device, a first identifier associated with the second user of the second wearable device; transmitting, to a remote monitoring system, said one or more physiological parameters of the user; transmitting, to the remote monitoring system, said first identifier, a second identifier associated with the first user, and said proximity data when said first wearable device is within said threshold proximity to the second wearable device; receiving, from the remote monitoring system, said risk state associated with said likelihood that said first user has said one or more infections; generating a graphical user interface on the mobile computing device; and displaying, on at least a portion of the graphical user interface, at least one of said risk state, a visual or audio representation of said risk state, and an instruction associated with said risk state. (31) In some aspects of the disclosure, said displaying, on said at least said portion of the graphical user interface comprises displaying said risk state and an instruction associated with said risk state. In some aspects, said displaying, on said at least said portion of the graphical user interface further comprises displaying said visual or audio representation of said risk state. In some aspects, said one or more physiological parameters of the first user comprise one or more body temperature values. In some aspects, said one or more physiological parameters comprise only one type of physiological parameter, said one type of physiological parameter being body temperature. (32) In some aspects, said receiving said one or more distance values comprises receiving said one or distance values over a first time interval. In some aspects, said first time interval can be every minute.
- (33) In some aspects, said proximity data can be determined based on a detected Bluetooth® signal strength between the first and second wearable devices. In some aspects, said operations can further comprise wirelessly transmitting, to the remote monitoring system, information indicative of a test result of the first user associated with said one or more infections and inputted by the first user via the mobile computing device. In some aspects, said operations can further comprise wirelessly transmitting, to the remote monitoring system, information indicative of one or more symptoms of the first user associated with said one or more infections and inputted by the first user via the mobile computing device. In some aspects, said threshold proximity can be about 30 ft. In some aspects, said operations can further comprise: receiving said one or more physiological parameters,

said proximity data, and said first identifier from the first wearable device over a first wireless communication protocol; and transmitting said first identifier, said second identifier, said one or more physiological parameters, and said proximity data to the remote monitoring system over a second wireless communication protocol, said second wireless communication protocol being different than said first wireless communication protocol.

- (34) A wearable device for monitoring a user's health status can comprise: at least one physiological sensor configured to measure one or more physiological parameters of a first user, said at least one physiological sensor comprising a temperature sensor configured to generate one or more signals responsive to a thermal energy of the first user; a first wireless transceiver configured to communicate with a mobile computing device of the first user; and a processor. The processor can be configured to: receive said one or more signals generated by the temperature sensor and determine one or more body temperature values of the first user based on said received one or more signals; instruct the first wireless transceiver to transmit to the mobile computing device, at a first time interval, said determined one or more body temperature values; and determine one or more proximity values indicative of distance between the first wireless transceiver and a second wireless transceiver of a separate wearable device that is coupled to a second user when said first and second wireless transceivers are within a threshold proximity to one another, said one or more proximity values can be determined based on a detected wireless signal strength between the first and second wireless transceivers. The processor can be further configured to, when said first and second wireless transceivers are within said threshold proximity based on said detected wireless signal strength, instruct the first wireless transceiver to transmit to the mobile computing device at a second time interval: a first identifier associated with the second user; and said one or more proximity values, said mobile computing device configured to wirelessly transmit said first identifier, a second identifier associated with the first user, said one or more body temperature values, and said one or more proximity values to a remote monitoring system for determination of a risk state of the first user, said risk state associated with a likelihood that said first user has one or more infections.
- (35) In some aspects of the disclosure, the wearable device can be configured to determine only one type of physiological parameter of the first user, said type of physiological parameter being temperature of the first user. In some aspects, the wearable device can further comprise one or more substrates configured to secure the wearable device to skin of the first user. In some aspects, said threshold proximity can comprise about 20 ft. In some aspects, said threshold proximity can comprise about 30 ft.
- (36) In some aspects, the processor can be configured to instruct the first wireless transceiver to transmit, to the mobile computing device, said first identifier and said one or more proximity values only when said first and second wireless transceivers are within said threshold proximity, and the processor can be configured to instruct the first wireless transceiver to transmit, to the mobile computing device, said one or more body temperature values continuously at said first time interval regardless of whether said first and second wireless transceivers are within said threshold proximity. In some aspects, said first time interval can comprise every minute.
- (37) In some aspects, the wearable device can further comprise a battery. In some aspects, the wearable device can further comprise a housing configured to be coupled to the first user. In some aspects, said one or more proximity values can be determined based on a detected Bluetooth® signal strength between the first and second wireless transceivers.
- (38) A system can comprise the wearable device of any one of the preceding paragraphs and said mobile computing device.
- (39) A system can comprise the wearable device of the preceding paragraphs and a mobile software application configured for execution by one or more hardware processors of the mobile computing device. The mobile software application can be configured to execute commands to enable the mobile computing device to: wirelessly receive said one or more body temperature values, said first

identifier, and said one or more proximity values; and wirelessly transmit said one or more body temperature values, said first identifier, said second identifier, and said one or more proximity values to said remote monitoring system for determination of said risk state. In some aspects, the mobile software application can be further configured to execute commands to enable the mobile computing device to: wirelessly receive, from the remote monitoring system, said risk state of the first user; generate a graphical user interface on a display of the mobile computing device; and display, in at least a portion of the graphical user interface, at least one of said risk state and an instruction associated with said risk state.

- (40) In some aspects, each of the first and second time intervals can comprise one minute. In some aspects, the first and second time intervals can be the same. In some aspects, the first and second time intervals can be different.
- (41) A wearable device for monitoring a user's health status can comprise: at least one physiological sensor configured to measure one or more physiological parameters of a first user; a first wireless transceiver configured to communicate with a mobile computing device of the first user; and a processor. The processor can be configured to: instruct the first wireless transceiver to transmit to the mobile computing device said one or more physiological parameters measured by said at least one physiological sensor; determine one or more proximity values indicative of distance between the first wireless transceiver and a second wireless transceiver of a separate wearable device that is coupled to a second user when said first and second wireless transceivers are within a threshold proximity; when said first and second wireless transceivers are within said threshold proximity, instruct the first wireless transceiver to transmit to the mobile computing device a first identifier associated with the second user, and said one or more proximity values. (42) In some aspects of the disclosure, said at least one physiological sensor can comprise a temperature sensor configured to generate one or more signals responsive to a thermal energy of the first user, and said processor can be further configured to: receive said one or more signals generated by the temperature sensor and determine one or more body temperature values of the first user based on said received one or more signals; instruct the first wireless transceiver to transmit said determined one or more body temperature values to the mobile computing device at a first time interval; and determine one or more proximity values based on a detected wireless signal strength between the first and second wireless transceivers. In some aspects, mobile computing device can be configured to wirelessly transmit said first identifier, said second identifier, said one or more body temperature values, and said one or more proximity values to a remote monitoring system for determination of a risk state of the first user, said risk state associated with a likelihood that said first user has one or more infections.
- (43) A system can comprise the wearable device of any one of the preceding paragraphs and a mobile software application configured for execution by one or more hardware processors of the mobile computing device. The mobile software application can be configured to execute commands to enable the mobile computing device to: wirelessly receive said one or more body temperature values, said first identifier, and said one or more proximity values; and wirelessly transmit said one or more body temperature values, said first identifier, said second identifier, and said one or more proximity values to said remote monitoring system for determination of said risk state. In some aspects, the mobile software application can be further configured to execute commands to enable the mobile computing device to: wirelessly receive, from the remote monitoring system, said risk state of the first user; generate a graphical user interface on a display of the mobile computing device; and display, in at least a portion of the graphical user interface, at least one of said risk state and an instruction associated with said risk state. In some aspects, said one or more proximity values can be determined based on a detected Bluetooth® signal strength between the first and second wireless transceivers. In some aspects, the processor can be configured to instruct the first wireless transceiver to transmit, to the mobile computing device, said first identifier and said one or more proximity values only when said first and second wireless

transceivers are within said threshold proximity, and the processor can be configured to instruct the first wireless transceiver to transmit, to the mobile computing device, said one or more body temperature values continuously at said first time interval regardless of whether said first and second wireless transceivers are within said threshold proximity. In some aspects, said first time interval can comprise every minute.

- (44) A system can comprise the wearable device of any one of the preceding paragraphs and said mobile computing device. In some aspects, the wearable device can be configured to determine only one type of physiological parameter of the first user, said type of physiological parameter being temperature of the first user.
- (45) In some aspects, the wearable device can further comprise a housing configured to be coupled to the first user. In some aspects, the wearable device can further comprise one or more substrates configured to secure the wearable device to skin of the first user.
- (46) In some aspects, the wearable device can further comprise a battery. In some aspects, said threshold proximity can comprise about 30 ft. In some aspects, said threshold proximity can comprise about 20 ft.
- (47) A system for remotely monitoring and managing health statuses of a plurality of users can comprise software instructions storable on a memory device usable by a computing device configured to be operated by a monitor user. The software instructions can cause one or more hardware processors of the computing device to receive a plurality of sets of health-related information from a plurality of mobile computing devices of a plurality of users, said plurality of sets of health-related information comprising a first set of health-related information associated with a first one of the plurality of users. The first set of health-related information can comprise: physiological information derived from at least one wearable device when attached to the first one of the plurality of users, said physiological information indicative of an onset of symptoms experienced by the first one of the plurality of users and associated with one or more infections, said physiological information comprising at least a body temperature of the first one of the plurality of users; contact tracing data comprising information indicative of proximity of the first one of the plurality of users to a second one of the plurality of users, said proximity determined based on a detected wireless signal strength between a first wearable device of the first one of the plurality of users and a second wearable device of the second one of the plurality of users when the first and second wearable devices are worn by the first and second users; and diagnosis or test result data associated with the first one of the plurality of users and indicative of a positive or negative result to at least one of said one or more infections. The software instructions can further cause one or more hardware processors of the computing device to: determine an accumulated duration, over a first time period, that said proximity between the first and second ones of the plurality of users is within a threshold proximity; determine an exposure level for the first one of the plurality of users based on said contact tracing data, said accumulated duration, and a risk state of the second one of the plurality of users associated with a likelihood that said second one of the plurality of users had said one or more infections during at least a portion of said first time period; determine a risk state of the first one of the plurality of users based on at least said physiological information, said diagnosis or test result data, and said exposure level, said risk state of the first one of the plurality of users associated with a likelihood that said first one of the plurality of users has said one or more infections; and wirelessly transmit, to a first mobile computing device of the first one of the plurality of users, at least one of said risk state and an instruction associated with said risk state, said first mobile computing device configured to indicate on a display of said first mobile computing device at least one of said at least one of said risk state and said instruction, and a representation of said at least one of said risk state and said instruction.
- (48) In some aspects of the disclosure, said contact tracing data can further comprise information indicative of: proximity of the first one of the plurality of users to a third one of the plurality of users, said proximity determined based on a detected wireless signal strength between the first

wearable device of the first one of the plurality of users and a third wearable device of the third one of the plurality of users when the first and third wearable devices are worn by the first and third users. In some aspects, said software instructions can further cause one or more hardware processors of the computing device to: determine an accumulated duration, over a second time period, that said proximity between the first and third ones of the plurality of users is within the threshold proximity; and determine said exposure level for the first one of the plurality of users based on said contact tracing data, said accumulated durations, and a risk state of the third one of the plurality of users had said one or more infections during at least a portion of said second time period.

(49) In some aspects, said contact tracing data can further comprise information indicative of:

- proximity of the first one of the plurality of users to at least two other ones of the plurality of users, said proximity determined based on detected wireless signal strengths between the first wearable device of the first one of the plurality of users and wearable devices of said at least two other ones of the plurality of users when the first wearable device is worn by the first one of the plurality of users and the wearable devices of said at least two other ones of the plurality of users are worn by the said at least two other ones of the plurality of users. In some aspects, said software instructions can further cause one or more hardware processors of the computing device to: determine an accumulated duration that said proximity between the first and each of the at least two other ones of the plurality of users is within the threshold proximity; and determine said exposure level for the first one of the plurality of users based on said contact tracing data, said accumulated durations, and a risk state of each of the at least two other ones of the plurality of users associated with a likelihood that each of said at least two other ones of the plurality of users had said one or more infections when within said threshold proximity of said first one of the plurality of users.

 (50) In some aspects, said risk state of the second one of the plurality of users can be determined by the one or more hardware processors of the computing device based on at least: physiological
- information associated with the second one of the plurality of users and derived from said second wearable device when attached to the second one of the plurality of users, said physiological information comprising at least a body temperature of the second one of the plurality of users; and an exposure level for the second one of the plurality of users. The exposure level for the second one of the plurality of users can be determined based on at least: contact tracing data associated with said second one of the plurality of users, said contact tracing data associated with said second one of the plurality of users comprising information indicative of proximity of the second one of the plurality of users to at least a third one of the plurality of users, said proximity determined based on a detected wireless signal strength between the second wearable device of the second one of the plurality of users and a third wearable device of the third one of the plurality of users when the second and third wearable devices are worn by the second and third ones of the plurality of users; an accumulated duration, over a second time period, that said physical proximity between the second and third ones of the plurality of users was within the threshold proximity; and a risk state of the third one of the plurality of users associated with a likelihood that said third one of the plurality of users had said one or more infections during at least a portion of said second time period. In some aspects, the first and second time periods can be the same. In some aspects, the first and second time periods can be different.
- (51) In some aspects, said plurality of sets of health-related information can further comprise a second set of health-related information associated with a third one of the plurality of users. The second set of health-related information can comprise: physiological information derived from at least one wearable device when attached to the third one of the plurality of users, said physiological information indicative of an onset of symptoms experienced by the third one of the plurality of users and associated with the said one or more infections, said physiological information comprising at least a body temperature of the third one of the plurality of users; contact tracing data associated with said third one of the plurality of users and comprising information indicative of

proximity of the third one of the plurality of users to a fourth one of the plurality of users, said proximity determined based on a detected wireless signal strength between a third wearable device of the third one of the plurality of users and a fourth wearable device of the fourth one of the plurality of users when the third and fourth wearable devices are worn by the third and fourth users. The one or more hardware processors of the computing device can be further configured to: determine an accumulated duration, over a second time period, that said proximity between the third and fourth ones of the plurality of users is within the threshold proximity; determine an exposure level for the third one of the plurality of users based on said contact tracing data associated with said third one of the plurality of users, said accumulated duration that said proximity between the third and fourth ones of the plurality of users is within the threshold proximity over the second time period, and a risk state of the fourth one of the plurality of users associated with a likelihood that said fourth one of the plurality of users had said one or more infections during at least a portion of said second time period; and determine a risk state for the third one of the plurality of users. The risk state for the third one of the plurality of users can be determined based on: said physiological information derived from at least one wearable device when attached to the third one of the plurality of users; and said exposure level for the third one of the plurality of users, said risk state of the third one of the plurality of users is associated with a likelihood that said third one of the plurality of users has said one or more infections. In some aspects, the first and second time periods can be the same. In some aspects, the first and second time periods can be different. In some aspects, said one or more hardware processors of the computing device can be further configured to cause the computing device to wirelessly transmit, to a third mobile computing device of the third one of the plurality of users, at least one of: said risk state of the third one of the plurality of users; and an instruction associated with said risk state of the third one of the plurality of users.

(52) In some aspects, said detected wireless signal strength can comprise a detected Bluetooth® signal strength. In some aspects, said determined risk state of the first one of the plurality of users can comprise one of: a confirmation that said first one of the plurality of users has the one of more infections; a confirmation that said first one of the plurality of users does not have the one of more infections; or a confirmation that said first one of the plurality of users is suspected to have the one of more infections and that said first one of the plurality of users is experiencing said symptoms associated with said one or more infections; or a confirmation that said first one of the plurality of users is suspected to have the one of more infections and that said first one of the plurality of users is not experiencing said symptoms associated with said one or more infections. In some aspects, said first set of health-related information can further comprise symptom information of the first one of the plurality of users recorded by the first mobile computing device. In some aspects, said one or more hardware processors of the computing device can be configured to wirelessly receive said plurality of sets of health-related information over a network. In some aspects, said computing device operated by said monitor user can be a desktop computer. In some aspects, said computing device operated by said monitor user can be a mobile phone. In some aspects, said computing device operated by said monitor user can be a tablet. In some aspects, said first mobile computing device can comprise a mobile phone. In some aspects, said first mobile computing device can comprise a smart watch. In some aspects, said threshold proximity can be about 30 ft. In some aspects, said threshold proximity can be about 20 ft.

(53) A system for remotely monitoring and managing health statuses of one or more users can comprise software instructions storable on a memory device usable by a computing device configured to be operated by a monitor user. The software instructions can be configured to cause one or more hardware processors of the computing device to receive a first set of health-related information from a first mobile computing device of a first user, said first set of health-related information comprising: physiological information derived from at least one wearable device when attached to the first user, said physiological information indicative of an onset of one or more

symptoms experienced by the first user and associated with one or more infections; and contact tracing data associated with the first user comprising information indicative of proximity of the first user to a second user, said proximity determined based on a detected wireless signal strength between a first wearable device of the first user and a second wearable device of the second user. The software instructions can further cause the one or more hardware processors of the computing device to: determine an accumulated duration, over a first time period, that said proximity between the first and second users is within a threshold proximity; determine an exposure level for the first user based on said contact tracing data, said accumulated duration, and a risk state of the second user associated with a likelihood that said second user had said one or more infections during at least a portion of said first time period; and determine a risk state of the first user based on at least said physiological information and said exposure level, said risk state of the first user associated with a likelihood that said first user has said one or more infections.

- (54) In some aspects of the disclosure, said software instructions can further be configured to cause one or more hardware processors of the computing device to: wirelessly transmit, to the first mobile computing device of the first user, at least one of said risk state of the first user and an instruction associated with said risk state of the first user. In some aspects, said first mobile computing device can be configured to indicate on a display of said first mobile computing device at least one of: said risk state of the first user and said instruction; and a representation of said at least one of said risk state of the first user and said instruction.
- (55) In some aspects, said first set of health-related information can further comprise diagnosis or test result data indicative of a positive or negative result to at least one of said one or more infections, and said one or more hardware processors can be further configured to determine said risk state of the first user based on said diagnosis or test result data. In some aspects, said first set of health-related information can further comprise symptom information of the first user recorded by the first mobile computing device, and said one or more hardware processors can be further configured to determine said risk state of the first user based on said symptom information. (56) In some aspects, said risk state of the second user can be determined by said one or more hardware processors based on at least: physiological information associated with the second user and derived from at least one wearable device when attached to the second user. In some aspects, said risk state of the second user can be determined by said one or more hardware processors further based on: an exposure level associated with the second user. In some aspects, said risk state of the second user can be determined by the said one or more hardware processors further based on an exposure level for the second user, said exposure level for the second user determined based on at least contact tracing data associated with said second user, said contact tracing data associated with said second user comprising information indicative of: proximity of the second user to at least a third user, said proximity determined based on a detected wireless signal strength between the second wearable device of the second user and a third wearable device of the third user when the second and third wearable devices are worn by the second and third users; an accumulated duration, over a second time period, that said proximity between the second and third users is within the threshold proximity; and a risk state of the third user associated with a likelihood that said third user had said one or more infections during at least a portion of said second time period. (57) In some aspects, said physiological information can comprise at least a body temperature of the first user. In some aspects, said first time period can comprise 7 days. In some aspects, said first time period can comprise 14 days. In some aspects, said detected wireless signal strength can comprise a detected Bluetooth® signal strength. In some aspects, said determined risk state of the first user can comprise one of: a confirmation that said first user has the one of more infections; a confirmation that said first user does not have the one of more infections; a confirmation that said first user is suspected to have the one of more infections and that said first user is experiencing said one or more symptoms associated with said one or more infections; and a confirmation that said first user is suspected to have the one of more infections and that said first user is not experiencing

said one or more symptoms associated with said one or more infections. In some aspects, said threshold proximity can be about 100 ft. In some aspects, said threshold proximity can be about 30 ft. In some aspects, said threshold proximity can be about 20 ft.

- (58) In some aspects, said physiological information can comprise body temperature of the first user. In some aspects, said physiological information can further comprise a heart rate of the first user. In some aspects, said physiological information can further comprise a respiratory rate of the first user. In some aspects, said physiological information can further comprise at least one of total hemoglobin levels, carboxyhemoglobin levels, and methemoglobin levels of the first user. In some aspects, said physiological information can further comprise oxygen saturation of the first user. In some aspects, said physiological information can further comprise at least one of a perfusion index of the first user and a pleth variability index of the first user. In some aspects, said at least one wearable device can comprise the first wearable device and a third wearable device separate from the first wearable device, the first wearable device can be configured to determine body temperature of the first user and the third wearable device can be configured to determine at least one of an oxygen saturation and a pulse rate of the first user.
- (59) In some aspects, said proximity can be determined based on a detected Bluetooth® signal strength between the first and second wearable devices.
- (60) A system for monitoring and managing a health status of a user can comprise a wearable device configured to couple to a first user comprising: at least one physiological sensor; a wireless transceiver configured to communicate with a mobile computing device of the first user; and a processor. The processor can be configured to: determine one or more physiological parameters of the first user based upon one or more signals received from the at least one physiological sensor, said one or more physiological parameters indicative of an onset of symptoms experienced by the first user and associated with an infection; and instruct the wireless transceiver to transmit to the mobile computing device said determined one or more physiological parameters; determine one or more proximity values indicative of distance between the wearable device and a separate wearable device that is coupled to a second user when said wearable device and said separate wearable device are within a threshold proximity, said one or more proximity values are determined based on a detected wireless signal strength between the wearable device and the separate wearable device. The processor can be further configured to, when said wearable device and said separate wearable device are within said threshold proximity based on said detected wireless signal strength, instruct the wireless transceiver to transmit to the mobile computing device: a first identifier associated with the second user of the separate wearable device; and said one or more proximity values. The system can further comprise a mobile software application configured for execution by one or more hardware processors of the mobile computing device of the first user. The mobile software application can be configured to execute commands to enable the mobile computing device to: wirelessly receive, from the wearable device, said one or more physiological parameters of the first user, said first identifier, a second identifier associated with the first user, and said one or more proximity values when said wearable device and said separate wearable device are within said threshold proximity; wirelessly transmit, to a remote monitoring system, said determined one or more physiological parameters of the first user, said first identifier, said second identifier, and said one or more proximity values; wirelessly receive, from the remote monitoring station, a risk state of the first user, the risk state associated with a likelihood that said first user has said infection; generate a graphical user interface on a display of the mobile computing device; and display, in at least a portion of the graphical user interface, at least one of said risk state and an instruction associated with said risk state.
- (61) In some aspects of the disclosure, said at least one physiological sensor can comprise one or more temperature sensors configured to generate one or more signals responsive to thermal energy of the first user, and said processor can be configured to determine one or more body temperature

values of the first user based on said one or more signals. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly receive, from the wearable device, said one or more body temperature values at a first time interval. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit said one or more body temperature values of first user, said first identifier, said second identifier, and said determined one or more proximity values at said first time interval. In some aspects, said first time interval can comprise every minute.

- (62) In some aspects, said one or more proximity values can be determined based on detected Bluetooth® signal strength between said wearable device and said separate wearable device. (63) In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly receive, from the remote monitoring system, information indicative of exposure of the first user to said infection. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to display, in at least a portion of the graphical user interface, at least one of said information indicative of said exposure and an instruction related to said information indicative of said exposure.
- (64) In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit, to the remote monitoring system, information indicative of a test result of the first user associated with said infection and inputted by the first user via the mobile software application. In some aspects, said mobile software application can be configured to execute commands to enable the mobile computing device to wirelessly transmit, to the remote monitoring system, information indicative of one or more symptoms of the first user associated with said infection and inputted by the first user via the mobile software application. In some aspects, said wearable device can be configured to detect only one type of physiological parameter of the first user, said one type of physiological parameter being body temperature. In some aspects, said threshold proximity can be about 30 ft. In some aspects, said threshold proximity can be about 10 ft. In some aspects, said threshold proximity can be about 6 ft.
- (65) A method for monitoring one or more contact events for a user to limit a spread of an infection can include providing a wearable device and providing a software application configured for execution by one or more hardware processors of a computing device. The wearable device can be configured to couple to a first user and can be further configured to determine proximity data indicative of distance between the wearable device and a separate wearable device that is configured to couple to a second user, said proximity data determined based on detected wireless signal strength between the wearable device of the first user and the separate wearable device of the second user. The software application can be configured to execute commands to enable the computing device to: receive, from the wearable device, a first identifier associated with the first user of the wearable device, a second identifier associated with the second user of the separate wearable device, and said proximity data; store said proximity data over time and determine one or more contact events based on said proximity data, wherein each of said one or more contact events is representative of the first and second users being within a threshold proximity from one another for a continuous period of time; generate a graphical user interface on a display of the computing device; display, in at least a portion of the graphical user interface, a timeline, said timeline being continuously updated over time; and display, in at least a portion of the graphical user interface, a visual representation of each one of said one or more contact events on said timeline. (66) In some implementations, the visual representation comprises a bubble, wherein a perimeter of
- (66) In some implementations, the visual representation comprises a bubble, wherein a perimeter of said bubble is indicative of said continuous period of time. In some implementations, a first point on said perimeter of said bubble is indicative of a time when each of said one or more contact events begins and a second point on said perimeter of said bubble is indicative of a time when each

of said one or more contact events ends. In some implementations, the first point is located 180° from said second point around said perimeter. In some implementations, the bubble comprises a circle. In some implementations, the bubble comprises an oval. In some implementations, a size of the visual representation is indicative of said continuous period of time.

- (67) In some implementations, the proximity data is determined based on a detected Bluetooth® signal strength between the wearable device and the separate wearable device. In some implementations, the computing device comprises a mobile computing device. In some implementations, the mobile computing device is a smartphone. In some implementations, the computing device is configured for operation by a third user. In some implementations, the threshold proximity is less than or equal to 20 ft. In some implementations, the threshold proximity is 6 ft.
- (68) In some implementations, the software application is configured to execute commands to enable the computing device to wirelessly receive said first identifier, said second identifier, and said proximity data over a network. In some implementations, the wearable device is configured to wirelessly transmit at least said second identifier and said proximity data to a mobile computing device, and wherein the software application is configured to execute commands to enable the computing device to wirelessly receive said first identifier, said second identifier, and said proximity data from the mobile computing device.
- (69) In some implementations, the mobile computing device is a smartphone. In some implementations, the wearable device is further configured to transmit said first identifier to said mobile computing device.
- (70) In some implementations, the visual representation comprises a circle, wherein a diameter of said circle is indicative of said continuous period of time. In some implementations, a first point on a perimeter of said circle is indicative of a time when each of said one or more contact events begins and a second point on said perimeter of said circle is indicative of a time when each of said one or more contact events ends. In some implementations, the first point is located 180° from said second point around said perimeter.
- (71) A system for monitoring one or more contact events for a user to limit a spread of an infection can include software instructions storable on a memory device usable by a computing device, the software instructions causing one or more hardware processors of the computing device to: receive, from a first wearable device configured to couple with a first user, proximity data indicative of distance between the first wearable device and a second wearable device that is configured to couple to a second user, said proximity data determined based on detected wireless signal strength between the first wearable device the second wearable device; receive, from the first wearable device, a first identifier associated with the first user of the first wearable device and a second identifier associated with the second user of the second wearable device; store said proximity data over time and determine one or more contact events based on said proximity data, wherein each of said one or more contact events is representative of the first and second users being within a threshold proximity from one another for a continuous period of time; generate a graphical user interface on a display of the computing device; display, in at least a portion of the graphical user interface, a timeline, said timeline being continuously updated over time; and display, in at least a portion of the graphical user interface, a visual representation of each one of said one or more contact events on said timeline.
- (72) In some implementations, the visual representation comprises a bubble, wherein a perimeter of said bubble is indicative of said continuous period of time. In some implementations, a first point on said perimeter of said bubble is indicative of a time when each of said one or more contact events begins and a second point on said perimeter of said bubble is indicative of a time when each of said one or more contact events ends. In some implementations, the first point is located 180° from said second point around said perimeter. In some implementations, the bubble comprises a circle. In some implementations, the bubble comprises an oval. In some implementations, a size of

the visual representation is indicative of said continuous period of time.

- (73) In some implementations, the proximity data is determined based on a detected Bluetooth® signal strength between the wearable device and the separate wearable device.
- (74) In some implementations, the computing device comprises a mobile computing device. In some implementations, the mobile computing device is a smartphone. In some implementations, the computing device comprises a desktop or a laptop. In some implementations, the computing device is configured for operation by a third user. In some implementations, the threshold proximity is less than or equal to 20 ft. In some implementations, the threshold proximity is 6 ft. (75) In some implementations, the software application is configured to execute commands to enable the computing device to wirelessly receive said first identifier, said second identifier, and said proximity data over a network. In some implementations, the wearable device is configured to wirelessly transmit at least said second identifier and said proximity data to a mobile computing device, and wherein the software application is configured to execute commands to enable the computing device to wirelessly receive said first identifier, said second identifier, and said proximity data from the mobile computing device. In some implementations, the mobile computing device is a smartphone. In some implementations, the wearable device is further configured to transmit said first identifier to said mobile computing device.
- (76) In some implementations, the visual representation comprises a circle, wherein a diameter of said circle is indicative of said continuous period of time. In some implementations, a first point on a perimeter of said circle is indicative of a time when each of said one or more contact events begins and a second point on said perimeter of said circle is indicative of a time when each of said one or more contact events ends. In some implementations, the first point is located 180° from said second point around said perimeter.
- (77) For purposes of summarizing the disclosure, certain aspects, advantages, and novel feature are discussed herein. It is to be understood that not necessarily all such aspects, advantages, or features will be embodied in any particular embodiment of the disclosure, and an artisan would recognize from the disclosure herein a myriad of combinations of such aspects, advantages, or features.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

- (1) The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.
- (2) FIG. **1** illustrates an exemplary system or environment in accordance with aspects of this disclosure.
- (3) FIGS. 2A-2I illustrate exemplary wearable devices in accordance with aspects of this disclosure.
- (4) FIG. **2**J illustrates exemplary components that can be incorporated into any of the wearable devices described herein in accordance with aspects of this disclosure.
- (5) FIGS. **3**A-**3**B illustrate exemplary interactions of wearable devices of users in accordance with aspects of this disclosure.
- (6) FIG. **4** illustrates exemplary components of a remote monitoring system in accordance with aspects of this disclosure.
- (7) FIG. **5**A illustrates exemplary interactions between one or more user computing devices and a remote monitoring system in accordance with aspects of this disclosure.
- (8) FIG. **5**B illustrates exemplary risk states in accordance with aspects of this disclosure.
- (9) FIG. **6**A-**6**B illustrate exemplary diagrams showing how one or more risk states can be determined and/or modified in accordance with aspects of this disclosure.
- (10) FIG. 7A illustrates exemplary interactions between one or more wearable devices, a user

- computing device, and a remote monitoring system in accordance with aspects of this disclosure.
- (11) FIG. 7B illustrates a diagram indicative of proximity data of one or more users in accordance with aspects of this disclosure.
- (12) FIG. 7C illustrates an exemplary contact tracing table in accordance with aspects of this disclosure.
- (13) FIGS. **8**A-**8**B illustrate exemplary methods of determining and receiving exposure levels and risk states.
- (14) FIGS. **9**A-**14**B illustrate exemplary user interfaces or portions thereof that can be employed by any of the computing devices discussed herein in accordance with aspects of this disclosure. DETAILED DESCRIPTION
- (15) Although certain embodiments and examples are described below, this disclosure extends beyond the specifically disclosed embodiments and/or uses and obvious modifications and equivalents thereof. Thus, it is intended that the scope of this disclosure should not be limited by any particular embodiments described below.

Overview

- (16) FIG. 1 illustrates an exemplary schematic diagram of a system or network environment 100 where information relating to one or more users 102, 112 can be communicated (for example, over a network 110) from wearable device(s) 104, 114, user computing devices 106, 116, and/or connectivity hubs 108, 118 to a remote monitoring and system 120 (also referred to herein as "remote monitoring system"). System 100 can be associated with and/or representative of an organization, such as a corporation, school, hospital, company managing a sports or concert or attraction venue, among others. System 100 can include any number of users. For example, system 100 can include user 102 and any number of additional users 112, such as one, two, three, four, five, six, seven, eight, nine, or ten or more, between 1 and 5000, between 1 and 2000, between 1 and 1000, 1 and 500, 1 and 200, 1 and 100, 1 and 50, or 1 and 20 users or any number within these ranges or bounded by any range including any value within these ranges. System 100 can also include any number of wearable devices 104, 114, connectivity hubs 108, 118, and/or user computing devices 106, 116 corresponding to the number of users 102, 112.
- (17) Any number of wearable devices **104**, **114** can be associated with (for example, coupled to) users associated with the system **100** (such as users **102**, **112**) and can be configured to measure and/or monitor a variety of types of information associated with the user, such as physiological information as well as other types of information (such as location data, movement data, etc.). Wearable device(s) **104**, **114** can communicate physiological and/or other information associated with the users **102**, **104** to the remote monitoring system **120** over a network **110**, for example, via a connectivity hub **108** and/or a user computing device **106**. Additionally or alternatively, wearable device(s) 104, 114 can communicate physiological and/or other information associated with the users 102, 104 directly to the remote monitoring system 120 (for example, without utilization of connectivity hub 108, 118 and/or user computing devices 106, 116) for example, over network 110 or over a wireless communication protocol such as any of those listed herein. For example, if the wearable device **104**, **114** is within a relatively short distance from the remote monitoring system **120**, wearable device **104**, **114** can be configured to transmit physiological and/or other information associated with the users **102**, **104** directly to the remote monitoring system **120**. As another example, any of such wearable devices **104**, **114** can be a smart watch configured to determine one or more types of physiological information (e.g., oxygen saturation, heart rate, pulse rate, etc.) and/or other information (e.g., location and/or movement data from accelerometer(s), gyroscope(s), magnetometer(s) of the smart watch, proximity data between one or more other wearable devices of other users such as that discussed herein) and can transmit such information directly to the remote monitoring system **120**. One, two, three, four, or five or more wearable devices **104**, **114** can be coupled with the user **102**, **112** and can measure and/or monitor (non-invasively or invasively) physiological information as well as other types of information of the user **102**, **112**. In

some cases, only one wearable device 104, 114 is secured to a user 102, 112. Any or all of the wearable devices and/or the user computing devices discussed herein can include one or more sensors that can obtain information associated with position, acceleration, orientation, and/or movement of a user, for example, an accelerometer, a gyroscope, and/or a magnetometer. (18) Wearable devices **104**, **114** can communicate with any of connectivity hub **108**, **118** and/or user computing device 106, 116 via a wired connection (for example, a cable) and/or wirelessly over any of a variety of wireless communication protocols, such as Wi-Fi (802.11x), Bluetooth®, ZigBee®, Z-Wave®, cellular telephony, infrared, RFID, satellite transmission, proprietary protocols, combinations of the same, among others. Similarly, any of connectivity hub 108, 118 and/or user computing device 106, 116 can wirelessly communicate with the wearable devices 104, **114** over any of such mentioned wireless communication protocols. In some cases, any of connectivity hub **108**, **118** and/or user computing device **106**, **116** can wirelessly communicate with the remote monitoring system **120** over any of such mentioned wireless communication protocols, among others. In some cases, the wearable device **104**, **114** communicate (e.g., respectively) with user computing device 106, 116 via a first wireless communication protocol and the user computing device **106**, **116** communicate with the remote monitoring system **120** over a second wireless communication protocol. Such first and second wireless communication protocols can be different or, alternatively, the same.

(19) Wearable devices **104**, **114** can be any device that can be (at least partially) coupled with (for example, secured to) a user **102**, **112** and can measure, monitor, and/or detect information associated with the user **102**, **112**, such as physiological information or other information (e.g., location and/or movement data and/or proximity data such as that discussed herein). Wearable devices 104, 114 can non-invasively and/or invasively measure or monitor physiological information of a user 102, 112. As an example, wearable devices 104, 114 can be devices capable of administering one or more medications to the user **102**, **112**. Wearable devices **104**, **114** can be any of the wearable devices discussed herein, such as wearable device 200, 210, 220, 230, 240, **250**, **260**, and/or **270**, among others. As another example, wearable devices **104**, **114** can be any commercially available wearable device from Masimo Corporation of Irvine California, or other medical device manufacturer, including but not limited to noninvasive, minimally invasive, or microinvasive glucose sensors, oximetry or cooximetry sensors, pulse rate sensors, cuff and/or continuous noninvasive blood pressure sensors, capnography sensors, acoustic sensors, motion sensors including accelerometers and gyroscopes, pH sensors, image capture sensors using virtually any type of signal and/or wavelength filters, ECG, depth of sedation, pulse transit time or other parameter responsive to pulse transit time, cardiac parameter sensor, ultrasonic sensor, magnetic imagining sensor, x ray sensor, infrared sensor, proximity sensors, GPS or other location sensors, or the like or combinations thereof. In some cases, wearable devices 104, 114 can be configured to secure to various locations of a user's body including, but not limited to, chest, torso, back, shoulder, arms, legs, neck, or head. Various means can be used to attach the wearable devices **104**, **114** to a user. For example, the wearable devices **104**, **114** can be secured to the skin of a user with an adhesive. In another example, the wearable devices **104**, **114** can be attached to a user with a fastener, such as tape, laid over at least a portion of the wearable devices **104**, **114**. Additionally or alternatively, the wearable devices **104**, **114** can be attached to a user via one or more straps. (20) Connectivity hub **108**, **118** can be a Wi-Fi hotspot, router, or "smart home hub" such as those commercially available by Amazon®, Google®, Samsung®, Apple®, or others. User computing device 106, 116 can be a laptop, mobile phone (for example, smart phone), watch (for example, a smart watch that can measure and/or monitor one or more physiological parameters), tablet, desktop, personal digital assistant (PDA), smart glasses, or other computing device capable of communicating with wearable device **104**, wirelessly or via a wired connection, such as those discussed herein. In some cases, wearable devices **104**, **114** can communicate with (for example, transmit data to) one of the connectivity hub 108, 118 or the user computing device 106, 116

depending on which has a more reliable connection. User computing device **106**, **116** can include a processor, storage device, and/or wireless (and/or wired) communication capabilities that can allow communication (for example, receipt and transmission of information) to and from wearable device **104**, **114** and/or remote monitoring system **120**. In some implementations, system **100** does not include a connectivity hub, such as connectivity hub **108**, **118**.

- (21) User computing device **106**, **116** and/or connectivity hub **108**, **118** can transmit health-related information and/or other information received from the wearable device 104, 114 to the remote monitoring system 120 for analysis, storage, and/or monitoring/management. Additionally or alternatively, user computing device **106**, **116** can transmit health-related information and/or other information obtained by the user computing device **106**, **116** itself (for example, as opposed to being obtained from the wearable device **104**, **114**) to the remote monitoring system **120** for analysis, storage, and/or monitoring/management. Such health health-related information (which may also be referred to herein as "health status information" and/or "health risk information") can include any information that may be associated with, representative of, and/or indicative of a user's health. Such health health-related information can include, without limitation: physiological information of a user; information related to proximity of the user to one or more (or a plurality of) other users (for example, for determination of contact tracing and/or exposure to potential infections and/or diseases); information and/or data related to a user's diagnosis and/or test result(s) with respect to one or more infections and/or diseases (e.g., positive and/or negative test results, diagnosis obtained from a medical professional); and information and/or data related to symptom(s) experienced by the user (which can be input by the user into a computing device operated by a user, for example).
- (22) In some implementations, the user computing device 106, 116 can allow a user 102, 112 to authorize the transmission (for example, "sharing") of health-related information with the remote monitoring system 120 and/or other third parties or third party devices that may be able to communicate with and/or access remote monitoring system 120. In some implementations, the user computing device 104, 114 can transmit an alert to the remote monitoring system 120 based on health-related information received from the wearable devices 104, 114 and/or inputted or determined by the user computing device 106, 116. Such alert can be associated with, by way of non-limiting example: a body temperature of a user 102, 112 over a threshold value measured by the wearable device 104, 114 and transmitted to the user computing device 106, 116; contact tracing data determined by the wearable device 104, 114 and/or user computing device 106, 116 indicative of proximity of the user 102, 112 to one or more other users over a period of time and/or health statuses (for example, risk state(s)) of such one or more other users over such period of time; a diagnosis received from a care provider associated with the user 102, 112 and inputted by the user 102, 112 into the user computing device 106, 116; and/or symptom(s) information of, and inputted by, the user 102 into the user computing device 106, 116.
- (23) Connectivity hubs **108**, **118** can be configured in a similar or identical manner as discussed above with reference to user computing device **106**, **116**. In some implementations, the user computing device **106**, **116** can be utilized to configure (for example, program) connectivity hub **108**, **118** such that it can carry out any of functions/operations described above with reference to the user computing device **106**, **116**, alone or in combination with the user computing device **106**, **116** (for example, when there is a stronger connection between the wearable device **104**, **114** and the connectivity hub **108**, **118** than with the user computing device **106**, **116**).
- (24) In some implementations, a user **102** can authorize their health-related information or other information to be shared with another user **112**. For example, in some implementations, a user **102** can authorize (via user computing device **106**) the transmission of health-related information determined by the wearable device(s) **104** from connectivity hub **108** and/or user computing device **106** to the connectivity hub **118** and/or user computing device **116**. Similarly, in some implementations, a user **102** can authorize (via user computing device **106**) the receipt of health-

related information determined by the wearable device(s) 114 from connectivity hub 118 and/or user computing device **116** to the connectivity hub **108** and/or user computing device **106**. (25) User computing device **106**, **116** (and/or any of the other computing devices discussed herein) can be configured to execute one or more applications that can present graphical user interfaces on, for example, a display of the user computing device **106**, **116**. Such applications and/or graphical user interfaces can advantageously display physiological and/or other information received from the wearable device(s) 104, 114 and/or can communicate information to the user 102, 112, for example, instructions and/or information received from the remote monitoring system **120**. User computing device **106**, **116** can allow a user **102**, **112** to share health-related information that evidences their current physiological condition. By way of non-limiting example, utilizing the user computing device **106**, a user **102** could clear themselves for work each day, clear themselves to enter a particular business establishment, like a diner, shopping, sports venue, concert venue, attraction venue, or gym, clear themselves as a spectator or participant for large or small event gatherings, including sports, marriages, religious endeavors, concerts, performances, school attendance, hospital or nursing home admittance, admittance to flights, car services, public transportation of all manners, even meeting with a small group of friends or going on a date. Being able to provide electronically obtained evidence (for example, physiological information obtained from the wearable device(s) **104** and/or inputted into the user computing device **106**) that a person's current wellness is "normal" (e.g., within medically accepted standards) for that person can easily be the gating function for virtually any and all daily interactions and activities. For example, showing a mobile phone's displayed indication that "I'm green," or transmitting some signal indicating the same, may advantageously become a default greeting or admittance requirement for an almost limitless number of possible scenarios.

(26) User computing device **106**, **116** can allow a user **102**, **112** to input various health-related information, including but not limited to: a diagnosis received from a care provider (for example, whether the user is confirmed for an infection); symptom(s) information (for example, fever, chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, loss of taste or smell, congestion or runny nose, nausea or vomiting, diarrhea, among others); and/or contract tracing data (for example, proximity with other user who had or are suspected to have an infection). Diagnosis and/or symptom(s) information can be any of that which is described herein, among others. Symptom(s) information can be obtained by the user computing device **106**, **116** based on questionnaire(s) provided to the user 102, 112, among other methods (e.g., allowing the user to manually enter symptoms). The questionnaire(s) can include questions related to the symptoms the user (e.g., symptoms related to COVID-19 or other communicable diseases) is experiencing or medical tests that the user has taken. For example, the user computing device **106**, 116 can include an application that can present (e.g., via execution by one or more processors of the user computing device **106**, **116**) the following example symptoms questionnaire to the user via a display of the user computing device **106**, **116**: In the last 24 hours have you: Developed a cough? Experienced shortness of breath? Experienced chills? Experienced muscle pain? Lost the sense of taste or smell? Experienced nausea, vomiting, or diarrhea? Experienced loss of appetite? Experienced fatigue? As another example, the application can present the following example medical tests questionnaire to the user: "In the last two weeks have you had a PCR Coronavirus Test?" "If yes, when and what was the result?" "Have you had an Antibody Test?" "If yes, when and what was the result?" These questions are not exhaustive of those that can be used. Further it will be appreciated that additional questions related to other diseases could also be utilized. The frequency of the questionnaires can be configured to be any amount of time. For example, the application can present the symptoms questionnaire to the user **102**, **112** on a daily basis and the medical tests questionnaire on a weekly basis. If the user 102, 112 fails to complete the questionnaires every day or every week, then the remote monitoring system **120** can modify a risk state of the user 102, 112 accordingly, for example, by increasing the user's risk state which is

described in more detail elsewhere herein (for example, can determine that the user is in a "yellow" risk category).

- (27) Remote monitoring system **120** can be configured to communicate with (for example, receive information from and/or transmit information to) any number of user computing devices 106, 116, connectivity hubs **108**, **118**, and/or wearable devices **104**, **114** associated with any number of users **102**, **112**. For example, remote monitoring system **120** can be configured to receive data from and/or transmit data to one, two, three, four, five, six, seven, eight, nine, or ten or more, between 1 and 5000, between 1 and 2000, between 1 and 1000, between 1 and 500, between 1 and 200, between 1 and 100, between 1 and 50, or between 1 and 20 of user computing devices 106, 116, connectivity hubs **108**, **118**, and/or wearable devices **104**, **114**, or any number within these ranges or bounded by any range including any value within these ranges. Advantageously, as will be discussed in greater detail below, remote monitoring system **120** can be utilized by an organization (e.g., business, school, hospital), or a user thereof (for example, a "monitor user" tasked with overseeing and/or taking action with respect to the remote monitoring system 120), to monitor and/or manage health statuses of users 102, 112 associated with the organization in order to limit the spread of an infectious disease or otherwise protect the health of such users 102, 112. As also discussed herein, the remote monitoring system **120** can advantageously allow continuous, automatic, and simultaneous receipt of health-related and/or other information from a large number of users associated with an organization and also allow health statuses, exposure levels, and/or risk states/statuses of each user to be dynamically determined and updated in real time.
- (28) Exemplary Wearable Devices
- (29) FIGS. **2**A-**2**I illustrate exemplary wearable devices **200**, **210**, **220**, **230**, **232**, **240**, **250**, **260**, **270**, and are described further below. As discussed previously, wearable devices **104**, **114** can be any of wearable devices **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**, among others.
- (30) FIGS. **2**A-**2**B illustrate a wearable device **200** that can continuously or periodically measure and/or monitor body temperature of a user, among other physiological parameters and/or information. Wearable device **200** can include a housing **202** and one or more substrates **204***a*, **204***b*, **204***c*, **204***d*, **204***e*, **204***f*, which are coupled to the housing **202** and/or other components of the wearable device **200** and which can enable, among other things, the wearable device **200** to couple with (for example, secure to skin of) a user. Wearable device 200 can additionally include a processor, a storage device, a wireless transceiver, a power source (for example, a battery), information element, and/or one or more temperature sensors (such as one, two, or three temperature sensors). For example, as discussed elsewhere herein, wearable device **200** can include any of processor **302**, storage device **304**, wireless transceiver **306**, power source **308**, information element **310**, physiological sensor(s) **312**, and/or other sensor(s) **314** discussed below with respect to FIG. 2J. Any of the processor, storage device, wireless transceiver, battery, information element, and/or one or more temperature sensors of wearable device 200 can be mounted and/or coupled with a circuit layer of the wearable device **200**, such as a circuit board **205** of the wearable device **200**, which can be enclosed or at least partially enclosed by the housing **202** (and/or a portion of the housing **202**) and/or one or more substrates **204***a*, **204***b*, **204***c*, **204***d*, **204***e*, **204***f*. In some implementations, wearable device **200** is configured to determine only one type of physiological parameter, for example, body temperature. In such configurations, a battery life of the wearable device **200** can be maximized.
- (31) As discussed above, the wearable device **200** can include one or more temperature sensors, and such one or temperature sensors can be or include, a thermocouple and/or a thermistor, for example. A thermocouple can produce a voltage when the contact spot differs from a reference temperature. Thermocouples may be self-powered and therefore may not require an external power source for operation. A thermistor is a type of resistor whose resistance value can vary depending on its temperature. Thermistors typically offer a high degree of precision within a limited temperature range. The one or more temperature sensors of the wearable device **200** can be a chip

that is electrically and mechanically coupled with the circuit board **205**. The one or more temperature sensors of the wearable device **200** can be configured to generate one or more signals responsive to detected thermal energy of a user, determine body temperature, and/or transmit such generated one or more signals and/or such determined body temperature to the processor of the wearable device **200** continuously and/or intermittently. For example, the one or more temperature sensors of the wearable device **200** can be configured to generate one or more signals responsive to detected thermal energy, determine body temperature, and/or transmit such generated one or more signals and/or such determined body temperature every 0.5 seconds, 1 second, 2 second, 3 seconds, 4 seconds, 5 seconds, 10 seconds, 30 seconds, 1 minute, 2 minute, 3 minutes, 4 minutes, 5 minutes, or at other intervals.

- (32) Wearable device **200** can be similar or identical to any of the wearable devices disclosed in copending U.S. patent application Ser. No. 17/206,907, filed on Mar. 19, 2021, titled "WEARABLE DEVICE FOR NONINVASIVE BODY TEMPERATURE MEASUREMENT," which is hereby incorporated by reference in its entirety.
- (33) FIGS. 2C-2I illustrate other exemplary wearable devices 210, 220, 230, 240, 250, 260, 270 that can be utilized alone or in combination with one another and/or with wearable device **200** in system **100**, for example, as wearable devices coupled and/or associated with user **102**, **112** and in communication (e.g., wireless) with user computing device **106**, **116** and/or connectivity hub **108**, 118. Any or all of wearable devices 210, 220, 230, 240, 250, 260, 270 can be secured to various portions of a user's body and/or can be configured to wirelessly communicate with separate devices which are not secured and/or not near the user's body. FIGS. 2C-2F illustrate an exemplary user computing device **206** that can be, for example, a smartphone. However, any of the wearable devices 210, 220, 230, 240, 250, 260, 270 can be configured to communicate (e.g., wirelessly or via a cable) with any type of computing device such as any of those discussed herein. (34) FIG. 2C illustrates a wearable device 210 that can secure to a user's arm (for example, wrist). Wearable device **210** can be secured to the user's wrist via a strap, as shown. Wearable device **210** can be similar or identical to any of the wearable devices and/or sensor systems disclosed in U.S. Patent Pub. No. 2020/0138288, filed on Oct. 10, 2019, titled "SYSTEM FOR TRANSMISSION OF SENSOR DATA USING DUAL COMMUNICATION PROTOCOL," which is hereby incorporated by reference in its entirety. Wearable device **210** does not have to be physically attached to a monitoring device or a computing device (such as user computing device 106, 116), for example, via a cable, and can be configured for wireless communication. Therefore, a user may be able to move around, for example, in their home, hospital room, hotel room, place of employment, school, or outdoor area (for example, parks, beaches, and malls), without having to worry about cables or cords limiting their range of movement. Wearable device **210** can establish wireless communication with nearby devices to securely transmit physiological data or other data collected from a user. As illustrated in FIG. 2C, wearable device 210 can be configured to wirelessly communicate with a separate computing device **206**, which can be a mobile phone, for example, among other types of computing devices such as any of those discussed herein (for example, laptop, desktop, tablet, among others). Wearable device **210** can be configured to communicate with computing device **206** (or any other computing device) over a wireless communication protocol such as any of those discussed elsewhere herein. For example, wearable device **210** can be configured to communicate to computing device **206** via Bluetooth®. (35) FIG. **2**D illustrates another example wearable device **220**. Wearable device **220** can include a sensor 222 and a cable assembly 224. As shown, the sensor 222 can be coupled to computing device **206** via the cable assembly **224**. Accordingly, the computing device **206** may receive user physiological data from the sensor **222** via the cable assembly **224**. The sensor **222** can be powered by a power source of the user computing device **206**, which may have greater capacity than a battery of the wearable device **220** (for example, a battery that may be within sensor **222**). As such, the configuration of the wearable device **220** and the computing device **206** can collect

physiological data for a longer period of time relative to some other types of devices and/or configurations. User physiological data can be transmitted to the computing device **206** via the cable assembly **224**, which may avoid some security challenges present in some wireless data transmission methods. A portion of the wearable device **220** can be secured to a user. For example, the sensor **222** can be secured to a user's finger or toe, or another portion of a user. The sensor **222** can be a pulse oximeter, for example the Masimo Rainbow® pulse oximeter. Wearable device **220** can be similar or identical to any of the physiological monitoring systems disclosed in U.S. Pat. No. 9,877,650, issued on Jan. 30, 2018, titled "PHYSIOLOGICAL MONITOR WITH MOBILE COMPUTING DEVICE CONNECTIVITY," which is hereby incorporated by reference in its entirety.

- (36) FIG. 2E illustrates another example wearable device **230**. Wearable device **230** can be, for example, a smartwatch configured to measure and/or monitor one or more physiological parameters of a user (e.g., oxygen saturation, pulse rate, heart rate) and/or other information of a user (e.g., location and/or movement data determined from accelerometer(s), gyroscope(s), magenetometer(s) of the smartwatch). In some implementations, wearable device **230** can be configured to detect proximity to other wearable devices that may be associated with (e.g., attached to) other users, in a similar or identical manner as that discussed elsewhere herein. Wearable device **230** can be configured to communicate over a wireless communication protocol such as any of those discussed elsewhere herein. Wearable device **220** can be similar or identical to any of the wearable devices, physiological sensors, and/or watches disclosed in U.S. patent application Ser. No. 17/148,303, filed on Jan. 13, 2021, titled "WEARABLE DEVICE WITH PHYSIOLOGICAL PARAMETERS MONITORING," which is hereby incorporated by reference in its entirety.
- (37) FIG. **2**F illustrates another example wearable device **240**. Wearable device **240** can be a fingertip pulse oximeter, for example, the MightySat® Rx Fingertip Pulse Oximeter by Masimo Corporation, Irvine, CA. Wearable device **240** can be configured to wirelessly communicate one or more physiological parameters of the user (e.g., oxygen saturation, pulse rate, heart rate) to the user computing device **206**.
- (38) FIGS. 2G-2I illustrate additional exemplary wearable devices 250, 260, 270 that can measure and/or monitor physiological data of a user and transmit indications of the user's physiological parameters to a user computing device, such as computing device **206**. As illustrated, wearable devices **250**, **260**, **270** can transmit such data to a computing device **206** via a cable. (39) Wearable device **250** can include a processor and an electrocardiogram (ECG) sensor and/or an electroencephalograph (EEG) sensor. A portion of the wearable device **250** can be secured to a user to measure and/or monitor one or more physiological parameters and/or detect signals (for example, electrical signals) generated by the user. The ECG sensor may capture one or more physiological signals related to cardiac activity. The processor of the wearable device **250** can process the one or more physiological signals to measure the user's cardiac activity and/or to detect arrhythmias, such as bradycardia, tachyarrhythmia, or ventricular fibrillation. In some implementations, wearable device **250** can transmit unprocessed data to a separate computing device for processing thereon, for example, to determine such above-mentioned cardiac-related characteristics. Alternatively or additionally, wearable device **250** can include EEG sensor that can be configured to measure electrical activity along the scalp and/or forehead. Wearable device **250** can be similar or identical to any of the forehead sensors or systems disclosed in U.S. Pat. No. 8,821,397, issued on Sep. 2, 2014, titled "DEPTH OF CONSCIOUSNESS MONITOR INCLUDING OXIMETER," which is hereby incorporated by reference in its entirety. Wearable device **250** can be similar or identical to any of the modular physiological sensors or systems disclosed in U.S. Pat. No. 10,154,815, issued on Dec. 18, 2018, titled "MODULAR PHYSIOLOGICAL SENSORS," which is hereby incorporated by reference in its entirety. (40) FIG. 2H illustrates a wearable device **260** that includes a capnometer or capnograph that can

be configured to measure components of expired breath.

- (41) FIG. 2I illustrates a wearable device **270**, a portion of which can secure to a user. Wearable device **270** an acoustic respiration sensor that can capture one or more physiological signals related to vibrational motion from the user's body (e.g., the user's chest) that are indicative of various physiologic parameters and/or conditions, including without limitation, heart rate, respiration rate, snoring, coughing, choking, wheezing, and respiratory obstruction (e.g., apneic events). Wearable device **270** includes an acoustic respiratory monitor sensor that can be configured to measure respiration rate using an adhesive sensor with an integrated acoustic transducer. Additional details regarding an example acoustic respiration sensor are described in U.S. Pat. No. 8,771,204 titled "ACOUSTIC SENSOR ASSEMBLY," which is hereby incorporated by reference in its entirety. (42) Any of the wearable devices discussed herein, such as wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**, can be similar or identical to any of the devices for measuring and/or monitoring one or more physiological parameters disclosed in U.S. Pat. Pub. No. 2020/0329993, published on Oct. **22**, 2020, titled "ELECTROCARDIOGRAM DEVICE," which is hereby incorporated by reference in its entirety.
- (43) FIG. 2J illustrates a block diagram of exemplary components which can be incorporated, all or in part, into any of the wearable devices discussed herein, such as wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**. Any of the wearable devices discussed herein, such as wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**, can include one or more of a processor **302**, storage device **304**, communication interface such as a wireless transceiver **306**, power source 308, and/or information element 310. Any of the wearable devices discussed herein, such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270, can include one or more physiological sensors 312 configured to monitor and/or measure one or more physiological parameters of a user and/or generate one or more signals responsive to detecting characteristics of the user. Such sensors 312 can be for example, optical sensors (which also may be referred to herein as "oximetry sensors" and/or "pulse oximeters"), moisture sensors, impedance sensors, ECG sensors, EEG sensors, acoustic respiration sensors, and/or temperature sensors, among others. Any of the wearable devices discussed herein, such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270, can be configured to measure and/or monitor physiological data including, but not limited to, temperature, blood pressure, pulse rate, heart rate, respiratory rate (RRa), total hemoglobin (SpHb®), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), oxygen content (SpOCTM), oxygen saturation (SpO2), pulse rate (PR), perfusion index (Pi), blood pressure, pleth variability index (PVi®), electroencephalogram (EEG) data, trending values of the same or combinations of the same, wellness indexes, or the like. Any of the wearable devices discussed herein, such as wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**, can include one or more other sensors **314**, such as one or more accelerometers, gyroscopes, magnetometer (compass), among others. Such sensors 314 can provide information associated with the user that can be used, processed, and/or transmitted alone or in combination with physiological data such as that discussed above. Any of such physiological data or other user information can be measured, monitored, and/or detected by sensor(s) 312 and/or 314 continuously and/or intermittently.
- (44) The processor **302** can be configured, among other things, to process data, execute instructions to perform one or more functions, and/or control the operation of the wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**. For example, the processor **302** can process physiological data obtained from the wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270** and can execute instructions to perform functions related to storing and/or transmitting such physiological data, for example, to a separate computing device. For example, the processor **302** can process data received from one or more physiological sensors **312** and can execute instructions to perform functions related to storing and/or transmitting such received data. (45) The storage device **304** can include one or more memory devices that store data, including

without limitation, dynamic and/or static random access memory (RAM), programmable read-only memory (PROM), erasable programmable read-only memory (EPROM), electrically erasable programmable read-only memory (EEPROM), and the like. Such stored data can be processed and/or unprocessed physiological data obtained from the wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**, for example.

- (46) Any of the wearable devices discussed herein, such as wearable device 104, 114, 200, 210, **220**, **230**, **240**, **250**, **260**, and/or **270**, can include a wireless transceiver **306** or other communication interface or component configured to allow wireless communication with other wearable devices, computing devices (such as user computing device 106, 116), connectivity hubs (such as connectivity hub 108, 118), remote monitoring systems (such as remote monitoring system 120, and/or other devices or systems (such as remote monitoring system **120**) over a variety of wireless communication protocols, such as Wi-Fi (802.11x), Bluetooth®, ZigBee®, Z-Wave®, cellular telephony, infrared, RFID, satellite transmission, proprietary protocols, combinations of the same, and the like. Additionally or alternatively, any of the wearable devices discussed herein (such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270) can include near field communication (NFC) structure and/or functionality that can enable the wearable device to communicate with another wearable device (for example, to determine proximity thereto as discussed elsewhere herein) and/or with any of the computing devices discussed herein. For example, any of the wearable devices discussed herein (such as wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**) can include an active or passive RFID tag that can allow an NFC reader of a separate device to register, track, and/or determine information about the wearable device such as an device identifier, among other things.
- (47) With continued reference to FIG. 2J, any of the wearable devices discussed herein, such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270, can include a power source 308, such as a battery. The power source 308 can provide power for hardware components of the wearable device. The power source 308 can be, for example, a lithium battery. Additionally or alternatively, any of the wearable devices discussed herein (such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270) can be configured to obtain power from a power source that is external to the wearable device. For example, any of the wearable devices discussed herein (such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270) can include or can be configured to connect to a cable which can itself connect to an external power source to provide power to the wearable device.
- (48) Any of the wearable devices discussed herein, such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270, can include an information element 310 which can be a memory storage element that stores, in non-volatile memory, information used to help maintain a standard of quality associated with the wearable device. Illustratively, the information element 310 can store information regarding whether the wearable device has been previously activated and whether the wearable device has been previously operational for a prolonged period of time, such as, for example, four hours. The information stored in the information element 310 can be used to help detect improper re-use of the wearable device for example.
- (49) FIGS. **3A-3B** illustrate a first wearable device **200** coupled to a user **102** and a second wearable device **200**' coupled to another user **112**. Wearable device **200**' can be identical to wearable **200** or alternatively, can be different (for example, can be the same as any other wearable device discussed herein). Wearable device **200**, **200**' can secure to a portion of a user's body, such as a torso, chest, back, arm, neck, leg, among other portions of the user's body. In some embodiments, multiple different, similar, or same wearable devices (such as any of those discussed herein) can be removably secured to virtually any one or more portions of the users' bodies. (50) Advantageously, in some implementations, each of wearable device **200**, **200**' can determine proximity to one another and/or to other wearable devices. Accordingly, the wearable devices **200**, **200**' can determine distance(s) between users **102**, **112** when the wearable devices **200**, **200**' are

coupled to the users **102**, **112**. Wearable device **200**, **200**′ can transmit and/or receive one or more (or a plurality of) signals from each other, for example, at various time intervals (e.g., every 1 second, 3 seconds, 5 seconds, 10 seconds, 30 seconds, 1 minute). Such signal(s) can be communicated over one or more, or a plurality of wireless communication protocols, including but not limited to Wi-Fi (802.11x), Bluetooth®, ZigBee®, Z-Wave®, cellular telephony, infrared, RFID, satellite transmission, proprietary protocols, near-field communication (NFC), combinations of the same, and the like.

- (51) In some cases, a strength of a signal received and/or transmitted by the wearable device **200**, **200**' can be a function of a distance between the two devices, for example, a distance between a wireless transceiver (or transmitter) of one of the wearable device 200, 200' and a wireless transceiver (or receiver) of the other one of the device **200**, **200**′. FIG. **3**A illustrates a first user **102** being a distance D1 from a second user 112 and FIG. 3B illustrates the first and second users 102, 112 being a distance D2 apart. As the two users 102, 112 move closer to one another, the distance between the two wearable device **200**, **200**′ decreases to a value of D**2**, which is smaller than D**1**. Accordingly, signal strength of transmitted and received signals between the two wearable device **200**, **200**' can increase. In some implementations, each of wearable device **200**, **200**' can determine a proximity from one another based on a detected signal strength. For example, processors of the wearable device **200**, **200**' can compare one or more received signals and/or associated signal strength to one or more reference points in order to determine proximity values, for example, distances in feet, meters, or inches. In some implementations, wearable device 200, 200' (for example, processors thereof) can compare detected signal strength to one or more signal thresholds. For example, if the signal strength is over a signal threshold, the wearable device **200**, **200**′ can determine that the distance between the devices 200, 200' and other devices and/or sensors is within some range or category. Such range or category can be, for example, "low", "medium", "high", "close", "far", and/or can be associated with ranges such as 0-6 ft, 6-20 ft, 20-50 ft, 50-100 ft for example. In some implementations, wearable devices **200**, **200**' are configured to detect proximity between one another when the distance between the two is within a proximity threshold. Such proximity threshold can be, for example, 200 ft, 100 ft, 80 ft, 70 ft, 60 ft, 50 ft, 40 ft, 30 ft, 20 ft, 15 ft, 10 ft, 9 ft, 8 ft, 7 ft, 6 ft, 5 ft, 4 ft, 3 ft, 2 ft, 1 ft, or any value between any of these values, or any range bounded by any combination of these values, although values outside these values or ranges can be used in some cases.
- (52) Although FIGS. **3**A-**3**B illustrate wearable devices **200**, **200**′ and the above-described proximity detection functionality is described with reference to wearable devices **200**, **200**′, any of the wearable devices discussed herein (wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**) can include such functionality and can be configured to detect proximity to one or more, or a plurality of, other wearable devices coupled to other users.
- (53) Any of the wearable devices discussed herein, such as wearable device **104**, **114**, **200**, **210**, **220**, **230**, **240**, **250**, **260**, and/or **270**, can be configured to detect proximity to one or more other wearable devices on other users (for example, when within a proximity threshold such as that discussed above) and can transmit proximity data (e.g., one or more proximity values) to a user computing device (such as computing device **206**, **106**, **116**) at various intervals, for example, at every 0.5 seconds, 1 second, 2 second, 3 seconds, 4 seconds, 5 seconds, 10 seconds, 30 seconds, 1 minute, 2 minute, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 30 minutes, or at other intervals. (54) Although FIGS. **3A-3B** illustrate just wearable device **200**, **200**′ coupled to a user **102**, **112**, various other numbers and/or types of wearable devices can be coupled to a user **102**, **112** and/or other wearable devices coupled to other users. By way of non-limiting example, wearable device **200** and wearable device **210** (each of which are discussed above) can both be coupled to a user **102** and either of both of which can be configured to detect proximity to other wearable devices coupled to other users and/or can transmit data (e.g., physiological of other data) measured

from and/or associated with the user **102**, for example, to a user computing device (such as user computing device **206**, **106**, **116**, among others).

- (55) Any of the wearable devices discussed herein (such as wearable device 104, 114, 200, 210, 220, 230, 240, 250, 260, and/or 270) can be configured for short, intermediate, or long term use. In some implementations, any of the wearable devices discussed herein (or portions thereof) can be configured to be coupled to (for example, adhesively secured to skin of) a user for a long period of time (for example, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days), can monitor (continuously or periodically) physiological information (for example, body temperature) and/or other information (for example, movement, orientation, location data) can transmit (for example, wirelessly) such physiological and/or other information to separate devices (for example, a mobile computing devices such as mobile phones). In some implementations, any of the wearable devices discussed herein are configured for hourly to daily one-time use, multi-day use, or even monthly use. In some implementations, any of the wearable devices discussed herein (or portions thereof) have reusable and/or disposable portions, and the reusable portions. In some implementations, any of the wearable devices discussed herein (or portions thereof) are fluid resistant and user sterilizable, for example, to allow a user to take a shower.
- (56) Remote Monitoring System
- (57) As discussed above, remote monitoring system **120** can be configured to communicate with (for example, receive data from and/or transmit data to) any number of user computing devices **106**, **116**, connectivity hubs **108**, **118**, and/or wearable devices **104**, **114** associated with any number of users **102**, **112**. As also discussed above, remote monitoring system **120** can advantageously be used by an organization (e.g., business, school, hospital), and/or a user thereof (for example, a "monitor user" of the organization), to monitor and/or manage health statuses of users **102**, **112** associated with the organization in order to limit the spread of an infectious disease or otherwise monitor the health of such users **102**, **112**. As another example, the remote monitoring system **120** can be utilized by an organization to facilitate clearance of one or more users for an event or gathering (e.g., by a sports or concert venue).
- (58) FIG. 4 illustrates exemplary components any or all of which can be incorporated into remote monitoring system **120**. The remote monitoring system **120** can include several subsystems and/or modules that can be implemented in hardware and/or software. The example modules or components shown may group functionality of examples of the remote monitoring system 120 together under logical descriptions. It should be understood, however, that the various modules and systems shown in the remote monitoring system **120** or portions thereof could be implemented together in a single system. In addition, not all of the systems or modules shown need be implemented on the same computing device but could instead be implemented in separate computing devices. Further, some of the modules shown may be omitted in various examples. The remote monitoring system 120 can be implemented on and/or accessed by one, or more than one computing device, such as a desktop, laptop, or other computing device (for example, mobile phone or tablet). The remote monitoring system **120** can include and/or be configured to interact with one or more servers. The remote monitoring system **120** can allow interaction, communication, monitoring, among other things, via a mobile and/or web application (for example, via a browser) of information received from one or a plurality of user computing devices (such as user computing device **106**, **118**) and/or connectivity hubs **108**, **118**. For example, by way of nonlimiting examples, the remote monitoring system **120** can allow for interaction, communication, monitoring with one, two, three, four, five, six, seven, eight, nine, or ten or more, between 1 and 5000, between 1 and 2000, between 1 and 1000, 1 and 500, 1 and 200, 1 and 100, 1 and 50, or 1 and 20 user computing devices, connectivity hubs, wearable devices, and/or users, or any number within these ranges or bounded by any range including any value within these ranges. The remote monitoring system **120** can be implemented across one, or more than one location. The remote monitoring system **120** and/or components thereof can be implemented by one or more virtual

- machines implemented in a hosted computing environment. The hosted computing environment may include one or more rapidly provisioned and/or released computing resources. The computing resources may include hardware computing, networking and/or storage devices configured with specifically configured computer-executable instructions. Hosted computing environments can be referred to as "cloud computing" environments. The remote monitoring system **120** can be utilized and/or accessed by one or more computing devices, for example, by a monitor user of the organization via an application (e.g., web and/or mobile) usable on a computing device (e.g., desktop, laptop, smartphone, tablet).
- (59) Remote monitoring system **120** can include a network management module **402**. The network management module **402** can manage network communications with other networks, including networks in organizations (e.g., offices, school, hospitals) as well as communications with user computing devices and/or connectivity hubs. Remote monitoring system **120** can also include one or more information database(s) **404** that can generally store data received from any of the user computing devices **106**, **116** and/or connectivity hubs **108**, **118** and/or directly received from any of wearable devices **102**, **112**. Such information stored in database(s) **404** can be any information received from the user computing devices **106**, **116**, connectivity hubs **108**, **118**, and/or wearable devices **102**, **112**, including but not limited to health-related information and/or other information such as that discussed herein.
- (60) A monitoring portal **406** of the remote monitoring system **120** can provide a user interface or user interfaces that can be accessed by users associated with the organization via a computing device (for example, a mobile phone, tablet, desktop, or laptop). For example,
- (61) monitoring portal **406** of the remote monitoring system **120** can provide a user interface that can be accessed by a monitor user of the organization. Such "monitor user" can be a user or users affiliated with the organization who are tasked with monitoring and/or managing aspects of the remote monitoring system **120**, for example, monitoring health-related information associated with user of the organization, viewing and/or modifying exposure levels and/or risk states of the users in the organization, sending notifications and/or instructions to users in the organization, among other things. The monitoring portal **406** may, for example, be implemented in one or more web pages, mobile applications, or other network applications and may provide information including and/or associated with the information received from the user computing devices **106**, **116**, connectivity hubs **108**, **118**, and/or wearable devices **102**, **112**. For example, the monitoring portal **406** can display health-related information, exposure levels, and/or risk states of one or more users, each of which are discussed in more detail elsewhere herein.
- (62) Remote monitoring system **120** can include a user profile manager **408**. The user profile manager **408** can manage user profiles, which can include information about user demographics, user notification (e.g., alarm) settings, user conditions and so forth. Remote monitoring system **120** can additionally or alternatively include a device profile manager **410** that can manage and store device profiles for wearable devices and/or user computing devices that interact with the remote monitoring system **120** as well as optionally other computing devices. In some implementations, the user profile manager **408** allows configuration, creation, and/or management of groups within the organization, such as the groups discussed below with respect to various exemplary user interfaces.
- (63) Remote monitoring system **120** can include a notification system **412**. The notification system **412** can issue notifications to user computing devices **106**, **116**, such as alerts of exposure to infections and/or instructions (for example, "quarantine for 7 days", "do not come into the office"). Such notification system **412** can be configurable by the organization, for example, by monitor users of the organization. For example, the notification system **412** can be configurable to enable the notification discussed with respect to the user interface **1207** in FIG. **12**F below. (64) In some implementations, the remote monitoring system **120** can include an information
- (64) In some implementations, the remote monitoring system **120** can include an information exchange system **414** that can facilitate communicating information about users to government or

research institutions. One scenario where user information may be submitted (anonymously) to government or research institutions is where a disease outbreak has occurred within an organization.

- (65) Remote monitoring system **120** can receive health-related and other information from a plurality of user computing devices **106**, **116**, connectivity hubs **108**, **118**, and/or wearable devices **104**, **114** and can store such received information in one or more user databases **404**. Example health-related information can be any of that discussed herein, including, without limitation: physiological information of one or more users; information related to proximity of the user to one or more (or a plurality of) other users (for example, for determination of contact tracing and/or exposure to potential infections and/or diseases); information and/or data related to a user's diagnosis and/or test result(s) with respect to one or more infections and/or diseases (e.g., positive and/or negative test results, diagnosis obtained from a medical professional); and information and/or data related to symptom(s) experienced by the user (which can be input by the user into a computing device operated by a user, for example). Exemplary physiological information, which can be measured by the wearable devices 104, 114 can be any of that discussed herein, including but not limited to temperature, blood pressure, pulse rate, heart rate, respiratory rate (RRa), total hemoglobin (SpHb®), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), oxygen content (SpOCTM), oxygen saturation (SpO2), pulse rate (PR), perfusion index (Pi), pleth variability index (PVi®), electroencephalogram (EEG) data, trending values of the same or combinations of the same, wellness indexes, or the like.
- (66) Remote monitoring system **120** can receive health-related and/or other information from a plurality of users in an organization and can be configured to determine various exposure levels and/or risk states of any of the plurality of users based on such received information. With continued reference to FIG. 4, remote monitoring system 120 can include a contact tracing engine **416** and a risk engine **418**. The contact tracing engine **416** can receive contact tracing data from one or more user computing devices **106**, **116**, connectivity hubs **108**, **118**, and/or wearable devices 104, 114. Such contact tracing data can include any information and/or data that may be associated with, representative of, and/or indicative of a user's (physical) proximity to one or more (or a plurality of) other users (e.g., within a proximity threshold as discussed herein), for example. (67) The contact tracing engine **416** and/or risk engine **418** can receive other information that may be related to such proximity data from one or more databases **404** forming part of or accessible to the remote monitoring system **120**. For example, such other information that may be related to such proximity data can include, without limitation: a duration of time that a user is within proximity (for example, with a proximity threshold) to one or more (or a plurality of) other users, a number of times (e.g., events) where a user is within proximity to one or more (or a plurality of) other users over a given period or time (e.g., 5 days, 7 days, 10 days, 14 days, 30 days, etc.); and/or and healthrelated information of any of such one or more other users that such user was within proximity of (e.g., a risk state of any of such one or more other users).
- (68) Additionally or alternatively, the contact tracing engine **416** and/or risk engine **418** can receive such other information that may be related to such proximity data from one or more user computing devices **106**, **116**, connectivity hubs **108**, **118**, and/or wearable devices **104**, **114**.
- (69) The contact tracing engine **416**, which is described in more detail further below, can keep track of locations and/or interactions of any of the plurality of users in the organization and determine potential exposure(s) that any of such users had to users who may be infected with an infectious disease (e.g., COVID-19) over a period of time. As will be discussed in more detail below, the contact tracing engine **416** can advantageously allow the remote monitoring system **120** to send notifications and/or instructions to any user in the organization related to determinations made by the contact tracing engine **416** and/or risk engine **418**, such as notifications that a particular user was within a threshold proximity (e.g., 100 ft, 50 ft, 20 ft, 6 ft) of a user during some time period who was confirmed for an infectious disease, for example, within that same time period.

- (70) The risk engine **418**, which is described in more detail below, can be configured to calculate a risk state (which also be referred to herein as a "risk level") associated with any or all of the users of an organization associated with the remote monitoring system 120. Such risk state can be representative of and/or indicative of a user's risk or likelihood of having one or more infections. By way of non-limiting example, the risk engine **418** can determine if a user falls under one of four risk categories that is associated with the user's likelihood of being infected with a disease or illness, for example, COVID-19. The risk engine 418 can determine a risk state of any or all of a plurality of users within an organization based on a variety of information, including but not limited to physiological information of one or more users (such as that discussed elsewhere herein), contact tracing data (such as proximity data with one or more other users, accumulation durations of time of proximity with other users, risk states of other users who were in proximity to the user, etc.), information and/or data related to a user's diagnosis and/or test result(s) with respect to one or more infections and/or diseases (e.g., positive and/or negative test results, diagnosis obtained from a medical professional), and/or information and/or data related to symptom(s) experienced by the user (which can be input by the user into a computing device operated by a user, for example). (71) FIG. **5**A illustrates, in a simplified form, how user computing devices **106**, **116** can interact with remote monitoring system **120**, and in particular, with the contact tracing engine **416** and the risk engine **418**. As illustrated and as discussed previously, any or all of a plurality of user computing devices **106**, **116** associated with (for example, employees of) and organization can transmit health-related information and/or other information such as that discussed above to the remote monitoring system **120**. The contact tracing engine **416** and risk engine **418** can carry out the functions discussed above and elsewhere herein, and the remote monitoring system **120** can transmit various information back to one or more of the plurality of user computing devices 106, **116**, for example, simultaneously. Such information transmitted to the one or more of the plurality of user computing devices **106**, **116** can include, among other things, a risk state of a user associated with the user computing device **106**, **116**, instructions that may be related to such risk state (e.g., instructions to avoid coming into the organization's facilities or to quarantine a certain amount of time), and/or notifications such as exposure to other users who may be confirmed as having a particular infection.
- (72) FIG. **5**B illustrates exemplary risk states that can be determined and/or transmitted by the remote monitoring system **120** to user computing devices **206** associated with users. While FIG. **5** illustrates mobile phones (smart phones) as user computing devices **206**, any other type of computing device can be used as discussed elsewhere herein. Accordingly, the discussion below with respect to risk states being sent to and/or displayed on user computing devices **206** is equally applicable to any of the user computing devices discussed herein.
- (73) With reference to FIG. **5B**, risk states determined and transmitted by the remote monitoring system **120** to the user computing devices **206** can be: "Clean" or "Negative" or "No risk" which can represent that a user does not have and/or is not at risk for having a particular infection and/or that the user is at no or low risk to infect others with the infection; "Suspected without signs or symptoms" which can represent that a user is suspected to have a particular infection (for example, based on contact tracing data in relation to other users who may be positive for the infection) but does not appear to currently have symptoms that may be associated with the particular infection; "suspected with signs or symptoms" which can represent that a user is suspected to have a particular infection (for example, based on contact tracing data in relation to other users who may be positive for the infection) and has one or more symptoms that may be associated with the particular infection; and/or "Confirmed" or "Positive" which can represent that a user does have a particular infection. Any of such risk states can be determined by the remote monitoring system **120** (for example, via the risk engine **418**) based on one or more of physiological data, contact tracing data, diagnosis and/or test result data, and/or symptom(s) data, each of which are discussed elsewhere herein.

- (74) The user computing device **102** (for example, all or a portion of a user interface on the user computing device **206**) may illuminate green to indicate that the user is unlikely to be infected. If the risk engine **135** determines that the user may be suspected of being infected but the user hasn't presented any symptoms, the user computing device **102** (for example, all or a portion of a user interface on the user computing device **206**) may illuminate yellow. If the risk engine **135** determines that the user may be showing symptoms and may be suspected of being infected, the user computing device **102** (for example, all or a portion of a user interface on the user computing device **206**) may illuminate orange. The user computing device **102** (for example, all or a portion of a user interface on the user computing device **206**) may illuminate red to indicate that the user is confirmed to be infected.
- (75) With reference to FIG. 5A-5B, the remote monitoring system 120 can send such risk state(s) and/or instructions or notifications associated with such risk states to user computing devices 106, 116. The user computing devices 106, 116 can be configured to display, for example, on a display thereof, the risk states and/or instructions or notifications associated with such risk states. For example, the user computing devices 206 can illuminate, for example, a portion or an entirety of a graphical user interface on a display thereof, a certain color which can be associated with said risk states. For example, as illustrated, the user computing device 206 can be configured to illuminate (e.g., flash): a green color associated with the "Clean" or "Negative" or "No risk" which is described above; a yellow color associated with the "Suspected without signs or symptoms" which is described above; an orange color associated with "Suspected with signs or symptoms" which is described above; and/or a red color associated with "Confirmed" or "Positive" which is described above. In some implementations, the remote monitoring system 120 can send instructions to the user computing device 106, 116 to enable a processor of the user computing device 106, 116 to execute an application to cause display of any of such risk state visual representations on all or a portion of a graphical user interface of the user computing device 106, 116.
- communicate with an external device to cause the external device to emit a visual and/or audio notification representative of these above-described risk states. For example, the user computing device 106, 116 may be configured to communicate with a nametag or other device that is configured to emit such visual and/or audio notifications. Such an exemplary nametag or other device can include suitable electronic hardware and/or software to enable communication with user computing device 106, 116 and emission of such visual and/or audio notifications. For example, such nametag or other device can include a processor, a wireless transceiver configured to communicate with the user computing device 106, 116 over any of the communication protocols discussed herein (such as Bluetooth® and/or NFC), one or more light emission sources (such as light emitting diodes (LEDs)) configured to illuminate the color that corresponds to the user's risk state, one or more audio devices configured to emit a sound and/or phrase associated with the risk state, and a power source configured to power these components (for example, a battery). (77) As an example, if the risk engine 418 determines a user is in an "orange" category (see above

(76) In some configurations, the user computing device **106**, **116** can be configured to

- discussion), the remote monitoring system **120** can communicate such information to the user computing device **106**, **116** and the user computing device **106**, **116** can communicate with a separate electronic nametag associated with (and/or coupled to) the user to instruct the nametag to cause the LEDs to illuminate orange. The illuminated nametag can advantageously allow an employer, for example, to quickly screen large numbers of employees in a short period of time, for example, before they enter a workplace. As another example, such illuminated nametag can allow a sports or concert venue to similarly screen large numbers of guests before allowing them into the venue
- (78) User computing device **106**, **116** can communicate with an electronic device different than such exemplary nametag discussed above in a similar manner. For example, use computing device **106**, **116** can communicate information and/or instructions associated with such risk states to an

electronic screening device such as a handheld wand or walkthrough screening device which can have similar electronic components and/or functionality as that discussed above with reference to the nametag. Such handheld wand or walkthrough screening device can be configured to notify a screener (for example, a person associated with the organization) of a user's risk state. When the user computing device **106**, **116** (and/or user associated such computing device **106**, **116**) is in sufficient proximity with the handheld wand or walkthrough screening device, the user computing device **106**, **116** can instruct the handheld wand or walkthrough screening device to illuminate the color associated to the user's risk state (such as "green", "yellow", "orange", or "red" as discussed above with reference to the described risk states).

- (79) In some scenarios, for example, where the remote monitoring system **120** is operated and/or monitored by a third party not directly affiliated with the organization to whom the users **102**, **112** belong, the remote monitoring system **120** can be configured to automatically send a notification to the organization (for example, a particular employee tasked with monitoring the system **120**) if a user's risk state is in a certain category (for example, "yellow", "orange", or "red"). In such cases the organization can then make a determination of whether to allow the user to come into the a facility of the organization. In some situations, the organization can utilize the remote monitoring system **120** to send instructions (for example, via a message) to the user to instruct the user to not come into the facility. In other scenarios where the organization (for example, a particular employee tasked with monitoring the system **120**) directly monitors or implements (for example, without the use of a third party) the system **120**, the organization may initiate the sending of such instructions to the user.
- (80) FIG. **6**A shows an exemplary diagram which illustrates how the remote monitoring system **120** can be used to determine and/or adjust risk states for various users associated with an organization. Advantageously, the remote monitoring system **120** can dynamically determine risk state(s) of various users based on health-related information and/or other information continuously received from the user computing devices **102**, **112** and/or the wearable devices **104**, **114**. As discussed above, the remote monitoring system **120** can receive sets of health-related information including physiological data from one or more wearable devices coupled to each of a plurality of users and other data. Such physiological data can be analyzed by the risk engine **418** to determine risk state(s). Additionally, as discussed previously, contact tracing data, diagnosis or test result data, and/or symptoms information, such as any of that described herein, can be received by the remote monitoring system **120** from the user computing devices **102**, **112** and/or the wearable devices **104**, **114** and can be utilized to determine risk state(s).
- (81) With reference to the exemplary diagrams of FIGS. **6**A-**6**B, the remote monitoring system **120** (via the risk engine 418) can determine the risk state of a user based on test results (for example, inputted by a user into the user's computing device and sent to the remote monitoring system **120**), exposure to one or more other users who have been determined have a certain risk state (for example, "red"), experienced symptom(s) (for example, which are inputted by a user into the user's computing device and sent to the remote monitoring system 120), among other things. For example, the remote monitoring system **120** (via the risk engine **418**) may automatically determine a user is in the red category (which can be indicative of the user being "Confirmed" for an infection) based on a positive test result to a particular infection (e.g., COVID-19). As another example, the remote monitoring system **120** (via the risk engine **418**) may automatically determine the user is in the yellow category based on a negative test result, low level exposure to another user who was determined to be in the red category, the user quarantining for a required amount of time, and/or the user not experiencing symptoms of the particular infection. As another example, the remote monitoring system **120** (via the risk engine **418**) may automatically determine that a user is in the orange category based on high-level of exposure to a user who was determined to be in the red category and/or the user experiencing symptoms of the infection. FIGS. **6**A-**6**B also illustrate how signs or symptoms can be used by the risk engine **418** to adjust a risk state (see "S&S" in FIG.

- **6**A). Such automatic determination by the remote monitoring system **120** (via risk engine **418**) allows for efficient and continuous monitoring and/or management of up to a vast amount of users and brings significant improvements to conventional approaches at limiting a spread of an infection at an organization.
- (82) Advantageously, the remote monitoring system **120** can be configured to allow manual adjustments and/or modifications to risk states by the organization, for example, based on other factors. For example, a monitor user tasked with monitoring the system **120** for an organization may manually change a risk state of a given user based on standards and/or guidance of the organization and/or of the monitor user. Such action is represented in FIGS. **6**A and **6**B as "Supervisor Approval" and "Supervisor Push" and can represent a monitor user "approving" a certain risk state for a certain user (for example, in response to a user's request) and "pushing" the user's risk state to another risk state. Such action can accordingly allow, for example, the employee to gain access to a facility of the organization. For example, such manual adjustment can be utilized to change a user's risk level from orange to yellow, yellow to orange, and/or yellow to green (see FIGS. **6**A-**6**B).
- (83) The remote monitoring system **120** can be configured to automatically change a user's risk state based on contact tracing data. For example, as indicated by the solid arrows in FIGS. **6**A-**6**B, certain events/factors related to contact tracing can automatically change the risk state of a user. For example, in some implementations, if the contact tracing engine **416** determines a first user in the green category had a low level exposure to a second user in the red category (e.g., the first and second user were a far distance apart for a short period of time), then the first user's risk state can automatically be changed to yellow. As another example, in some implementations, if the contact tracing engine **416** determines that a first user in the yellow category had a medium exposure to a second user in the red category (e.g., the first and second users were a medium distance apart for a medium period of time), then the first user's risk level can automatically be changed to orange. As another example, in some implementations, if the contact tracing engine **416** determines that a first user in the green category had a high level exposure to a second user in the red category (e.g., the first and second users were in close proximity for a long period of time), then the first user's risk level can automatically be changed to orange. Any of such terms "far", "medium", "close" can be represented by the values discussed elsewhere herein, for example, with respect to FIGS. 3A-3B and/or FIG. 7B.
- (84) As discussed above, a user's risk level may be manually changed by an assigned person of associated with the organization, such as the user, a manager, or a teacher. For example, an employer may assign certain screening roles to certain people in the organization. A senior employee may be assigned to be an initial screener with limited approval capabilities. For example, the senior employee may be able to clear an employee in the yellow category to be in the green category. However, the senior employee may not be able to clear an orange category. A manager or an administrator can be assigned to be a screener with more approval capabilities than the initial screener. For example, the administrator can clear an employee in the yellow or orange category to be in the green category. For employees in the red category, an authorized caregiver may be required to clear the employee to return to work.
- (85) In some implementations, the remote monitoring system **120** (for example, the risk engine **418**) may require the employer's approval before changing a user's risk state from one category, such as the yellow category, to another category, such as the green category. In some aspects, the employer may change and/or allow the change of a user's risk state from the yellow category to the orange category.
- (86) Any or all of the health-related information and/or other information received by the remote monitoring system **120** from the user computing devices **106**, **116** (or directly via the wearable devices **104**, **114**) can be stored in one or more database associated with the remote monitoring system **120**, for example, database(s) **404**. Additionally, any or all of the exposure levels and/or risk

states determined by the remote monitoring system **120** can be stored in such databases or different databases. The remote monitoring system **120** (for example, via the contact tracing engine **416** and/or risk engine **418**) can determine exposure levels and/or risk states of one or more users every 30 seconds, 1 minute, 2 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 1 hour, 2 hour, 3 hours, 6 hours, once per day, once per week, etc. Additionally or alternatively, the remote monitoring system **120** can be configured to determine exposure levels and/or risk states of one or more users at any point upon request from a user **102**, **112** (for example, via user computing device **106**, **116**) and/or a monitor user monitoring the system **120**. For example, in some implementations, an authorized user of the organization can request a report of all the individual risk states of the users associated with the organization. For example, an employer who owns a warehouse may want to monitor the employees' individual risks of being infected with COVID-19. The remote monitoring system **120** can be utilized to produce a report for the employer, which shows the risk state for each of the employees.

(87) Contact Tracing

(88) As discussed above, the remote monitoring system **120** (for example, via risk engine **418**) can determine one or more users risk states based on, among other things, contact tracing data. Such contact tracing data can include without limitation: any information and/or data that may be associated with, representative of, and/or indicative of a user's (physical) proximity to one or more (or a plurality of) other users (e.g., within a proximity threshold as discussed herein); a duration of time that a user is within proximity (for example, with a proximity threshold) to one or more (or a plurality of) other users; a number of times (e.g., events) where a user is within proximity to one or more (or a plurality of) other users over a given period or time (e.g., 5 days, 7 days, 10 days, 14 days, 30 days, etc.); and health-related information of any of such one or more other users that such user was within proximity of (e.g., a risk state of any of such one or more other users). (89) FIG. 7A illustrates a user **102**, a wearable device **200** coupled to user **102**, a user **112**, a wearable device **200**′ coupled to user **112**, a user **112**′, and a wearable device **200**″ coupled to user 112' which can be identical to the wearable devices 200, 200' discussed previously. Although FIG. 7A illustrates one wearable device **200**, **200**′, **200**″ coupled to the user **102**, **112**′, as discussed previously, any number of wearable devices of same or different type can be coupled to the user 102, 112, 112' and can operate as described below and elsewhere herein. Such wearable devices **200**, **200**′, **200**″ can be the same in some or all respects as any of the wearable devices discussed herein. Additionally, the discussed below with respect to any of wearable devices 200, 200', 200" is equally applicable to any of the wearable devices discussed herein (such as wearable devices **104**, **114**). Additionally, the discussed below with respect to user computing device **106** is equally applicable to any of the other user computing devices discussed herein. (90) As discussed previously, wearable device **200** can be configured to detect proximity to one or more other wearable devices coupled to one or more other users. For example, wearable device 200 can be configured to detect proximity form wearable device 200' and/or 200" simultaneously or non-simultaneously, based on detected signal strength between the devices **200**′, **200**″ and the wearable device **200**. The wearable device **200** can wirelessly communicate with wearable devices **200**′, **200**″ over any wireless communication protocol such as those discussed herein and signals transmitted and/or received over such protocols can be used for such proximity detection. Additionally, wearable device **200** can be configured to receive and/or transmit identifier(s) between wearable devices **200**′, **200**′ which can be associated with the users **112**, **112**′. Such information is advantageous as it allows the wearable device 200, and an associated user computing device **106**, to keep track of each user that comes into proximity with user **102** over various time periods, as well as keeping track of actual proximity values (e.g., distances). (91) In some configurations, wearable device **200** can detect proximity values when the wearable devices **200**′, **200**″ are within some threshold proximity, as discussed above (e.g., within 200 ft, 100 ft, 50 ft, 30 ft, 20 ft, 15 ft, 10 ft, 6 ft, 3 ft etc.) and can transmit such information to the user

computing device **106** at various time intervals (e.g., every second, every 3 seconds, every 5 seconds, every 30 seconds, every minute, every 2 minutes, every 5 minutes, every 10 minutes, every 30 minutes, every hour, etc.). In some implementations, wearable device **200**, user computing device **106**, and/or remote monitoring system **120** categorizes a user's **102** proximity to one or more other users (such as user **112**, **112**′). For example, in some implementations, wearable device **200**, user computing device **106**, and/or remote monitoring system **120** categorizes a user's proximity to user 112, 112' as "far", "medium", and/or "close" based on one or more proximity values determined between the wearable devices 200, 200', 200", as illustrated in FIG. 7B. With reference to FIG. 7B, the "far" category can be between about 20 ft and about 200 ft, between about 20 feet and about 100 feet, between about 20 feet and about 50 feet, between about 30 ft and about 200 ft, between about 30 feet and about 100 feet, between about 30 feet and about 50 feet, or any number within these ranges or bounded by any range including any value within these ranges. The "medium" category can be between about 10 ft and about 50 ft, between about 10 ft and about 40 ft, between about 10 ft and about 30 ft, between about 10 ft and about 20 ft, between about 10 ft and about 15 ft, or any number within these ranges or bounded by any range including any value within these ranges. The "close" category can between about 6 inches and about 20 ft, between about 1 ft and about 20 ft, between about 1 ft and about 15 ft, between about 1 ft and about 10 ft, between about 1 ft and about 6 ft, within 20 ft, within 15 ft, within 10 ft, within 6 ft, within 3 ft, or any number within these ranges or bounded by any range including any value within these ranges. (92) In some cases, the wearable device **200** and/or wearable devices **200**′, **200**″ are configured to communicate over only one wireless communication method or protocol so as to limit or prevent communication with other devices or systems. In some cases, the wearable device 200 and/or wearable devices **200**′, **200**″ are configured to communicate only with authorized devices (such as authorized user computing devices) and/or the remote monitoring system 120. In one example, the wearable devices **200**, **200**′, **200**′′ can be configured to detect only Bluetooth® signals from other wearable device(s) or other designated devices. Such configurations can enable the wearable device(s) to more easily track other wearable devices by limiting interferences from devices outside the system and/or prevent inadvertent tracking of devices outside the system. Such configuration can also advantageously improve battery life of the wearable devices by limiting the signals sent and received by the wearable devices.

- (93) With continued reference to FIG. 7A, the wearable device **200**, user computing device **106**, and/or remote monitoring system **120** can detect, register, and/or record a contact event when the wearable device **200** is within a threshold proximity to one or more other wearable devices (such as wearable device **200**′, **200**″). Such threshold proximity can be, as discussed above, for example, 200 ft, 100 ft, 80 ft, 70 ft, 60 ft, 50 ft, 40 ft, 30 ft, 20 ft, 15 ft, 10 ft, 9 ft, 8 ft, 7 ft, 6 ft, 5 ft, 4 ft, 3 ft, 2 ft, 1 ft, or any value between any of these values, or any range bounded by any combination of these values, although values outside these values or ranges can be used in some cases. Such threshold proximity can be associated with the "far" distance threshold and the associate dotted circle illustrated in FIG. 7B, for example, or alternatively, can be represented by the "medium" or "close" dotted circles in FIG. 7B. In some cases a contact event can represent and/or be associated with an amount of time that two users were within the threshold proximity to one another. For example, a contact event can occur when two users are within 6 ft, 10 ft, or 15 ft from one another for a period of greater than 2 minutes, greater than 5 minutes, greater than 10 minutes, or greater than 15 minutes.
- (94) FIG. 7B illustrates an exemplary display (for example, that may be displayed on the user computing device **106** or a display associated with the remote monitoring system **120**) showing proximity between user **102**, wearable device **200** and other users **112**, **112**′, **112**″ and wearable devices **200**′, **200**″. As shown, user **112** and wearable device **200**′ are depicted as being a "close" distance from user **102** and wearable device **200**, user **112**′ and wearable device **200**″ are depicted as being "medium" distance from user **102** and wearable device **200**, and user **112**″ and

wearable device **200**" are depicted as being a "far" distance from user **102** and wearable device **200**.

- (95) In some implementations, the wearable device **200** can continuously detect and transmit proximity data (e.g., one or more proximity values) with one or more other wearable devices to user computing device **106** (and/or directly to remote monitoring system **120**) when such wearable devices are within such threshold proximity. The user computing device **106** and/or the remote monitoring system **120** can keep track of the accumulated duration of time of such proximity for each respective pair of users, for example, until the pair of users are not within such threshold proximity. Additionally and/or alternatively, the user computing device **106** and/or the remote monitoring system **120** can keep track of the accumulated duration of time of such proximity over a period of time, for example, over a span of 1 day, 3 days, 5 days, 7 days, or 14 days. Detected proximity data and contact events can be transmitted by each of the wearable devices in any given pair that come within threshold proximity to each other and can be transmitted to user computing devices associated with such wearable devices and/or directly to the remote monitoring system 120. (96) The more time two or more wearable devices **200** are proximate to each other, the higher the risk that a given infection will be transmitted if one of the users associated with the wearable devices is positive and/or contagious. In some implementations, the user computing device **106** and/or the remote monitoring system **120** are configured to categorize a contact event, for example, by how much time a given user was within a threshold proximity of another user. For example, the user computing device **106** and/or the remote monitoring system **120** can categorize a contact event of any two users as a "short time period" or "short exposure" if such users were within a threshold proximity for less than or equal to 30 minutes, less than or equal to 20 minutes, less than or equal to 15 minutes, less than or equal to 10 minutes, less than or equal to 9 minutes, less than or equal to 8 minutes, less than or equal to 7 minutes, less than or equal to 6 minutes, less than or equal to 5 minutes, less than or equal to 4 minutes, less than or equal to 3 minutes, less than or equal to 2 minutes, less than or equal to 1 minute, less than or equal to 30 seconds, among other values and/or ranges. As another example, the user computing device **106** and/or the remote monitoring system **120** can categorize a contact event of any two users as a "medium time period" or "medium exposure" if such users were within a threshold proximity for between about 5 minutes and 30 minutes, between about 10 minutes and 25 minutes, between about 10 minutes and 20 minutes, between about 10 minutes and 1 hour, or any value therebetween or any range bounded by any value therebetween. As another example, the user computing device **106** and/or the remote monitoring system **120** can categorize a contact event of any two users as a "long time period" or "long exposure" if such users were within a threshold proximity for greater than or equal to 10 minutes, greater than or equal to 15 minutes, greater than or equal to 20 minutes, greater than or equal to 25 minutes, greater than or equal to 30 minutes, greater than or equal to 40 minutes, greater than or equal to 50 minutes, greater than or equal to 1 hour, between about 15 minutes and about 1 hour, between about 30 minutes and about 5 hours, between about 30 minutes and about 2 hours, among other values and/or ranges.
- (97) Exposure Level and Risk State Determinations
- (98) Remote monitoring system **120** (for example, via contact tracing engine **416** or risk engine **418**) can be configured to determine a variety of metrics related to a user's exposure level to various other users (for example, associated with an organization) who may be or are infected with a communicable infection based on the above-described contact tracing data. A user's exposure level can include any information and/or data that may be associated with, representative of, and/or indicative of a user's exposure to one or more other users who may or may not be infected with a particular infection.
- (99) Remote monitoring system **120** can dynamically store, for each user associated with an organization, contact tracing data such as that described herein along with other health-related and other information, over time. Such contact tracing data can be indicative of all of the exposure

(e.g., contact events) for each user, proximity data indicative of the distance(s) between each user and other users, and/or duration of time of each contact event and/or accumulated duration of contact time over a given time period (e.g., 3 days, 5 days, 7 days, 10 days, 14 days, etc.). In some cases, weight factors can be applied to contact events depending on the associated proximity(ies) values of such contact events and/or the duration of such contact events. In some cases, the remote monitoring system **120** can determine total number of users (in the organization) with confirmed infections and/or a ratio of confirmed infections over the total number of users.

(100) There are a variety of ways that the remote monitoring system **120** can determine an exposure level of a user. For example, a user's exposure level can be determined based on (and/or can be indicative of) a summation, over a given time period (e.g., 3 days, 5 days, 7 days, 10 days, 14 days) of the time for each and every contact event with a user who was confirmed for the infection (e.g., in the "red" category described above) as described below with reference to Equations 1 and 2. With reference to Equation (1) below, E.sub.1 can represent a summation of each contact event where a user was within a threshold proximity to an infected user multiplied by the time of such contact event. Such "threshold proximity" here can be any of the "far", "medium", or "close" categories discussed above or any of the other values discussed herein with respect to threshold proximity. As another example, such "threshold proximity" utilized in Equation 1 can be 20 ft, 15 ft, 10 ft, 6 ft, or 3 ft, for example.

E.sub.1=Σ.sub.t proximity* Δt (Equation 1)

(101) A user's exposure level (represented by E.sub.total in Equation 2 below) can be determined, as illustrated in Equation 2, by a summation of E.sub.1 over all infected contacts over a period of time, for example.

E.sub.total=Σ.sub.# of All ContactsΣE.sub.1 (Equation 2)

(102) As another example, a user's exposure level can be determined based on (and/or can be indicative of) an average exposure with infected cases over a given period of time (e.g., 3 days, 5 days, 7 days, 10 days, 14 days). For example, as illustrated in Equation 3, the average exposure of a user can be determined based on an average of the exposure of E.sub.total discussed above in view of the total number of infected contacts (represented by "n" in Equation 3).

(103) $E_{\text{average}} = \frac{1}{\pi}$.Math. E_{total} (Equation3)

(104) As another example, a user's exposure level can be determined based on (and/or can be indicative of) a maximum amount of exposure the user has had with infected contacts over a given period of time (e.g., 3 days, 5 days, 7 days, 10 days, 14 days). For example, as illustrated in Equation 4, the maximum exposure of a user can be determined based on a maximum of the exposure of E.sub.total discussed above:

 $E.sub.maximum=max(\Sigma E.sub.total)$ (Equation 4)

(105) As another example, a user's exposure level can be determined based on (and/or can be indicative of) a number of contact events the user has had with infected users over a given period of time (e.g., 3 days, 5 days, 7 days, 10 days, 14 days) which exceeds a certain amount of time (for example, 3 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 30 minutes, or 1 hour). For example, the user's exposure level can be determined based on the number of times a user was within a threshold proximity (e.g., 6 ft) to an infected user for 15 minutes or more. As an example, such contact events can be defined as events where the user was within a threshold proximity that can be equal to any of the "far", "medium", or "close" categories discussed above, and/or can be equal to 20 ft, 15 ft, 10 ft, or 6 ft, for example.

(106) In some cases, the remote monitoring system **120** can determine (for example, via the contact tracing engine **416**) an exposure density of a group of users or all users in an organization, which can be the ratio of the number of infected users (i.e., users in the red category) to a total number of users in that group or organization. For example, an employer may want to monitor the exposure

density of a subset of the organization, for example, that work in a particular office, facility, or building. In this scenario, the exposure density of the particular subset is the ratio of the number of infected employees/users to the total number of employees/users that within that subset. (107) The remote monitoring system 120 can determine (for example, via the contact tracing engine 416) exposure levels of users based on additional or alternative information. For example, information such as: whether a contact event was inside a large or small confined space or outside; ambient weather conditions (temperature being hot or mild, humidity, weather), and/or other information. The above described exposure levels can be modified based on such additional information.

(108) In some cases, the remote monitoring system **120** can determine (for example, via the contact tracing engine **416**) isolation levels of one or more users in the organization. Such isolation level can be defined by and/or representative of a total number of contact events (e.g., for a particular user) weight by proximity(ies) between users associated with the contact events. (109) Remote monitoring system **120** (for example, via contact tracing engine **416**) can be configured to store information indicative of user exposure levels in one or more databases of the remote monitoring system **120**. Such database(s) can be configured to store this data for a certain period of time. For example, the database(s) can be configured to automatically delete the data after one week, two weeks, three weeks, four weeks, 1 month, 2 months, or 6 months of storage. (110) Remote monitoring system **120** can be configured to maintain contact tracing table(s) and/or lists for each user associated with an organization that records various information related to the users. FIG. 7C illustrates an exemplary contact tracing table **702** that can be associated with a user in the organization. Such contact tracing table **702** can include a plurality of columns that can show: a timestamp of when a contact event occurred; a user or subject identifier of the other user involved in the contact event; a risk state of the other user; a distance between the user and the other user (i.e., between at least one wearable device coupled with each user); a proximity level of the contact event; a disease or infection state of the other user; and/or a guarantine state of the other

(111) Such "Risk" column in table **702** can include values (e.g., numbers) that can represent a risk state of the user in a similar manner as that described herein with reference to the color coordinated risk states ("red", "green", "yellow", "orange"). Such risk state can be assigned and/or created by the organization to aid convenient categorization of infection risks of users of the organization. The "Proximity Level" column in table **702** can include values (e.g., numbers) that can represent a category of the proximity between users in a similar manner as that described above with reference to the categories "far", "medium", and "close". For example, a proximity level of "3" can be associated with proximity between users of between 1 ft and 6 ft and a proximity level of "2" can be associated with proximity between users of between 6 ft and 15 ft, between 6 ft and 20 ft, or between 6 ft and 30 ft, for example. In some cases, a proximity level of "0" can be associated with proximity between users of at least 15 ft, at least 20 ft, at least 30 ft, or at least 50 ft, for example. (112) The "Disease State" column in table **702** can reflect whether the other user has been confirmed to be infected or not with a particular infection. For example, the "Disease State" column in table **702** can have a "1" for users who have tested positive and/or have otherwise been determined to be positive for an infection and a "0" for users who have tested negative and/or are otherwise determined to be negative for an infection, or vice versa. The remote monitoring system **120** can dynamically update such table **702** over time simultaneously for a plurality of users in the organization as various types of information is received and/or determined by the remote monitoring system **120**. The remote monitoring system **120** can dynamically update the table with external information or instructions (e.g., supervisor escalation or approval, positive or negative test results).

(113) The "Quarantine State" column of table **702** can reflect whether a user is in a state of isolation from others. For example, a value of "1" in such column can reflect that the user is (or is

supposed to be) in a state of quarantine from others, and a value of "0" in such column can reflect that the user is not in a state of quarantine from others, or vice versa.

(114) Remote monitoring system **120** (for example, via risk engine **418**) can determine a risk state of a user based on, at in part, exposure level determined for each user, which can itself be determined as described above. Other information that can be utilized by the remote monitoring system **120** (for example, via risk engine **418**) to determine risk state includes, but is not limited to, physiological data of the users (such as any of that discussed above), symptom(s) information (such as any of that discussed above), and/or diagnosis and/or test result data (such as any of that discussed herein). In some implementations, remote monitoring system 120 generates, stores, and/or update (e.g., continuously over time), a contact tracing table (such as table **702**) for every user associated with the organization (for example, every user in an organization including a plurality of users such as any of the numbers of users discussed herein). In some implementations, remote monitoring system **120** determines exposure levels for any or all users associated with the organization based on contact tracing tables associated with each user (such as table 702) alone or in combination with one or more of the exemplary methods listed above with respect to determining exposure levels (e.g., via any of Equations 1-4 and/or combinations thereof). (115) In some implementations, remote monitoring system **120** may be configured to execute certain administrative protocols or include certain features that are designed to avoid bias or retribution towards certain users. The protocols and/or features can also be configured to prevent manipulation by a user, such as an individual in the organization and/or a monitor user of the organization who is tasked with monitoring the organization's users over the remote monitoring system **120**. At the start of a workday, for example, an employee can be required to present a screen with their user computing device **106** (e.g., smartphone) before entering a building of an organization. If the user computing device **106** is illuminated green, then the employee can be allowed into the building. If the user computing device **106** is not green, then the employer may request the employee to stay home to prevent the spread of a communicable disease. The user's user computing device **106** can be configured to present a unique daily barcode, which can be an encrypted version of the user's ID and the current date so the organization's remote monitoring system **120** can log in the employee. If a screener at the entrance to the building scans the barcode and there's an issue, then the remote monitoring system **120** can notify the screener. Thus, such unique daily barcode can help prevent an infected employee (i.e., an employee in the red category) from showing the screener a screenshot of a green screen from a different day and being allowed into the building. Such implementations can also advantageously be used in other types of settings, such as sports or concert venues.

(116) As another example, a first user not infected with a communicable disease (e.g., COVID-19) and a second user infected with the disease may both spend at least some overlapping time in a subway station. In one example scenario, the first and second users were in the same station for a certain period of time. If the users stay a certain distance apart (such as six feet or more apart), as determined by wearable devices of the users (such as any of those discussed herein), then the risk state of the first user can remain green. If the users are in close proximity with one another (for example, within 6 ft) for a certain period of time (e.g., 5 minutes or more), then the risk state of the first user may change to yellow. In a second example scenario, the first and second users are in the same subway car. Since a subway car is more enclosed than a subway station, the first user's risk state may change to yellow if the two users are in the same subway car for a certain period of time (e.g., 5 minutes or more). In a third example scenario, the first and second users sat next to each other in the subway car. The first user's risk state may change to yellow in this scenario since the distance between the users is low. In a fourth example scenario, the second user was instead in the orange category and the first user's risk state was changed from green to yellow due to the first user's contact with the second user. If the second user later tested negative for the disease, then the first user's risk state may automatically change back to green. Such dynamic change of risk states

of the users can be carried out as discussed above via the remote monitoring system **120**, wearable devices, and user computing devices discussed herein.

(117) Remote monitoring system **120** can be configured to notify users who may have come into contact with a user that is infected with the disease For example, a first user may have been infected with the disease and is in the red category. If the first user, for example, takes a flight, the system **110** can notify every user that was in proximity to the first user. For example, the system **120** can notify a second user that they shared a plane with a user in the red category (i.e., the first user) and/or change (e.g., automatically) the second user's risk state to the yellow category. This allows the second user to determine whether they should get tested, talk to their primary caregiver, quarantine themselves, inform others, stay home from work, etc.

(118) Any of the user computing devices discussed herein can include one or more applications can be configured to execute various commands and/or operations which allow users to view their risk state and a plurality of other risks states of other users. For example, a user may be using a mobile or web application on their user computing device to find a restaurant nearby. The application can show the user which restaurants have the lowest risk based on the people currently at the restaurant. For example, a first restaurant may have five people in the red category and a second restaurant may have one person in the red category and four people in the yellow/orange categories. The application can indicate this, for example, by having a green, yellow, orange, or red indicator next to the restaurant. This added functionality allows a user to consider a restaurant's risk level when deciding on a place to eat at. In another example, a ridesharing application may include a risk level based on the driver's risk level and/or the passengers' risk level. Users can set a minimum risk level threshold such that only drivers that are at or below the threshold can pick up the user. For example, a user can set the threshold to be yellow so that only drivers in green or yellow categories can pick them up. Additionally, drivers can set a minimum risk level threshold such that only riders with certain risk levels will appear on the drivers' application.

(119) Example Methods

(120) FIGS. **8**A-**8**B illustrate exemplary methods **800**, **820** by which the remote monitoring system **120**, user computing device(s) **106**, and wearable device **104** can interact to facilitate determination of an exposure level and/or risk state of one or more users associated with the remote monitoring system **120** (for example, associated with an organization utilizing a remote monitoring system **120**).

(121) With reference to the method **800** illustrated in FIG. **8**A, at block **802**, remote monitoring system **120** receives health-related information from one or more user computing devices. Remote monitoring system **120** can receive a plurality of sets of health-related information from a plurality of user computing devices associated with a plurality of users and a plurality of wearable devices that can be coupled to such plurality of users. One or more wearable devices (such as any of the wearable devices discussed herein) can be coupled and/or otherwise associated with each user to obtain physiological information and/or other information related to the user. A user computing device (such as any of the user computing devices discussed herein) of and/or used by the user can receive physiological and/or other information from the one or more wearable devices, for example, over any wired and/or wireless communication (such as any of the wireless communications protocols discussed herein).

(122) Each user computing device can transmit (e.g., over a network) a set of health-related information to the remote monitoring system continuously and/or at various time intervals (e.g., every 30 seconds, every minute, every 2 minutes, every 5 minutes, every 10 minutes, every 20 minutes, every 30 minutes, every hour, every 2 hours, every day, etc.). Additionally or alternatively, in some implementations, wearable devices are configured to transmit health-related information directly to the remote monitoring system. Such set of health-related information can include any of that which is described elsewhere herein, including but not limited to: physiological information/data of a user; contact tracing data including information related to proximity of the

user to one or more (or a plurality of) other users (for example, for purposes of determination of contact tracing and/or exposure to potential infections and/or diseases); information and/or data related to a user's diagnosis and/or test result(s) with respect to one or more infections and/or diseases which can be input by the user into the user computing device (e.g., positive and/or negative test results and/or diagnosis obtained from a medical professional); and information and/or data related to symptom(s) experienced by the user (which can be input by the user into a user computing device operated by a user, for example).

- (123) Physiological information/data of a user can be any of that discussed herein including, but not limited to, temperature, blood pressure, pulse rate, heart rate, respiratory rate (RRa), total hemoglobin (SpHb®), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), oxygen content (SpOC™), oxygen saturation (SpO2), pulse rate (PR), perfusion index (Pi), pleth variability index (PVi®), electroencephalogram (EEG) data, trending values of the same or combinations of the same, wellness indexes, or the like. Such physiological information can be derived from the user from one or more wearable devices when coupled to the user. Such physiological information/data can be indicative of an onset of symptoms experience by the user and which can be associated with one or more infections.
- (124) Contact tracing data can include any of that which is discussed elsewhere herein. Such contact tracing data can be indicative of physical proximity of the user to one or more other users which can be determined based on detected wireless signal strengths between one or more wearable device coupled to each of the user and the one or more other users. As discussed elsewhere herein, accumulated duration(s) of time where a user was within a threshold proximity to one or more other users (for example, any of the threshold proximities discussed herein) over a first time period (e.g., 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, etc.) can be determined by the remote monitoring system 120 (and/or user computing devices) based on data received from the user computing devices and/or wearable devices. As discussed elsewhere herein, one or more risk states associated with other users with which a given user has encountered (e.g., had a "contact event" with) can be utilized as contact tracing data by the remote monitoring system to determine exposure levels and/or risk states of the given user.
- (125) Each set of health-related information received by the remote monitoring system can additionally or alternatively include information/data related to a user's diagnosis and/or test result(s) with respect to one or more infections and/or diseases. Such diagnosis and/or test result information can be manually input by a user and/or input by a third party (e.g., a medical professional) who has access to the remote monitoring system and/or accessibility to interact with an application on the user's user computing device in order to input such diagnosis.
- (126) Each set of health-related information received by the remote monitoring system can additionally or alternatively include information/data related to symptom(s) experienced by the user. Such symptom(s) can be manually input by the user into a user into a user computing device operated by a user, for example. Including an ability for a user to enter experienced symptom(s) can advantageously capture how a user is "subjectively" feeling, and can useful to supplement more "objectively" obtained information (e.g., physiological information obtained by the wearable device(s) coupled to the user). Such symptom(s) can include, without limitation, fever, chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, loss of taste or smell, congestion or runny nose, nausea or vomiting, diarrhea, among others).
- (127) While not illustrated in method **800**, the method **800** can further include receiving other information from the user computing device(s), such as location data, movement data, orientation data, among other things, measured by a magnetometer, accelerometer, and/or gyroscope or other components of the wearable device and/or user computing device.
- (128) At step **804**, the remote monitoring system determines an exposure level for a user. Such exposure level can be determined in any of the manners described elsewhere herein for all or a subset of users in an organization simultaneously or non-simultaneously. Further, such exposure

level can be continuously and dynamically updated as information is received from user computing devices and/or wearable devices over time.

(129) At step **806**, the remote monitoring system determines a risk state for a user (and/or all or a subset of users in an organization). Such risk state (also referred to herein as "risk level") can be determined in any of the manners described elsewhere herein. For example, a risk state of a particular user can be determined based on one or more of user physiological information, contact tracing data, diagnosis and/or test result data, symptom(s) information, exposure levels, and/or risk state(s) of other users if available. At step **808**, the remote monitoring system sends (e.g., over a network) the determined risk state and/or other information or instructions associated with such risk state to the user computing device(s). Such other information or instructions can be, without limitation: instructions to the user concerning whether to quarantine (e.g., stay home) or come into a facility of the organization; and/or information related to exposure and/or risk states of any other users who may have come into contact with the user over a period of time and/or any visual representation thereof (e.g., graphs, tables, lists illustrating such information).

(130) Advantageously, not only can the method **800** described above be carried out for each user computing device and user associated with a given organization simultaneously, but such method **800** can be carried out on an ongoing basis, continuously determining exposure levels and risk states of such users and updating the users with such information. Although not illustrated in FIG. **8**A, the method **800** can additionally involve allowing for adjustment of exposure level(s) and/or risk state(s), for example, by a monitor user of an organization tasked with overseeing the remote monitoring system. Such adjustment can be as that described elsewhere herein (e.g., with respect to FIGS. **6**A-**6**B).

(131) FIG. **8**B illustrates a method **820** by which a user computing device (such as any of those discussed herein) can interact with one or more wearable devices associated with a user (such as any of the wearable devices discussed herein) and a remote monitoring system (such as any of the remote monitoring systems described herein). At step 822, the user computing device (such as a smart phone) of a user receives physiological information from one or more wearable devices associated with (e.g., coupled to) the user, such as any of the physiological information/data discussed herein. In some implementations, the user computing device also receives other information, such as location data and/or movement data as discussed elsewhere herein. At step **824**, the user computing device can receives contact tracing data from the wearable device, such as any of the contact tracing data discussed herein. For example, such contact tracing data can include proximity data (such as any of that discussed herein) indicative of the user's proximity to one or more other users (for example, when within a threshold proximity of such one or more other users). Such contact tracing data can advantageously additionally include identification information that uniquely identifies the one or more other users and/or wearable devices coupled to the users, for example, by associating identifiers (e.g., user IDs) with the one or more other users and the user itself. In some implementations, the user computing device only receives contact tracing data (e.g., proximity data) when the user is within the threshold proximity, but continuously receives physiological information (for example, regardless of whether the user is within the threshold proximity to other users) from a wearable device.

(132) At step **826**, the user computing device sends the health-related information to the remote monitoring system, for example, over a network as described above. At step **828**, the user computing device receives a risk state for the user associated with the user computing device, for example, after such risk state has been determined by the remote monitoring system. As shown and as described elsewhere herein, the user computing device can receive additional information and/or instructions related to the risk state. In some implementations, the user computing device can be configured to determine exposure levels and/or risk states alone or in combination with the remote monitoring system, and can include structure and/or functionality similar or identical to that described with respect to remote monitoring system to make such determinations.

- (133) At step **830**, the user computing device can notify (e.g., display) the risk state and/or instructions or information related to the risk state to the user. For example, the user computing device can execute, via a processor thereof, instructions and/or an application enabling visual and/or audio notifications of the risk state and/or instructions or information related thereto. As another example, the user computing device can execute, via a processor thereof, instructions and/or an application enabling the user computing device to generate a graphical user interface on a display thereof, and display, in one or more portions of the graphical user interface, the risk state and/or instructions or information related thereto. Advantageously, such method **820** can allow a user to be continuously made aware of its risk state/status and/or the risk states of other users associated with the organization.
- (134) Exemplary Graphical User Interfaces
- (135) FIGS. **9**A-**13**E illustrate various graphical user interfaces that may be accessed (e.g., viewed) by any of the user computing devices discussed herein, including user computing devices associated with user in an organization and monitor users tasked with overseeing and/or monitoring a remote monitoring system as discussed above. Such user interfaces can be accessed, for example, via a mobile or web application (for example, accessed via a browser).
- (136) Each of the user interfaces shown includes one or more user interface elements or controls that can be selected by a user. The user interface elements shown are merely illustrative examples and can be varied in other embodiments. For instance, any of the user interface elements shown may be substituted with other types of user interface elements. Some examples of user interface elements that may be used include buttons, dropdown boxes, select boxes, text boxes or text fields, checkboxes, radio buttons, toggles, breadcrumbs (e.g., identifying a page or interface that is displayed), sliders, search fields, pagination elements, tags, icons, tooltips, progress bars, notifications, message boxes, image carousels, modal windows (such as pop-ups), date and/or time pickers, accordions (e.g., a vertically stacked list with show/hide functionality), and the like. Additional user interface elements not listed here may be used.
- (137) Further, the user interfaces shown may be combined or divided into other user interfaces such that similar functionality or the same functionality may be provided fewer or more screens. Moreover, each of the user interface elements may be selected by a user using one or more input options, such as a mouse, touch screen input (e.g., finger or pen), or keyboard input, among other user interface input options. Although each of these user interfaces are shown implemented in a mobile device via a mobile application or desktop/laptop via a web application, the user interfaces or similar user interfaces can be output by any computing device, examples of which are described elsewhere herein.
- (138) FIGS. **9**A-**9**B illustrate user interfaces which display, on a user computing device **206**, various physiological parameters that are received from one or more wearable devices, such as any of those discussed herein. In FIG. **9**A, the depicted graphical user interface includes user physiological parameter values **902**. As shown, example physiological parameters **902** can include blood oxygen saturation (SpO.sub.2), pulse rate (PR), and/or perfusion index (PI). Values indicative of such physiological parameters **902** can be dynamically updated in real-time. In FIG. **9**B, another graphical user interface is depicted that includes user physiological parameters. The graphical user interface of FIG. **9**B can further include historical data. In particular, the graphical user interface can include a visualization **904** that presents historical trends of user physiological parameter values. As shown, the visualization **904** can include one or more graphs with an x-axis of time and a y-axis of parameter values. The underlying historical data can originally be generated, at least in part, by the one or more wearable devices.
- (139) FIGS. **10**A-**10**E illustrate example graphical user interfaces of an application that can be utilized by a user computing device (such as any of those discussed herein). FIG. **10**A illustrates a graphical user interface **1000** of an application, such as a mobile application. The graphical user interface **1000** can include a feed **1006**, which can present the user interface option(s) **1008** that

correspond to a user interface that has been shared with the user (here the "COPD Maintenance with MightySat" user interface). The graphical user interface **1000** can provide further access to the user to other aspects of the application. For example, the user can access a dashboard user interface, which can present physiological parameters, via the dashboard element **1002**. An example dashboard user interface is described in further detail below with respect to FIG. **10**B. As another example, the user can access a sharing configuration user interface via the sharing element **1004**. As described herein, a sharing configuration user interface can allow a user to modify their sharing permissions, such as by identifying and/or modifying other users (for example, within a remote monitoring system) that are permissioned to view at least some the user's data/receive alerts regarding the user.

(140) FIG. 10B illustrates an example dashboard user interface 1000′ of the application. The dashboard user interface 1000′ can include one or more physiological parameter summaries 1010A, 1010B, 1010C, 1010D. As shown, each of the example physiological parameter summaries 1010A, 1010B, 1010C, 1010D can be associated with different physiological parameters. The dashboard user interface 1000′ can include more or less physiological parameter summaries based on the particular configuration or embodiment. The physiological parameter summaries 1010A, 1010B, 1010C, 1010D can allow a user to review physiological parameters. The one or more physiological parameter summaries 1010A, 1010B, 1010C, 1010D can be associated with physiological parameters including, but not limited to, blood pressure, blood oxygen saturation, heart rate, respiration rate, body weight, or body temperature. A user can select the one or more physiological parameter summaries 1010A, 1010B, 1010C, 1010D to access additional details related to the physiological parameter associated with the selected physiological parameter summary 1010A, 1010B, 1010C, 1010D.

(141) The physiological parameter summary **1010**A can include a physiological parameter name **1012**, a physiological parameter value **1014**, and a visualization **1020**. The physiological parameter value **1014** (here an oxygen saturation value) can be associated with a date and/or time **1018**, such as when the measurement was taken. An example visualization **1020** can be a graph of physiological parameter values, such as a trend graph. The visualization **1020** can display an overall trend of the parameter associated with the physiological parameter summary **1010**A. The visualization **1020** may be based on physiological data from one or more wearable devices that collect data from a user.

(142) The dashboard user interface **1000**′ can include one or more elements **1030** that indicate users that are authorized to view and/or access user data, such as the physiological parameter summaries **1010**A, **1010**B, **1010**C, **1010**D. Accordingly, a user of the application can readily identify who has access to the physiological parameter summaries **1010**A, **1010**B, **1010**C, **1010**D. A user may add other users as authorized users via the add user element **1040**. Once added as authorized users, those other users may be able to view and/or access the physiological parameter summaries **1010**A, **1010**B, **1010**C, **1010**D associated with the user. User selection of the add user element **1040** may cause the application to present a graphical user interface that can allow the user to identify one or more users to be added as authorized users.

(143) FIGS. **10**C-**10**E illustrate example physiological parameter detail user interfaces of the application. In particular, FIG. **10**C illustrates a physiological parameter detail user interface **1001** associated with blood oxygen saturation. The physiological parameter detail user interface **1001** can include a statistical measurement value **1001**A, such as an average physiological parameter value (here an average blood oxygen saturation of 97.5 percent). The physiological parameter detail user interface **1001** can include a visualization **1001**B, such as a graph showing blood oxygen saturation values over time. As shown, the visualization **1001**B can include user interface elements that allow a user to interact with the visualization **1001**B, such as by changing the time period associated with the visualization. Additional example visualizations (not shown) can include, but are not limited to, a bar graph, scatter plot, pie chart, etc. In some embodiments, the

visualization **1001**B can use different indicators to display different data points in. For example, the visualization **1001**B can use the color green for data points within a predetermined range, the color yellow for data points within a different predetermined range, and the color red for data points outside of those predetermined ranges.

(144) FIG. **10**D illustrates another physiological parameter detail user interface **1003** associated with respiratory rate. FIG. **10**E illustrates yet another physiological parameter detail user interface **1005** associated with peripheral perfusion index. The physiological parameter detail user interfaces **1003**, **1005** of FIGS. **10**D and **10**E can be similar to the physiological parameter detail user interface **1001** of FIG. **10**C, such as by including similar user interface elements and/or operating in a similar manner. For example, the physiological parameter detail user interfaces **1003**, **1005** of FIGS. **10**D and **10**E can each include a visualization, like visualization **1001B**. However, the physiological parameter detail user interfaces **1003**, **1005** of FIGS. **7**D and **7**E can have different selected time periods than the selected time period of the physiological parameter detail user interface **1001** of FIG. **10**C.

(145) FIGS. **11**A-**11**C illustrate additional example user interfaces of an application that can be utilized by any of the user computing devices discussed herein. The user interface of FIGS. 11A-11C can be directed towards one or more infections, such as the novel coronavirus and/or COVID-19 health condition(s). FIG. 11A illustrates an example user interface 1100. In FIG. 11A, the graphical user interface **1100** includes a timeline **1102**. As shown, the current day in the timeline 1102 has several items 1104A, 1104B, 1104C, 1104D to be completed by a user. The example items 1104A, 1104B, 1104C, 1104D can be questionnaire and/or action items to be completed and/or inputted by the user. The items **1104**A, **1104**B, **1104**C, **1104**D can include prompts that elicit user responses. The items 1104A, 1104B, 1104C, 1104D can correspond to an initial questionnaire related to symptoms that may be associated with health condition(s) and/or infections. In the case of the novel coronavirus and/or COVID-19 and/or other use cases, example questions/prompts can include: "What is your age?", "Do you have pre-existing conditions", "Are you experiencing any symptoms", "Have you been in contact with anyone who has test positive for COVID-19?", or any other questions described herein. The responses to the questions can be transmitted by the user computing device to the remote monitoring system as described elsewhere herein. (146) FIG. **11**B illustrates another example user interface **1100**′. The user interface **1100**′ can include an input area 1112 for a question and/or action item (here an item to receive a user's temperature as user input). As shown, a user can input a temperature value. Alternatively, in some embodiments, instead of being received via manual user input, a user interface be configured to display one or more temperature values of the user obtained and received from one or more wearable devices, as discussed elsewhere herein.

(147) FIG. 11C illustrates yet another example user interface 1100". The user interface 1100" of FIG. 11C can be similar to the user interface 1100 of FIG. 11A. In particular, the user interface 1100" of FIG. 11C can represent a progression of completed items (e.g., answered questions, etc.) from the user interface 1100 of FIG. 11A. For example, the user interface 1100" of FIG. 11C can include indicators of the user's progress (such as a visual icon representing a completed status for a particular day in the timeline 1102, such as a visual star icon, and/or the text "100% complete"). The user interface 1100" can include a visual representation 1122 of a user device configuration. The user device configuration can facilitate the interface between the application and one or more wearable devices coupled to the user of the user computing device where the application is running. (148) The user interface 1100" can further include several items 1124A, 1124B, 1124C. The example items 1124A, 1124B, 1124C can be questions and/or action items, which can be completed by the user. For example, the item 1124A with the prompt (such as "Are you having trouble breathing?") can elicit a yes/no response to be provided from the user. The user can select the second item 1124B that can cause presentation of the user interface 1100' of FIG. 11B. The third item 1124C (shown as a respiration rate item) can be an item that can receive user input and/or that

displays physiological information derived from one or more wearable devices in communication with the user computing device. Similar to the items 1104A, 1104B, 1104C, 1104D of FIG. 11A that can be directed towards the novel coronavirus and/or COVID-19, the items 1122, 1124A, 1124B, 1124C of FIG. 11C can likewise be directed towards the novel coronavirus and/or COVID-19. For example, the items 1122, 1124A, 1124B, 1124C of FIG. 11C can be directed towards the symptoms of COVID-19 or any other respiratory disease (that can potentially be very dangerous) such as low oxygen saturation, high body temperature, difficulty breathing, and/or too low or too high of a respiration rate. However, any of the user interfaces 1100, 1100′′, 1100″ can be directed to diseases other than COVID-19, for example, to flu or common cold.

- (149) FIG. **12**A illustrate exemplary user interfaces that can be associated with any of the remote monitoring systems described herein. As discussed previously, the remote monitoring systems can be viewed by one or more monitor users of an organization who is tasked with overseeing and/or interacting with one or more user computing devices and associated users of the organization. The exemplary user interfaces of FIGS. **12**A-**12**G can be displayed on one or more computing devices operated by such monitor users and accessed via a web application (e.g., via a browser) and/or via a mobile application on a mobile device operated by such monitor use (e.g., a tablet, laptop, mobile phone, etc.).
- (150) FIG. 12A illustrates an exemplary user interface 1200 that can be used by a monitor user of a remote monitoring system. User interface 1200 can advantageously display one or more user profile/statuses (as shown by the array of boxes with user name and status) in the view. Such can be available in a "Dashboard" view of the application, which can be one of various other types of "views" available to the monitor user, such as "Access", "Groups", "Stats", "Settings", "Careprogram." The user profile and status appearing in this figure can be linked with one or more databases of a remote monitoring system, such as database(s) 404 as discussed elsewhere herein with respect to remote monitoring system 120. As shown in FIG. 12A, the user interface 1200 can display user names, user statuses (for example, risk states such as those discussed elsewhere herein), and/or can include various other information that can help efficiently and simply convey such statuses, such as color coding associated with risk state ("red", "yellow", such as that discussed elsewhere herein) and/or a risk state/status label (such as "Confirmed", "Symptomatic", "Exposed", "Cleared", etc.).
- (151) FIG. 12B illustrates another exemplary user interface 1201. User interface 1201 can represent a view that can appear if the monitor user selected one of the box icons in user interface 1200 which included a particular user (e.g., "User 1"). User interface 1201 can advantageously present information specific to the particular user, including but not limited to, contact information (e.g., email, phone number, location, job title, groups within the organization that the particular user is associated with, etc.). As shown, information concerning status, tasks or instructions, and/or contact tracing can be displayed. For example, as shown, the user interface 1201 can display tasks related to a user quarantining for a given period of time (e.g., "48 days of quarantine left") and/or tests for a particular infection (e.g., COVID-19). As also shown, user interface 1201 can display activity and/or history of the particular user, for example, along a timeline. Such activity and/or history information can include specific tasks, status, and/or daily questions.
- (152) User interface **1201** can represent a view that a monitor user would see if accessing an application via the a computing device of the remote monitoring system and/or can represent a view that a particular user would see if the particular user accessed the application via a computing device such as a laptop or desktop via a web browser. Where accessed in such manner by the particular user, in some implementations the application allows the user to input information and edit various aspects of the application. User interface **1201** can allow the monitor user and/or the user represented in the user interface **1201** to edit the user's profile and/or status. User interface **1203** in FIG. **12**C illustrates a view that can appear if the monitor user and/or another user selected the "Update Status" icon in user interface **1201**. As illustrated in user interface **1203**, various

aspects of a user's status can be modified/updated, such as a "Health Status" (e.g., "symptomatic", "clean", "confirmed", "infected", "asymptomatic", etc.), "Symptom Starting Date" (e.g., an "onset" date of symptoms), "Symptoms" (e.g., fever or temperature over a threshold such as 100.4° F. or 38° C.), chills, cough, sore throat, fatigue, shortness of breath, vomiting, diarrhea, loss of taste and/or smell, or other symptoms, and/or "Notes" which can include other information such as whether the user was asked to self-quarantine.

(153) FIG. **12**D illustrates another exemplary user interface **1205** that can allow entry and/or verification of exposure data indicative exposure a user has had to one or more other users. Such exposure can be representative of and/or associated with a "contact event" such as those discussed elsewhere herein where a user is within a threshold proximity of one or more other users for a given amount of time. For example, as shown in FIG. **12**D, an "exposure" can be a contact event with another user within 6 ft for a period of greater than or equal to 15 minutes. However, various other threshold distances and/or time periods can be used to define such "exposure", such as any of those discussed herein. User interface **1205** can display a list of contacts (e.g., users), groups which may be a subset of the organization to which a particular user belongs, a box which can be indicative of an exposure (see "Exposed" text), and a "Notes" list which can allow entry and/or verification of descriptions related to contact events.

(154) FIG. **12**E illustrates another exemplary user interface **1207** which allowing viewing and/or modification of groups of users within an organization. User interface **1207** can advantageously facilitate subdividing all the users in an organization into groups which can be defined by sets of users who work together in certain portions of the organization's facilities and/or who share similar tasks or job descriptions. The viewing and/or modification of such groups can allow simple and efficient monitoring and management of users. As shown, a plurality of groups can be created which subdivide the users in the organization by job title and/or location, for example, "Engineering", "Marketing", "Warehousing", "Central Warehouse", "Eastside Warehouse", "Westside Warehouse", etc.). Selection of any of such plurality of groups can allow "Bulk Actions" to be undertaken, such as modifying risk states and/or instructions for all users within a particular group.

(155) FIG. **12**F illustrates another exemplary user interface **1207**. User interface **1207** illustrates an exemplary "Settings" view that can allow, for example, a monitor user to change various settings of the remote monitoring system and/or an application associated therewith which can affect how the application is executed on any user computing device of any of the plurality of users of an organization. As shown, user interface **1207** can allow the creation and/or modification of, without limitation: risk labels or risk states (see "Label" column); associated visual characteristics (e.g., "Red" "Yellow", "White", "Dark grey", "light grey", etc.); risk label/state descriptions (see "Description" column); quarantine time (see "Quarantine (Days)" column); and whether a given risk label/state is "Active". As also shown, user interface **1207** can allow modification of exposure and/or risk state determination settings. For example, if a member of a group (such as the groups discussed above) is either symptomatic or confirmed to be infected, other members of that group might have been exposed. In such cases, the user interface 1207 can configure the a remote monitoring system and/or application associated therewith to automatically change a risk state of all members in such group to "Exposed" or alternatively, to qualify exposure of all members based on one or more parameters such as whether the member worked with a symptomatic/confirmed member whether the user can identify who they were in contact with, and subsequent to that qualification, determine whether to label the user as "exposed." User interface **1207** can also allow configuration for exposure notification messages (e.g., alerts) to be sent out to one or more users of a group if a determination is made that a user from that group was infected. The user interface 1207 can allow customization of the message and the method of transmission (e.g., email, in app notification viewable on the users' user computing device, text message, etc.). User interface **1207** can also allow for such "automatic" notifications to be disabled in view of manual notifications, for

example.

(156) FIG. **12**G illustrates another exemplary user interface **1209**. User interface **1209** illustrates an exemplary "Stats" view that can allow, for example, a monitor user to view statistics on all users of the organization or a subset (e.g., a group) of users within the organization. As shown, user interface **1209** can include information and/or a visual representation associated with: total number of cases of an infection (e.g., number of diagnosed users, number of symptomatic users, number of exposed users); trending information and/r graphs indicative of the number of open cases over a given time period (e.g., 1 day, 3 days, 5 days, 7 days, 14 days, 1 month, 2 months, 6 months, one year, etc.); "Daily Check-in" information which can be indicative of the number of users that are checking in (e.g., by registering their user computing device with a screening device or in another manner) to a facility of the organization; and/or "Estimated Return Date" information that can represent a timeline of return dates for users who are quarantining.

(157) FIGS. 13A-13E illustrate exemplary user interfaces 1300, 1302, 1304, 1306, 1308 that can be

- utilized in a mobile application of a user computing device (such as any of the user computing devices discussed herein). However, all or portions of such user interfaces 1300, 1302, 1304, 1306, **1308** can be utilized by a web application of a user computing device, for example, via a browser. FIG. **13**A illustrates a user interface **1300** that can include, among other things, a prompt for a user to answer daily questions that can be related to and/or indicative of an infection. Such daily questions can be any of the questionnaire and questions discussed elsewhere herein, for example, with reference to symptom information. Such daily questions may also be related to and/or indicative of diagnosis data (e.g., received from a medical professional), test results, contact tracing data (such as any of that discussed herein), among other information. Based on the user's answers to such daily questions and/or based on other determinations that may be made by a remote monitoring system receiving such answers (via a user computing device), the remote monitoring system can communicate with the user computing device and the user computing device can display the user's risk state/status and/or other information related thereto. For example, the user computing device can display: a "Cleared" notification accompanied by an instruction or suggestion to come into work and/or a color coordinated indicator (e.g., "green") as shown in user interface **1302** in FIG. **13**B; a "Exposed" notification accompanied by an instruction for the user to stay home and/or a color coordinated indicator (e.g., "yellow") as shown in user interface 1304 in FIG. **13**C; a "Symptomatic" notification accompanied by an instruction for the user to stay home and/or a color coordinated indicator (e.g., "red") as shown in user interface **1306** in FIG. **13**D; and/or a "Confirmed" notification accompanied by an instruction for the user to stay home and/or a color coordinated indicator (e.g., "red") as shown in user interface 1308 in FIG. 13E. (158) FIGS. 14A-14B illustrate additional exemplary user interfaces 1400, 1400' that may be generated by a one or more hardware processors of a computing device via a mobile and/or web
- with one or more other users, for example, in an organization. (159) Proximity data (such as any of that discussed herein) can be obtained from a wearable device (such as any of the wearable devices discussed herein) and can be transmitted to a user computing device (such as any of the user computing devices discussed herein) associated with (e.g., belonging to) a user. Such user computing device (e.g., smartphone) associated with the user can receive and transmit such proximity data to a remote monitoring system (such as any of the remote monitoring systems discussed herein). Additionally or alternatively, such proximity data can be obtained from the wearable device and can be directly transmitted to the remote monitoring system (e.g., without utilization of the user computing device).

based application executed by the computing device. User interfaces **1400**, **1400**′ advantageously can illustrate contact tracing data in a simple and effective manner. User interfaces **1400**, **1400**′ can illustrate, over a period of time and/or along a timeline, one or more contact events that a user has

(160) One or more hardware processors associated with the remote monitoring system can execute an application (e.g., software application, web or mobile application, etc.) that can execute

commands to enable a computing device associated with the remote monitoring system (e.g., a computing device operated by a monitor user tasked with overseeing the remote monitoring system and/or users, wearable devices, and/or user computing devices interacting with the remote monitoring system) to undertake various actions. Such actions can include, for example: receiving proximity data from the wearable device (either directly or via a user computing device), the proximity data indicative of distance between the wearable device and a separate wearable device coupled to a second user; receiving a first identifier associated with the user and/or the wearable device of the user; receiving a second identifier associated with the second user and/or the separate wearable device; store said proximity data over time along with the first and second identifiers; and/or determine one or more contact events based on the proximity data, where each of the one or more contact events is representative of the first and second users being within a threshold proximity (such as any of the threshold proximities discussed herein) for a continuous period of time. Such actions can additionally include generating a graphical user interface on a display of the computing device associated with the remote monitoring system (e.g., computing device used by a monitor user) and generating a timeline (that can be continuously updated over time) and a visual representation of such one or more contact events along a timeline.

- (161) Such visual representation(s) can be in the form of a shape and/or can have a color, for example. Such visual representation(s) can be a bubble, as illustrated in FIGS. **14**A-**14**B. In some implementations, a size and/or other characteristic of bubble correlates with and/or is indicative of the period of time in a contact event. For example, a first contact event between two users where the two users were within a threshold proximity (e.g., 6 ft) from one another for 20 minutes can be represented by a bubble that has a greater size, shape, perimeter, and/or other characteristic (e.g., radius, diameter) than a second contact event where the two users were within the threshold proximity for 5 minutes. The visual representation(s) can be represented by a square, diamond, among other shapes. As another example, each contact event can be represented by a circle, where a diameter of the circle corresponds to the length of time of the contact event (e.g., the duration of time that a user was within a threshold proximity of another user).
- (162) With reference to FIG. **14**A, a first point along a perimeter of a bubble representing a contact event can represent the time at which the contact event began and a second point along the perimeter of the bubble can represent the time at which the contact event ended. In some implementations, the bubble(s) can be color coordinated for each user (e.g., each user is represented with a different color) or can be color coordinated based on risk state of each user (e.g., user's confirmed with an infection can be represented by a "red" bubble and user's not infected can be represented by a "green" bubble). For example, multiple bubbles can be generated along the timeline to represent, for example, multiple, distinct contact events between the same users. Where a given user had contact events with multiple users at the same time, bubbles may overlap, thus causing, in some implementations a darker shade in that region. Advantageously, user interface **1400**, **1400**' can be generated, for example, continuously, for every user of an organization, and can be viewed by the object user and/or a monitor user of an organization. Such user interface **1400**, **1400**' accordingly presents a dynamic method by which contact events can be conveniently be monitored.
- (163) Any and all of the systems, methods, devices, and/or user interfaces described herein can incorporate and/or be used alongside any and all of the systems, methods, devices, and/or user interfaces described in co-pending U.S. patent application Ser. No. 17/207,469, filed on Mar. 19, 2021, titled "REMOTE PATIENT MANAGEMENT AND MONITORING SYSTEMS AND METHODS," which is hereby incorporated by reference in its entirety.

Additional Considerations and Terminology

(164) Although this invention has been disclosed in the context of certain preferred embodiments, it should be understood that certain advantages, features and aspects of the systems, devices, and methods may be realized in a variety of other embodiments. Additionally, it is contemplated that

various aspects and features described herein can be practiced separately, combined together, or substituted for one another, and that a variety of combination and subcombinations of the features and aspects can be made and still fall within the scope of the invention. Furthermore, the systems and devices described above need not include all of the modules and functions described in the preferred embodiments.

- (165) Conditional language used herein, such as, among others, "can," "could," "might," "may," "e.g.," and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain features, elements, and/or steps are optional. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required or that one or more embodiments necessarily include logic for deciding, with or without other input or prompting, whether these features, elements, and/or steps are included or are to be always performed. The terms "comprising," "including," "having," and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term "or" is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term "or" means one, some, or all of the elements in the list. Further, the term "each," as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term "each" is applied.
- (166) Conjunctive language such as the phrase "at least one of X, Y, and Z," unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.
- (167) Language of degree used herein, such as the terms "approximately," "about," "generally," and "substantially" as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms "approximately", "about", "generally," and "substantially" may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms "generally parallel" and "substantially parallel" refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 10 degrees, 5 degrees, 3 degrees, or 1 degree. As another example, in certain embodiments, the terms "generally perpendicular" and "substantially perpendicular" refer to a value, amount, or characteristic that departs from exactly perpendicular by less than or equal to 10 degrees, 5 degrees, 3 degrees, or 1 degree.
- (168) Although certain embodiments and examples have been described herein, it will be understood by those skilled in the art that many aspects of the systems and devices shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. A wide variety of designs and approaches are possible. No feature, structure, or step disclosed herein is essential or indispensable.
- (169) Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein may include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication.
- (170) The methods and tasks described herein may be performed and fully automated by a computer system. The computer system may, in some cases, include multiple distinct computers or computing devices (e.g., physical servers, workstations, storage arrays, cloud computing resources, etc.) that communicate and interoperate over a network to perform the described functions. Each such computing device typically includes a processor (or multiple processors) that executes program instructions or modules stored in a memory or other non-transitory computer-readable

storage medium or device (e.g., solid state storage devices, disk drives, etc.). The various functions disclosed herein may be embodied in such program instructions, and/or may be implemented in application-specific circuitry (e.g., ASICs or FPGAs) of the computer system. Where the computer system includes multiple computing devices, these devices may, but need not, be co-located. The results of the disclosed methods and tasks may be persistently stored by transforming physical storage devices, such as solid state memory chips and/or magnetic disks, into a different state. The computer system may be a cloud-based computing system whose processing resources are shared by multiple distinct business entities or other users.

- (171) Depending on the embodiment, certain acts, events, or functions of any of the processes or algorithms described herein can be performed in a different sequence, can be added, merged, or left out altogether (for example, not all described operations or events are necessary for the practice of the algorithm). Moreover, in certain embodiments, operations or events can be performed concurrently, e.g., through multi-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially.
- (172) Various illustrative logical blocks, modules, routines, and algorithm steps that may be described in connection with the disclosure herein can be implemented as electronic hardware (e.g., ASICs or FPGA devices), computer software that runs on general purpose computer hardware, or combinations of both. Various illustrative components, blocks, and steps may be described herein generally in terms of their functionality. Whether such functionality is implemented as specialized hardware versus software running on general-purpose hardware depends upon the particular application and design constraints imposed on the overall system. The described functionality can be implemented in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the disclosure.
- (173) Moreover, various illustrative logical blocks and modules that may be described in connection with the disclosure herein can be implemented or performed by a machine, such as a general purpose processor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. A general purpose processor can be a microprocessor, but in the alternative, the processor can be a controller, microcontroller, or state machine, combinations of the same, or the like. A processor can include electrical circuitry configured to process computer-executable instructions. A processor can include an FPGA or other programmable device that performs logic operations without processing computer-executable instructions. A processor can also be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration. Although described herein primarily with respect to digital technology, a processor may also include primarily analog components. For example, some or all of the rendering techniques described herein may be implemented in analog circuitry or mixed analog and digital circuitry. A computing environment can include any type of computer system, including, but not limited to, a computer system based on a microprocessor, a mainframe computer, a digital signal processor, a portable computing device, a device controller, or a computational engine within an appliance, to name a few.
- (174) The elements of any method, process, routine, or algorithm described in connection with the disclosure herein can be embodied directly in hardware, in a software module executed by a processor, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, or any other form of a non-transitory computer-readable storage medium. An exemplary storage medium can be coupled to the processor such that the processor can read information from, and write information to, the storage medium. In the alternative, the storage

medium can be integral to the processor. The processor and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor and the storage medium can reside as discrete components in a user terminal.

(175) While the above detailed description has shown, described, and pointed out novel features, it can be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As can be recognized, certain portions of the description herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of certain embodiments disclosed herein is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims

- 1. A wearable device for monitoring a user's health status, the wearable device comprising: at least one physiological sensor configured to measure one or more physiological parameters of a first user, said at least one physiological sensor comprising a temperature sensor configured to generate one or more signals responsive to a thermal energy of the first user; a first wireless transceiver configured to communicate with a mobile computing device of the first user; and a processor configured to: receive said one or more signals generated by the temperature sensor and determine one or more body temperature values of the first user based on said received one or more signals; detect a wireless signal strength between the first wireless transceiver of the wearable device and a second wireless transceiver of a separate wearable device that is coupled to a second user; based on at least the detected wireless signal strength, determine a distance between the wearable device and the separate wearable device; instruct the first wireless transceiver to transmit to the mobile computing device said determined one or more body temperature values continuously regardless of the distance between the wearable device and the separate wearable device; and in response to determining, based on at least the detected wireless signal strength, that the distance between the wearable device and the separate wearable device is within a threshold proximity, instruct the first wireless transceiver of the wearable device to transmit to the mobile computing device when the wearable device and the separate wearable device are within said threshold proximity: a first identifier associated with the first user and indicative of an identity of the first user; a second identifier associated with the second user and indicative of an identity of the second user, wherein the second identifier is wirelessly received at the wearable device from the separate wearable device; and the distance between the first wearable device and the separate wearable device without location information of the wearable device and the separate wearable device, said mobile computing device configured to wirelessly transmit said first and second identifiers, said one or more body temperature values, and said distance to a remote monitoring system for determination of a risk state of the first user based on analyzing said one or more body temperature values, said distance, and information associated with said second identifier, wherein said risk state indicates a likelihood that said first user has one or more infections.
- 2. The wearable device of claim 1, wherein the wearable device is configured to determine only one type of physiological parameter of the first user, said type of physiological parameter being temperature of the first user.
- 3. The wearable device of claim 1, wherein said threshold proximity comprises 20 ft.
- 4. The wearable device of claim 1, wherein the processor is configured to instruct the first wireless transceiver to transmit to the mobile computing device said determined one or more body temperature values continuously every minute.
- 5. The wearable device of claim 1, wherein said distance is determined based on a detected Bluetooth® signal strength between the first and second wireless transceivers.

- 6. A system comprising the wearable device of claim 1 and said mobile computing device.
- 7. The wearable device of claim 1, wherein the processor is configured to instruct the first wireless transceiver to transmit to the mobile computing device a duration of time that the distance between the wearable device and the separate wearable device is within the threshold proximity.
- 8. The wearable device of claim 1, wherein the processor is configured to instruct the first wireless transceiver to transmit to the mobile computing device a number of times that the distance between the wearable device and the separate wearable device is within the threshold proximity.
- 9. The wearable device of claim 1, wherein the information associated with the second identifier includes health-related information of the second user.
- 10. A method for monitoring a user's health status using a wearable device, the method comprising: generating one or more signals responsive to a thermal energy of a first user using a temperature sensor of a wearable device coupled to the first user; by one or more processors of the wearable device: receiving said one or more signals generated by the temperature sensor and determining one or more body temperature values of the first user based on said received one or more signals; detecting a wireless signal strength between a first wireless transceiver of the wearable device and a second wireless transceiver of a separate wearable device that is coupled to a second user; based on at least the detected wireless signal strength, determining a distance between the wearable device and the separate wearable device; receiving a second identifier associated with the second user from the separate wearable device; instructing the first wireless transceiver of the wearable device to transmit to a mobile computing device remote to the wearable device said determined one or more body temperature values continuously regardless of the distance between the wearable device and the separate wearable device; and in response to determining, based on at least the detected wireless signal strength, that the distance between the wearable device and the separate wearable device is within a threshold proximity, instructing the first wireless transceiver of the wearable device to transmit to the mobile computing device when the wearable device and the separate wearable device are within said threshold proximity: a first identifier associated with the first user and indicative of an identity of the first user; the second identifier associated with the second user and indicative of an identity of the second user; and the distance between the first wearable device and the separate wearable device without location information of the wearable device and the separate wearable device, said mobile computing device configured to wirelessly transmit said first and second identifiers, said one or more body temperature values, and said distance to a remote monitoring system for determination of a risk state of the first user based on analyzing said one or more body temperature values, said distance, and information associated with said second identifier, wherein said risk state indicates a likelihood that said first user has one or more infections.
- 11. The method of claim 10, wherein said threshold proximity comprises 20 ft.
- 12. The method of claim 10, further comprising instructing the first wireless transceiver to transmit to the mobile computing device said determined one or more body temperature values continuously every minute.
- 13. The method of claim 10, further comprising determining said distance based on a detected Bluetooth® signal strength between the first and second wireless transceivers.
- 14. The method of claim 10, further comprising instructing the first wireless transceiver to transmit to the mobile computing device a duration of time that the distance between the wearable device and the separate wearable device is within the threshold proximity.
- 15. The method of claim 10, further comprising instructing the first wireless transceiver to transmit to the mobile computing device a number of times that the distance between the wearable device and the separate wearable device is within the threshold proximity.
- 16. The method of claim 10, wherein the information associated with the second identifier includes health-related information of the second user.